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1. PREFACE 
 
The work of this PhD thesis was performed at the Inflammation Research Unit, Division of 
Internal Medicine, University Hospital of Zurich. This work is a part of the project number 31-
124861 of Swiss National Science Foundation. 
 
The aim of this thesis was to investigate novel mechanisms of inflammation in response to the 
emerging inflammatory mediators Wnt5A and IL-4 in human vascular endothelial cells.   
 
The data of this study are presented in the form of following manuscripts submitted for 
publication. 
 
1. Wnt5A/Ryk Signaling Critically Affects Barrier Function in Human Vascular 
Endothelial Cells 
Tom Skaria, Esther Bachli, Gabriele Schoedon 
 
2. IL-4 Causes Hyperpermeability of Vascular Endothelial Cells through Wnt5A 
Signaling 
Tom Skaria, Julia Burgener, Esther Bachli, Gabriele Schoedon 
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2. ABBREVIATIONS 
 
AJ  Adherens junctions 
CAM  Cell adhesion molecules 
CAMKII Calmodulin dependent protein kinase II 
CFL  Cofilin 
ECIS  Electric cell-substrate impedance sensing 
Fzd  Frizzled 
GO  Gene ontology 
GPCRs G-protein-coupled receptors 
HCAEC Human coronary artery endothelial cells 
HUVEC Human umbilical vein endothelial cells 
IEJ  Inter-endothelial junctions 
LIMK  LIM kinase  
PCP  Planar cell polarity 
ROCK  Rho-associated protein serine/threonine kinase 
RTKs  Receptor tyrosine-protein kinases 
sFRP  secreted Frizzled related protein 
SIR  Systemic inflammatory response  
TEER  Trans-endothelial electric resistance 
TH2 cell Type 2 helper T cell 
TLR  Toll-like receptor 
WIF  Wnt inhibitory factor  
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3.  ZUSAMMENFASSUNG 
 
Bei schwerer Sepsis und septischem Schock kommt es zu einer systemischen 
Entzündungsreaktion (systemic inflammatory response SIR) durch die  grosse Anzahl von 
Zytokinen, welche infolge der Kommunikation zwischen aktivierten Immunzellen und 
Gefässendothelzellen freigesetzt werden.  Die mit der SIR assoziierte Endotheldysfunktion ist 
der Auslöser für eine schwere Leckage der Gefässe und die Bildung von systemischen 
Gewebsödemen. Sepsis und Septischer Schock sind noch immer die häufigste Todesursache 
auf der Intensivstation. Es besteht ein grosser Bedarf an wirksamen Therapien, denn die 
Blockade der „klassischen Entzündungsmediatoren“ wie TNF-α und IL-1β konnte das 
Ueberleben der Patienten nicht verbessern. Andere Therapieversuche waren ebenfalls 
erfolglos. Vor kurzem entdeckte man hohe Konzentrationen von Wnt5A im Serum und 
Knochenmark von Patienten mit SIR und septischem Schock. Wnt5A, ein neues Chemokin, 
wird von menschlichen Makrophagen durch Aktivierung des Toll-like Rezeptors freigesetzt und 
ist massgeblich beteiligt an der Aufrechterhaltung der Entzündungsantwort dieser Zellen. Wie 
Wnt5A auf humane Gefässendothelzellen wirkt ist jedoch noch nicht bekannt. Mikrovaskuläre 
Leckage als Folge gestörter endothelialer Barrierefunktion tritt häufig bei Typ2 T-Helferzell 
abhängigen allergischen Entzündungsreaktionen auf. IL-4,  ein aus Typ2 T-Helferzellen 
stammendes Zytokin mit inflammatorischen Eigenschaften,  beeinträchtigt die Funktion der 
endothelialen Barriere. Allerdings ist auch über den effektiven Mechanismus der  IL-4 
abhängigen Endotheldysfunktion wenig bekannt. 
Ziele der vorliegenden Arbeit sind (1) Die Prozesse und Signalwege zu identifizieren welche 
durch Wnt5A in humanen Gefässendothelien aus Koronararterien (HCAEC) reguliert werden, 
(2) Die Effektoren und den Mechanismus zu identifizieren welcher die Barrierefunktion in IL-4 
behandelten Gefässendothelzellen beeinträchtigt. 
Mittels systembiologischer Vorgehensweise fanden wir, dass Wnt5A in HCAEC überwiegend 
Gene und Pathways beeinflusst, welche massgeblich beteiligt sind an der Bildung des 
Aktinzytoskeletts. Wnt5A beeinflusst die Rho-assoziierte Protein- Serin/Threonin- Kinase 
(ROCK), welche durch Phosphorylierung LIM-Kinase (LIMK)-2 aktiviert und diese wiederum den 
Aktin-Depolymerisierungsfaktor Cofilin (CFL)-1 deaktiviert. Durch Anfärbung von Aktinfasern in 
lebenden Zellen zeigte sich, dass Wnt5A-behandelte HCAEC wegen der gestörten 
Depolymerisierung vermehrt Aktin- Stressfasern bilden. Dies konnte durch WIF-1,  den Ryk-
Rezeptor spezifischen Wnt-Antagonisten, verhindert werden. Ausserdem wurden durch Wnt5A 
die zellulären Adhäsionsverbindungen über b-Catenin und VE- Cadherin gestört, was zu Lücken 
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zwischen den Zellen in HCAEC Monolayers führte. Kontinuierliche Messung des 
transendothelialen Widerstandes in lebenden Zellen wies auf erhöhte Permabilität der Wnt5A-
behandelten HCAEC Monolayers hin. Knock-down des Ryk-Rezeptors konnte dies verhindern. 
Diese Daten deuten darauf hin, dass Wnt5A hauptsächlich Prozesse reguliert, die für die 
Gestaltung des Zytoskeletts in HCAEC verantwortlich sind. Wnt5A, welches während einer 
systemischen Entzündungsreaktion von aktivierten Immunzellen freigesetzt wird,  könnte somit 
für die Störung der endothelialen Barrierefunktion verantwortlich sein. 
Differentielle Genexpressionsanalyse von IL-4 behandelten HCAEC  zeigte  
überraschenderweise, dass Wnt5A eines der am höchsten hochregulierten Gene ist. Die 
ontologische Gruppierung der Gene in entsprechenden Pathways zeigte, dass die 
signifikantesten Pathways diejenigen sind, welche Gene enthalten, die für die 
Zytoskelettstruktur verantwortlich sind. Gene, die diesen Pathways gehäuft zugeordnet wurden, 
waren wiederum LIMK-2 und  CFL-1. Nach Behandlung von HCAEC mit IL-4  waren LIMK-2 
und CFL-1 phosphoryliert, ein Hinweis auf vermehrte Bildung von Aktin-Stressfasern. Durch 
Sichtbarmachung der Aktinfasern in lebenden Zellen konnte die erhöhte Stressfaserbildung in 
IL-4 behandelten HCAEC bestätigt werden. Die Stressfaser-bildung  in IL-4 behandelten 
HCAEC war in Gegenwart von WIF-1 erheblich geringer. Nicht-invasive elektophysiologische 
Aufzeichnung des Widerstandes in HCAEC Monolayers zeigte, dass die Zellpermeabilität durch 
IL-4 erhöht wird. Durch spezifisches Silencing der Wnt5A-Epression konnte die Barrierefunktion 
in IL-4 behandelten HCAEC signifikant verbessert werden. IL-6, welches von IL-4 behandelten 
HCAEC in grossen Mengen gebildet wird, und von dem man bisher annahm, dass es die 
Gefässpermeabilität beeinflusst, hatte überraschenderweise keinen Effekt. Durch diese 
Untersuchung konnte Wnt5A als das Molekül identifiziert werden, welches massgeblich an der 
erhöhten Gefässpermeabilität beteiligt ist, die durch IL-4 verursacht wird.  
Die vorliegende Arbeit weist folglich darauf hin, dass der Wnt5A/Ryk/ROCK  Signalweg ein 
neuer Entzündungspathway ist, welcher unabhängig von proinflammatorischen Zytokinen wie 
TNF-α und IL-1β die Gefässpermeabilität beeinflusst. Gezielte Angriffspunkte im Wnt5A 
Signalweg könnten neue therapeutische Möglichkeiten für Patienten mit Sepsis und schweren 
systemischen Entzündungskrankheiten bieten.  
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4. SUMMARY  
 
In severe sepsis and septic shock, immune cells and vascular endothelial cells communicate 
with each other by releasing and responding to an array of pro-inflammatory cytokines and 
chemokines, thereby provoking a systemic inflammatory response (SIR). SIR associated 
endothelial dysfunction is the trigger for severe vascular leakage and systemic tissue edema 
formation. Sepsis/septic shock is still a major cause of death in intensive care. Efficient 
therapeutic strategies are in demand since blockade of classical inflammatory mediators like 
TNF-α and IL-1β failed to improve patient survival. Other therapeutic trials were also not 
successful so far.  Recently, high levels of Wnt5A have been detected in sera and bone marrow 
of patients with severe systemic inflammation and septic shock. Wnt5A is a novel chemokine 
secreted by Toll-like receptor-activated human macrophages, and is crucially involved in 
sustaining their inflammatory response. However, the targets and functional effects of Wnt5A on 
human vascular endothelial cells remain unclear. Microvascular leakage due to endothelial 
barrier dysfunction is a prominent feature of type 2 helper T cell (TH2 cell) mediated allergic 
inflammation. IL-4, a TH2 cell-derived cytokine with proposed inflammatory properties impairs 
the barrier function of vascular endothelial cells. However, the effector mechanism responsible 
for IL-4-induced endothelial barrier dysfunction remains poorly defined. 
The present study aims to (1) identify the targets and processes regulated by Wnt5A signaling 
in human coronary artery endothelial cells (HCAEC), (2) identify the effector and the 
downstream mechanism impairing barrier function in IL-4-activated HCAEC.  
By using a systems biology approach, we found that predominant targets of Wnt5A in HCAEC 
are clusters of genes significantly involved in actin cytoskeleton remodelling. Wnt5A targeted 
Rho-associated protein serine/threonine kinase (ROCK) to phosphorylate LIM kinase (LIMK)-2 
and inactivate the actin depolymerization factor Cofilin (CFL)-1. Live actin staining in Wnt5A-
treated HCAEC showed enhanced stress fiber formation in consequence of reduced actin 
depolymerization that was prevented by Ryk-specific antagonist Wnt inhibitory factor (WIF)-1. 
Wnt5A disrupted β-catenin and VE-cadherin adherens junctions forming inter-endothelial gaps 
in HCAEC monolayers. Live recording of trans-endothelial electric resistance revealed 
increased permeability of Wnt5A-treated HCAEC monolayers that was prevented by knockdown 
of Ryk.  These data indicate that Wnt5A principally regulates the process of cytoskeleton 
remodelling in HCAEC. Thus Wnt5A released by activated immune cells during systemic 
inflammatory response might be responsible for endothelial barrier dysfunction.  
8 
 
Differential gene expression profiling in IL-4-treated HCAEC surprisingly identified Wnt5A 
among the top upregulated genes, and gene ontology pathway clustering revealed that among 
the top most significant pathways were those containing genes associated with cytoskeleton 
remodelling. Genes clustered in these pathways were again LIMK-2 and CFL-1. Following IL-4 
treatment of HCAEC, LIMK-2 and CFL-1 were phosphorylated, thereby indicating the possibility 
of actin stress fiber formation. Live imaging of actin proved the enhanced formation of stress 
fibers in IL-4-treated HCAEC. Stress fiber formation in IL-4-treated HCAEC was notably 
decreased in the presence of WIF-1. Non-invasive electrophysiologic recording of HCAEC 
monolayer resistance demonstrated that IL-4 increased the cellular permeability. Specific 
silencing of Wnt5A expression significantly improved the barrier function of the HCAEC 
monolayer upon IL-4 treatment. Surprisingly, IL-6 which is generated in large amounts by IL-4- 
treated endothelial cells and which is supposed to be responsible for IL-4-induced vascular 
permeability, had no such effect. This study identifies Wnt5A as an effector molecule critically 
involved in IL-4 mediated vascular hyperpermeability.  
In conclusion, the present study reveals Wnt5A/Ryk/ROCK signaling as a novel inflammatory 
pathway that affects vascular permeability independent of the pro-inflammatory cytokines TNF-α 
and IL-1β. Targeting Wnt5A signaling could provide novel therapeutic options for patients with 
sepsis and severe systemic inflammatory diseases. 
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5. INTRODUCTION 
 
5.1 Inflammation and sepsis 
Inflammation is a pathophysiological process that develops in response to different stimuli such 
as infections or tissue injury. It involves the coordinated movement of blood leucocytes and 
plasma components to the site of infection or injury to minimize tissue damage, thereby 
providing an early protection to the host. Inflammatory responses caused by microbial infections 
are well characterized and involve the following mechanisms. Firstly, the innate immune 
receptors such as nucleotide-binding oligomerization-domain protein (NOD)-like receptors and 
Toll-like receptor (TLR) present on host mast cells and tissue resident macrophages recognize 
structures on microbial cells. These microbial structures belong to two major classes; the 
pathogen-associated molecular patterns (PAMPs) and virulence factors. PAMPs are present in 
all microorganisms while virulence factors are carried by only pathogens. The binding of these 
microbial structures  by TLR and NOD-like receptors activate macrophages and mast cells, 
resulting in the production of various inflammatory mediators including tissue factor (TF), 
cytokines, chemokines, proteolytic enzymes, complement components, eicosanoids, platelet 
activating lipid factors, vasoactive peptides and vasoactive amines [1]. These mediators along 
with complement components (eg.C5a) function via autocrine and paracrine signaling to further 
activate tissue resident macrophages, monocytes and endothelial cells. For example, 
macrophages challenged with bacterial lipopolysaccharide (LPS) secrete pro-inflammatory 
cytokines including TNF-α and IL-1β. These pro-inflammatory cytokines paracrinically act on the 
local endothelial cells and activate them to upregulate the expression of inflammatory mediators 
like IL-6, IL-8 and MCP-1 [2] and cell adhesion molecules (CAM).  
Sepsis/septic shock is defined as a severe systemic inflammatory response (SIR) to an 
infectious agent. Clinically, severe SIR also occurs without any obvious infection upon heavy 
trauma, in cancer, and in states of autoimmune inflammation. Prominent symptoms are rapid 
rise of body temperature accompanied by drop of systemic blood pressure, persistent 
hypotension despite fluid resuscitation [3], leucocytosis, thrombocytopenia, disseminated 
coagulation, hypoxemia, tachycardia and tachypnea, oliguria due to renal failure, metabolic 
acidosis, and finally organ failure and death. Still, septic shock is the major cause of death in 
intensive care units with mortality rates ranging from 40 to 70% [3]. A major symptom related 
with SIR is severe vascular leakage causing systemic tissue edema formation. Dysfunction of 
the vascular endothelium is suggested to be the major reason for vascular leakage during 
severe systemic inflammation and sepsis. Therapeutic trials targeting the prototypic 
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inflammatory mediators TNF-α and IL-1β have not been successful in treating sepsis and septic 
shock [4]. The effectors and associated molecular mechanisms responsible for endothelial 
dysfunction and consequent tissue edema formation in sepsis still remain not fully understood. 
 
5.2 Endothelial cells 
The vessel wall of arteries and veins is composed of three layers. The innermost layer is called 
intima which is constantly exposed to the blood flow as well as to cellular and soluble blood 
components. The vascular endothelial cells are located in this intima where they attach together 
at intercellular junctions and form a continuous monolayer to line up the blood vessels [5]. 
Vascular smooth muscle cells form the middle layer called media [6]. The media is separated 
from the endothelial and the outer adventitia layers by elastic lamina [7]. The adventitia is 
composed of fibroblasts, small capillaries, lymphatic vessels, nerves, endothelial progenitor 
cells and immune cells such as macrophages and dendritic cells [7]. The walls of tiny capillaries 
are composed of endothelial cells surrounded by basal lamina and few pericytes (Figure 1). 
The vascular endothelial cells play an important role in maintaining vascular homeostasis. They 
preserve blood fluidity [8,9], control blood pressure, prevent the adherence of leucocytes [8] and 
platelets [9] and regulate vascular permeability [8]. Endothelial cells control coagulation through 
the surface expression of tissue factor pathway inhibitors such as heparin sulphate 
proteoglycans and thrombomodulin. Moreover, resting endothelial cells retain the von 
Willebrand factor in their storage granules called Weibel-Palade bodies (WPBs), thus preventing 
interaction between endothelial membrane and platelets [8].  
Endothelial cells control blood pressure by secreting a number of vasodilator and 
vasoconstrictor mediators that increase and decrease the tone of the neighboring smooth 
muscle cell layers. Among such endothelium-derived mediators, nitric oxide acts as a 
vasodilator whereas endothelin type-1 acts as a vasoconstrictor for smooth muscle cells [9]. 
Under resting conditions, endothelial cells mask leucocyte interaction proteins such as 
chemokines and CAM like P-selectin by storing them in WPBs. Moreover, the expression of 
other CAM like VCAM-1, E- selectin and ICAM-1 are suppressed. This prevents the adherence 
of leucocytes to resting endothelial cells [8]. 
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Figure 1.  Composition of the vascular wall. IEL, internal elastic lamina; EEL, external elastic 
lamina. Figure adapted and modified from reference [7].  
 
Under physiological conditions, endothelial cells tightly control vascular permeability with the aid 
of ion channels and intercellular junction proteins. The free efflux of liquid, plasma proteins and 
blood cells to the underlying interstitial space and tissues are restricted. Thus, endothelial cells 
act as a semipermeable barrier that maintains the selective passage of blood components at a 
low rate.   
Endothelial cells from different parts of the vascular system exhibit different phenotypic 
characteristics. It means that even endothelial cells from different anatomic sites within the 
same individual express different receptors and surface antigens and produce different 
responses to identical stimuli [9]. 
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5.2.1 Structural components of endothelial barrier  
The barrier function of endothelial cells depends on the integrity of the structure that comprises 
of endothelial cell cytoskeleton, intercellular junction complexes, and cell attachments to 
basement membrane and extracellular matrix [10]. 
 
Endothelial cytoskeleton 
Endothelial scaffold structures are microtubules, intermediate filaments and actin filaments. 
Among these, actin filaments represent the most important cytoskeletal structure to regulate 
endothelial permeability. Actin filaments are polymers of filamentous actin (F-actin) arranged in 
a linear fashion. Their stability is highly dependent upon the concentration of intracellular 
globular actin (G-actin). G-actin monomers polymerize to form F-actin filaments when the 
intracellular concentration of G-actin reaches above the critical concentration of 0.1 μM.  Under 
physiological conditions, actin filaments are irregularly scattered all over the cell and even 
located at the cellular periphery as cortical actin. Signaling proteins such as Rho family 
GTPases (RhoA, Rac1 and Cdc42) modify the arrangement of the actin cytoskeletal network 
and generate specialized structures such as actin stress fibers or cortical actin [10]. Stress 
fibers are contractile actomyosin polymers with inverted polarity which are also linked to α-
actinin [11]. Actin cytoskeleton rearrangement and stress fiber formation increase endothelial 
permeability through mechanisms that are still not fully elucidated [10] .  
Microtubules are tubular polymers composed of dimers of alpha- and beta-tubulin subunits.  The 
microtubule consists of 13 polymeric filaments which are arranged in parallel to form a ring. As 
microtubules are crosslinked to actin filaments in endothelial cells, they alter endothelial 
permeability via mechanisms involving actin filaments. Stabilization of microtubules by 
polymerization inhibits actin stress fiber formation and hyperpermeability in endothelial cells. On 
the other hand, depolymerization of microtubules increases actin stress fiber formation, possibly 
through activation of guanine nucleotide exchange factors and Rho family GTPases like RhoA 
[10]. Intermediate filaments are composed of protein polymers, especially those of vimentin.  
 
Endothelial intercellular junction complexes 
The endothelial intercellular junction complexes or inter-endothelial junctions (IEJ, also referred 
as inter-endothelial adhesions) in microvascular endothelial cells are of mainly two types, the 
adherens junctions (AJ) and tight junctions (TJ).  AJ represent the most common endothelial 
cell-cell junctions found in microvascular endothelial cells including peripheral microvascular 
endothelial cells. AJ are impermeable to larger proteins such as albumin and thus act as 
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barriers to prevent the passage of macromolecules into tissues and organs. AJ are mainly 
composed of the transmembrane receptor protein VE-cadherin. The extracellular domain of VE-
cadherin of one endothelial cell binds to the extracellular domain of another VE-cadherin 
expressed on the membrane of an adjacent cell. This forms a seal that prevents the passage of 
molecules through the inter-endothelial space. The intracellular domain of VE-cadherin is 
connected to the actin cytoskeleton with the help of catenin family of proteins such as α-, β-, γ- 
and p120-catenins. A proper assembly and maintenance of VE-cadherin-catenin-actin 
cytoskeleton complex is highly essential for preserving the structural integrity and function of 
endothelial barriers.  In comparison with AJ, there is little expression of tight junction proteins in 
peripheral microvascular endothelial cells. TJ composed of proteins such as claudins, occludins 
and junctional adhesion molecule-A are commonly found in the microvascular endothelial cells 
of specialized tissues such as blood retinal or blood brain barriers [10].  
 
Endothelial focal adhesions 
Focal adhesions attach endothelial cells to their basement membrane. Focal adhesions are 
small regions in the basolateral membrane, composed of transmembrane receptors called 
integrins. Integrins are normally present as heterodimers of α- and β- subunits. The intracellular 
domain of integrins is associated with the actin cytoskeleton with the help of linker proteins such 
as α-actinin, talin, vinculin or paxillin. They are also able to associate with the actin cytoskeleton 
directly and function independent of linker proteins.  The extracellular domain of integrins binds 
to matrix proteins such as fibronectin, fibrinogen and vitronectin lodged in the laminin and 
collagen fibers of endothelial basement membrane. Focal adhesions keep the endothelial cells 
attached to the substratum and preserve endothelial barrier integrity [10]. Focal adhesion 
disassembly is regulated by RhoA through the activation of its downstream target Rho-
associated protein serine/threonine kinase (ROCK). Activation of ROCK leads to the activation 
of LIM kinase (LIMK) by phosphorylation, which in turn phosphorylates cofilin (CFL). 
Phosphorylation inactivates CFL and favours the stabilization of filamentous actin contained 
within the actomyosin bundles [11].  
 
5.3 Endothelial response in severe systemic inflammation and sepsis 
The functions of endothelial cells are heavily altered in diseases like severe systemic 
inflammation and sepsis [9]. These alterations include a change from the anticoagulant 
phenotype to a procoagulant state, increased production of vasoactive substances, expression 
of CAM, and the synthesis of inflammatory mediators including chemoattractants. The 
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endothelium at this stage is said to be activated. The pro-inflammatory cytokines TNF-α and IL-
1 secreted by activated leucocytes act as the prototypic mediators of endothelial activation. The 
binding of these pro-inflammatory cytokines to their corresponding receptors on endothelial cells 
initiate signaling mechanisms that activate mitogen-kinase kinase kinases (MAPKKKs). 
Activated MAPKKKs trigger the pathways activating the transcription factors nuclear factor-
kappa-light-chain-enhancer of activated B cells κB (NF-κB) and activator protein-1 (AP-1). The 
activated transcription factors turn on the gene expression of CAM and pro-inflammatory 
proteins (Figure 2). The CAM expressed on activated endothelial cells, E-selectin, ICAM-1 and 
VCAM-1 promote the recruitment and adhesion of leucocytes to endothelial cells. The pro-
inflammatory mediators include cytokines such as IL-6, chemokines such as IL-8 and MCP-1, 
enzymes such as cyclooxygenase-2 (COX-2) and effector proteins that are responsible for the 
rearrangements of actin filaments [8]. Cytokines such as IL-6 and chemokines act on leucocytes 
and facilitate their recruitment to inflamed tissue. COX-2 aids the biosynthesis of prostaglandin-
I2 to raise the blood pressure. Actin filament rearrangements disrupt IEJ [8] and might induce 
endothelial barrier dysfunction. But the exact mechanisms mediating these rearrangements 
remain still unidentified. 
 
Figure 2. Phenotypic changes in resting and activated vascular endothelial cells. Left 
side: vascular endothelial cells forming a tight cell-cell contact under resting conditions. Right 
side: activated endothelial cells showing upregulated expression of CAM and chemokines 
followed by disruption of inter-endothelial contacts. IEJ, inter-endothelial junction. 
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5.3.1 IL-4 signaling  
Activation of the vascular endothelium is also associated with cytokines such as IL-4, secreted 
by type 2 helper T cell (TH2 cell) population. IL-4 is a multifunctional cytokine that has crucial 
roles in the regulation of homeostasis and pathogenesis of diseases. Although activated TH2 
cells represent the major source of IL-4, it is also produced by basophils, eosinophils and mast 
cells [12]. IL-4 can bind to two different cell surface receptor complexes known as type I IL-4R 
and type II IL-4R.  Type I IL-4R is composed of IL-4Rα and γc chains and mainly found in 
hematopoietic cells. Type II IL-4R is expressed by both hematopoietic and non-hematopoietic 
cells and formed of IL-4Rα and IL-13Rα1 chains. The subunits of both IL-4 receptor complexes 
are constitutively associated with members of Janus protein kinases (Jaks) family such as Jak1 
(IL-4Rα), Jak2 (IL-13Rα1) and Jak3 (γc chain). Activation of Jaks followed by ligand-receptor 
interaction causes tyrosyl phosphorylation and dimerization of signal transducer and activator of 
transcription 6 (STAT6). STAT6 is then transported to the nucleus to activate the expression of 
IL-4 responsive genes [13].  
IL-4 triggers functionally different intracellular signaling mechanisms by binding to alternative 
receptors [12]. It induces the differentiation of antigen encountered naïve T cells to form mature 
effector TH2 cells capable of producing IL-4 and a number of other cytokines such as IL-5 and 
IL-13. It regulates immunoglobulin (Ig) class switching so that human B cells express IgE and 
IgG4 [14]. IL-4 induces the “alternative activation” of macrophages to form a group of highly 
specialized cells called M2 macrophages, the latter playing important roles in inflammation, 
parasite clearance and tissue repair [12]. Through its effects on multiple cell types, IL-4  plays 
critical roles in allergic inflammation including allergen-induced asthma, anaphylaxis and rhinitis 
[15], immune response to extracellular parasites, autoimmunity [14], and tumor inflammation 
and metastasis [12]. 
In vascular endothelial cells, IL-4 upregulates the expression of IL-6 and MCP-1 [16,17].  It 
induces endothelial cells to express VCAM-1 [17,18] that facilitates the adhesion of peripheral 
blood monocytes [19] and T cells to endothelial cells [20]. Further, IL-4 enhances endothelial 
permeability. Edema formation resulting from vascular leakage is an important symptom in 
allergy [21] and autoimmune inflammation. However, the effectors responsible for IL-4-induced 
endothelial barrier dysfunction remain so far unidentified.  
 
5.3.2 Endothelial barrier dysfunction and vascular leakage 
Endothelial barrier dysfunction causes increased efflux of plasma through the vessel wall into 
the neighboring tissues, leading to the formation of protein-rich tissue edema. Small molecules 
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and activated leucocytes can pass the endothelial monolayer either through transcellular or 
paracellular routes. Transcellular passage of proteins is supported by caveolae vesicles. 
Paracellular passage of leukocytes involves the IEJ. The permeability of the IEJ is dependent 
on the assembly of the adhesion proteins that constitute IEJ.  
Inflammatory mediators increase endothelial permeability through the activation of RhoA/ROCK 
and its downstream target LIMK. When activated by ROCK-mediated phosphorylation, LIMK 
phosphorylates the actin deploymerization factor CFL-1. Phosphorylation inactivates CFL-1 and 
prevents its ability to depolymerize actin filaments leading to the formation of contractile actin 
stress fibers. The contractile force stretches VE-cadherin inward, requiring a VE-cadherin 
extracellular domain of one cell to detach from the VE-cadherin extracellular domain of a 
neighboring cell, forming inter-endothelial gaps [22]. The exact mechanisms are, however, still 
not well defined. 
 
5.4 Wnts and their signaling mechanisms 
Wnts constitute a large family of secreted lipid modified signaling proteins [23-25] that are 
potent regulators of multiple biological processes such as cell proliferation, cell fate decision and 
differentiation during embryogenesis and adult homeostasis, and immune responses [26,27]. In 
mammals, there are 19 genes coding for Wnt proteins [28]. Frizzled (Fzd) proteins are generally 
suggested to function as receptors for Wnts [26,29]. Wnts function through either the β-catenin 
dependent canonical pathway or the β-catenin independent non-canonical pathway, the latter 
being also referred as Wnt/planar cell polarity (PCP) pathway [29]. 
 
Canonical Wnt signaling 
Canonical Wnt signaling is transduced mainly through Fzd receptors. Fzd receptors belong to 
the family of G-protein-coupled receptors (GPCRs) [29] and consist of a seven-pass 
transmembrane region and an extracellular cysteine-rich domain (CRD) homologous to the 
natural Wnt antagonist, secreted Frizzled related protein (sFRP)-1 [30]. A featured event in 
canonical Wnt signaling is an increase in cytoplasmic levels of β-catenin, followed by its 
translocation into the nucleus to regulate gene expression [25]. When Wnt ligands are absent, 
adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3), the scaffolding protein 
axin 1, casein kinase I (CKI) and others form a destruction complex. This destruction complex 
phosphorylates free β-catenin which is not bound to cadherin. The phosphorylated β-catenin 
gets ubiquitinated and is subsequently targeted for degradation by 26S proteasome, thereby 
maintaining β-catenin at low levels in resting cells [29,31]. Simultaneously, transcriptional 
17 
 
repressors like transducin-like enhancer proteins (TLEs) bind to DNA binding proteins of the T 
cell factor (TCF) and lymphoid enhancer-binding factor 1 (LEF1) in the nucleus, leading to the 
repression of Wnt target genes. Following interaction of a Wnt ligand with Fzd receptor-LRP6 
co-receptor complexes, the conformation of LRP6 co-receptor is changed leading to 
phosphorylation of the co-receptor. This in turn activates G proteins as well as dishevelled 
proteins, thereby enabling the recruitment of axin 1 to the co-receptor to induce disruption of the 
destruction complex. As a result, β-catenin increases in the cytoplasm which then translocates 
to nucleus and interacts with TCF or LEF1. This interaction dissociates TLE repressors from 
TCF and LEF1 and thus activates the transcription of number genes including MYC and axin 2. 
Axin 2 aids the assembly of more destruction complexes and thus functions as a feedback 
inhibitor to the signaling [31]. The sequence of events involved in canonical Wnt signaling is 
shown in Figure 3. Two examples of canonical Wnt ligands which signal through β-catenin are 
Wnt3A and Wnt8A [31]. In contrast, Wnt5A has been suggested to repress or inhibit β-catenin 
dependent canonical Wnt signaling. 
 
Figure 3. Canonical Wnt signaling. Interaction of Wnt with receptor releases β-catenin from 
the degradation complex. Gene transcription is activated following translocation of free β-
catenin from cytoplasm to nucleus. Figure adapted and modified from reference [31].  
 
18 
 
Non-canonical Wnt signaling 
Canonical Wnt signaling has been extensively studied while Wnt/PCP signaling still remains 
poorly understood with different β-catenin independent pathways existing in parallel [28,31]. The 
non-canonical Wnt signaling pathways involve either Fzd receptors or non-Fzd receptors such 
as receptor tyrosine kinase-like orphan receptor-2 (Ror2) and Ryk [29]. One branch is the 
Wnt/Ca2+ pathway and involves an increase in intracellular Ca2+  levels through the activation of 
phospholipase C (PLC). The Ca2+ flux in turn activates calmodulin-dependent protein kinase II 
(CAMKII), protein kinase C (PKC), and the nuclear factor of activated T cells (NFAT) 
transcription factor [29,31]. This pathway has been reported to be involved in dorsoventral 
patterning and separation of tissues in embryos and inhibition of Wnt3/β-catenin signaling. 
Recently, CAMKII activation was identified as an essential part of inflammatory Wnt5A/Fzd5 
signaling in human macrophages [26]. Another branch of Wnt/PCP pathway involves the 
activation of Rho which through the regulation of ROCK mediate actin remodelling [29] and alter 
cytoskeleton arrangement [31]. Wnt4, Wnt5A and Wnt11 are generally classified as non-
canonical Wnts [31]. Suggested pathways involved in non-canonical Wnt signaling are 
summarized in Figure 4. 
 
 
Figure 4. Non-canonical Wnt 
signaling. Interaction of Wnt with 
specific receptor leads to activation 
one of the three downstream pathways 
involving Rho GTPases, JNK and 
PLC. The type of cellular processes 
regulated depends on the downstream 
pathway involved. Dsh, dishevelled. 
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Receptor tyrosine-protein kinases 
Wnts can function through transmembrane tyrosine kinase family members called Ror2 and 
Ryk. Ror2 belongs to the family of the Ror family of receptor tyrosine-protein kinases (RTKs) 
[32]. Ror2 is distinguished as receptor or co-receptor for Wnt5A and can regulate different 
Wnt5A signaling pathways by acting alone or in combination with Fzd receptors. Ror2 contains 
an extracellular CRD domain similar to the extracellular Wnt binding domain of Fzd receptors 
and sFRP [30], and activates intracellular signaling pathways in response to Wnt5A [28,33]. 
Wnt5A/Ror2 non-canonical signaling has been described to inhibit canonical Wnt signaling and 
to play important roles in polarized cell migration [29,32], tumor growth, invasion and metastasis 
[32].  
Ryk is a member of the family of atypical RTKs. It is composed of an extracellular Wnt binding 
domain, a transmembrane domain and an intracellular kinase domain (Figure 5). Its 
extracellular domain is glycosylated and is homologous to the endogenous Wnt antagonist Wnt 
inhibitory factor (WIF)-1.  The intracellular kinase domain of Ryk, unlike other members of RTK, 
is atypical  because it lacks tyrosine kinase activity [34] due to the presence of mutations in its 
evolutionarily conserved tyrosine kinase regions [35].  Therefore, the precise mechanisms by 
which signals are transmitted from the cell surface to the intracellular compartment upon 
interaction of Ryk with Wnt ligands remain still unknown. It has been suggested that Ryk 
signaling activates MAPK pathway [36]. Ryk is overexpressed in epithelial ovarian cancer 
[37,38].  
  
 
Figure 5. Structure of Ryk 
receptor. The extracellular domain 
is composed of a Wnt inhibitory 
factor (WIF) module containing two 
cysteine residues (pink) that 
surround a tetrabasic cleavage site 
(TBC site), two leucine-rich repeats 
(green), and many putative N-linked 
sites for adding carbohydrates 
(black sticks). The transmembrane 
region is composed of tandem 
cysteine residues. The intracellular 
domain is composed of a 
juxtamembrane serine- and 
threonine (S/T)-rich sequence 
(white), a catalytically inactive PTK-
like domain and a PDZ-binding motif 
at the C-terminal end. Figure 
adapted and modified from [34].  
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A previous study demonstrated that Wnt5A/Ryk signaling inhibits the growth of adult rat 
corticospinal axons [39]. Moreover, Derailed, a member of Ryk family of receptors in Drosophila 
has been described to act as a receptor for Wnt5A in axon guidance [40].  Wnt5A signaling 
through Ryk causes repulsive axon guidance in mammals [41].  Recently, it has been shown 
that Wnt5A/Ryk suppresses the growth of mouse callosal axons [42]. Evidences are still scant 
to define the downstream mechanism of Wnt5A/Ryk signaling and how Wnt5A/Ryk signaling 
differs between non-differentiated and fully differentiated cells in terms of its targets and 
biological function. In the present thesis, we could define a Wnt5A/Ryk signaling pathway in 
human vascular endothelial cells, affecting vascular permeability (see chapter 6.1). 
 
5.5 Role of Wnt5A in inflammation 
Human Wnt5A is a 49kDa protein encoded by one of the Wnt family of genes located on 
chromosome 3 (in the region between 3p14-p21) [43]. Wnt5A regulates a number of cellular 
processes such as adhesion, differentiation, migration, polarity and proliferation and plays 
pivotal roles in post-natal cell functions, immune responses and developmental process of 
different organs.  This suggests that Wnt5A regulates multiple signaling pathways depending on 
the availability of specific receptors [43,44] and other mediators of the signaling pathway [44], 
cellular conditions [43], and the presence of natural inhibitors like sFRP. Evidence indicating a 
crucial role for Wnt signaling in immune response was initially obtained from studies using a 
„septic fly‟ model. It was demonstrated that WntD, a member of Wnt family of proteins in 
Drosophila, was induced through Toll/NF-κB signaling and regulated innate immune responses 
to infection. This study proved that mortality rates were higher in flies lacking WntD expression 
in comparison to flies expressing endogenous WntD. It suggested that under septic conditions, 
flies deficient of WntD would suffer overstimulated immune responses [45]. A consecutive study 
demonstrated a functional role for Wnt5A signaling in response to bacterial infections. In that 
study, human mononuclear cells stimulated with mycobacterial species upregulated Wnt5A and 
Fzd5 through the activation of Toll/NF-kB signaling. In response to microbial antigenic 
stimulation, Wnt5A/Fzd5 signaling upregulated the expression of IL-2 and IFN-γ by antigen 
presenting cells and T cells, respectively [27]. Increased expression of Wnt5A and Fzd5 has 
been detected in synovial tissues in rheumatoid arthritis [46], and blockade of Wnt5A/Fzd5 
signaling prevented the activation of rheumatoid synovial tissues [47]. Moreover, expression of 
Wnt5A has been detected in the macrophage-rich regions of murine and human atherosclerotic 
plaques [48] . 
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Recently, inflammatory Wnt5A signaling in human macrophages was found to be critically 
involved in severe systemic inflammatory response. Wnt5A protein was highly induced and 
released upon TLR targeting of macrophages, and was found in substantial quantity in sera of 
patients with severe sepsis. The study further demonstrated that Wnt5A was capable of 
sustaining the inflammatory response of macrophages through an autocrine 
Wnt5A/Fzd5/CAMKII signaling pathway [26].  This study indicates a pivotal role for Wnt5A  in 
inflammation and suggests therapeutic approaches targeting Wnt5A beneficial in treating 
diseases associated with severe systemic inflammation [49]. Wnt5A is released in substantial 
amounts from activated macrophages and the vascular endothelium plays an important role in 
systemic inflammation and septic shock. However, the knowledge of paracrine Wnt5A signaling 
in vascular endothelial cells is still scant. We addressed this issue in the course of this thesis.  
 
Inflammatory Wnt5A signaling in endothelial cells 
A previous study showed that human umbilical vein endothelial cells (HUVEC) treated with a 
cocktail of TNF-α, IL-1 and IL-8 upregulated the expression of Wnt5A mRNA [50]. As endothelial 
cells from different vascular environments exhibit functional heterogeneity, Wnt5A signaling in 
adult vascular endothelial cells may differ from the foetal tissue-derived HUVEC. Another study 
showed that human aortic endothelial cells (HAEC) treated with Wnt5A expressed pro-
inflammatory cytokines such as IL-1, IL-6, and IL-8 [51]. However, the specific targets of Wnt5A 
in adult human vascular endothelial cells and the precise downstream mechanism by which 
Wnt5A induces endothelial inflammation have remained unclear. 
 
5.6 Outline of the project 
The aim of this thesis was to study the response of human vascular endothelial cells to Wnt5A 
and IL-4 to define novel mechanisms and signaling pathways of these emerging inflammatory 
mediators.  Following specific aims were addressed: 
1. Define all genes and biological processes regulated by Wnt5A signaling in primary human 
vascular endothelial cells using a standardized genome-wide expression profiling approach.  
2. Identify the receptor(s) and the downstream signaling pathways specific for Wnt5A in human 
vascular endothelial cells. 
3. Describe the biological functions of Wnt5A signaling in human vascular endothelial cells. 
4. Identify the genes and pathways affecting barrier function in IL-4-activated human vascular 
endothelial cells using a whole genome transcriptome approach and specific endothelial barrier 
function assays. 
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Abstract 
 
Objective— Satisfactory therapeutic strategies for septic shock are still missing. Previously 
we found elevated levels of Wnt5A in patients with severe sepsis and septic shock. Wnt5A is 
released by activated macrophages but knowledge of its effects in the vascular system 
remains scant. Here we investigate the response of human coronary artery endothelial cells 
(HCAEC) to Wnt5A.  
Approach and Results—We used a genome-wide differential expression approach to 
define novel targets regulated by Wnt5A. Gene ontology analysis of expression profiles 
revealed clusters of genes involved in actin cytoskeleton remodeling as the predominant 
targets of Wnt5A. Wnt5A targeted Rho-associated protein serine/threonine kinase (ROCK), 
leading to phosphorylation of LIM kinase-2 (LIMK2) and inactivation of the actin 
depolymerization factor cofilin-1 (CFL1). Functional experiments recording cytoskeletal 
rearrangements in living cells showed that Wnt5A enhanced stress fiber formation as a 
consequence of reduced actin depolymerization. The antagonist Wnt inhibitory factor 1 
(WIF1) that specifically interferes with the WIF domain of Ryk receptors prevented actin 
polymerization. Wnt5A disrupted -catenin and VE-cadherin adherens junctions forming 
inter-endothelial gaps. Functional experiments targeting the endothelial monolayer integrity 
and live recording of trans-endothelial resistance revealed enhanced permeability of Wnt5A-
treated HCAEC. Ryk silencing completely prevented Wnt5A-induced endothelial 
hyperpermeability. Wnt5A decreased wound healing capacity of HCAEC monolayers; this 
was restored by the ROCK inhibitor Y-27632.  
Conclusions—Here we show that Wnt5A acts on the vascular endothelium causing 
enhanced permeability through Ryk interaction and downstream ROCK/LIMK2/CFL1 
signaling. Wnt5A/Ryk signaling might provide novel therapeutic strategies to prevent capillary 
leakage in systemic inflammation and septic shock.   
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Non-standard Abbreviations and Acronyms 
 
CFL1  cofilin-1 
ECIS  Electric Cell-substrate Impedance Sensing 
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HCAEC human coronary artery endothelial cells 
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LIMK2  LIM kinase-2   
qRT-PCR quantitative Real Time-PCR 
ROCK  Rho-associated protein serine/threonine kinase 
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Sepsis is a systemic inflammatory response of the organism to an infection. The most 
serious manifestations of the disease are severe sepsis and septic shock with organ 
dysfunction and profound hypotension. The pathophysiology is highly complex and includes 
deregulation of the immune response, severe coagulopathy and endothelial dysfunction1. A 
small number of randomized clinical trials showed improved survival in septic patients; 
however three of these have been disproven in larger studies. The latest example has been 
trials with activated protein C, which lead to withdrawal of the drug from the market2. Despite 
optimized therapies with replacement of organ function using artificial systems, mortality 
remains high with a rate of 40-–70%1. The clinical manifestations of sepsis have a strong 
vascular component, predominantly seen as enhanced vascular leakage due to endothelial 
barrier dysfunction3, 4. 
During systemic inflammation, activated immune cells communicate with the vascular 
endothelium by release of and response to an array of inflammatory mediators5. 
Inflammatory mediators such as tumor necrosis factor and interleukin (IL)-1 were identified 
as responsible for disturbed endothelial function with increased leukocyte adhesion and 
transmigration, loss of control of systemic vascular tone, increased pro-coagulant activity and 
pronounced vascular leakage. Therapeutic trials targeting these inflammatory mediators 
have not been efficacious in treating human sepsis6-8. 
Recently, Wnt5A was identified as a novel chemokine highly induced and released following 
Toll-like receptor dependent inflammatory activation of human macrophages and was found 
in substantial quantities in sera of patients with severe sepsis9, 10. Wnt5A is one of the 
members of the Wnt family of secreted lipid modified signaling proteins. Wnt5A is capable of 
sustaining the inflammatory phenotype of macrophages through an autocrine mechanism 
involving Frizzled (Fzd)-5/CaMKII signaling. This pathway is a target for anti-inflammatory 
interventions in human macrophages9, 11. 
In systemic inflammation and sepsis, inflammatory mediators secreted by activated immune 
cells act paracrinically on endothelial cells1, 12, 13. Therefore, Wnt5A secreted by activated 
macrophages might act in a similar manner and contribute to endothelial dysfunction. A 
recent report indicates inflammatory activation of vascular endothelial cells may occur 
following Wnt5A exposure14 but the exact mechanism by which Wnt5A contributes to the 
inflammatory response of vascular endothelial cells still remain unclear. In the present study, 
we applied a genome-wide transcriptome analysis to define the targets and pathways of 
paracrine Wnt5A signaling in our established system of primary vascular endothelial cells, 
human coronary artery endothelial cells (HCAEC)5. IL-1, a leading inflammatory cytokine in 
the vascular system5, 15, was used in parallel as a comparison to Wnt5A and a control for 
integrity and proper biological function of our HCAEC system. Our study revealed that Wnt5A 
principally regulated genes involved in cytoskeleton rearrangement. This contrasted with IL-
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1, which predominantly affected pathways and genes associated with an immune response. 
We found that Wnt5A critically affects endothelial barrier function and cell migration. We 
identified the receptor Ryk and downstream Rho-associated protein serine/threonine kinase 
(ROCK)/LIM kinase 2 (LIMK2)/cofilin-1 (CFL1) signaling as the pathway responsible for 
Wnt5A-induced cytoskeletal changes in HCAEC. Targeting the Wnt5A/Ryk interaction by 
either knockdown of Ryk expression or using the Ryk specific soluble antagonist Wnt 
inhibitory factor 1 (WIF1) abolished cytoskeletal changes and endothelial hyperpermeability. 
Wnt5A/Ryk signaling might provide novel strategies for therapeutic intervention in systemic 
inflammation and sepsis.  
 
Materials and Methods 
 
Materials and methods are available in the online-only Data Supplement. 
 
 
Results 
 
Differential gene expression profiling reveals that Wnt5A predominantly affects genes 
involved in cytoskeleton rearrangements 
To define the genes regulated by Wnt5A treatment in HCAEC, we performed competitive 
two-color differential gene expression profiling. The transcriptome profiles of HCAEC treated 
with Wnt5A for 8 h were compared with that of untreated cells (cultured in parallel) using 
human whole genome oligomicroarrays. Transcriptome profiling of IL-1 treated HCAEC was 
performed using the same approach. The well-defined cytokine IL-1 was used to compare 
its inflammatory properties with the suspected but not elucidated effects of Wnt5A in the 
HCAEC system. GeneSpring analysis of the Wnt5A transcriptome in HCAEC revealed 9854 
genes, of which 3317 genes were upregulated and 6537 genes were downregulated. 
GeneSpring analyses comparing Wnt5A and IL-1 transcriptomes showed that 3188 genes 
were commonly regulated by both treatments (Figure 1A). The presence of common targets 
for Wnt5A and IL-1 points to an inflammatory action of Wnt5A in HCAEC. 
The list of two hundred genes highly regulated by Wnt5A and IL-1 is provided in Tables 1 
and 2 of the Online Supplement. Complete data sets for Wnt5A and IL-1 are available in the 
NCBI GEO data repository with accession number GSE62281. 
To identify the biological processes regulated by Wnt5A or IL-1 in HCAEC, Metacore gene 
ontology (GO) analyses were conducted. Using this tool, genes regulated at least 2-fold in 
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their expression were clustered on the basis of their function to generate statistically 
significant cellular pathways.  
Gene ontology cluster analysis of genes regulated by Wnt5A treatment of HCAEC were 
mainly associated with cytoskeleton remodeling pathways. The ―Cytoskeleton 
remodeling_TGF, WNT and cytoskeletal remodeling‖ appeared as the most significant 
pathway for Wnt5A (Figure 1B), but appeared as only 25th out of 50 pathways significant for 
IL-1 (not shown). Genes regulated by both Wnt5A and IL-1 (Table 1), such as MAPK13 
and LIMK2, were mainly concerned with actin polymerization and cytoskeleton remodeling. 
Among the genes specifically regulated by Wnt5A (Table 2), ARPC1B and CFL1 are involved 
in actin polymerization, CRK is involved in cell motility and several other genes are involved 
in angiogenesis. The ―Cell adhesion_Chemokines and adhesion‖ pathway was the second 
most statistically significant pathway for Wnt5A (Figure 1B), but it appeared as only 45th out 
of 50 pathways significant for IL-1 (not shown). In this pathway, Wnt5A-regulated genes 
were mainly associated with the cytoskeleton targets described above. Additionally, FLNA, a 
gene involved in branching of actin filaments, was downregulated by Wnt5A (Table 2).  
In contrast to Wnt5A, gene ontology cluster analysis of genes regulated by IL-1 were mainly 
associated with immune response pathways. The ―Immune response_HMGB1/RAGE 
signaling pathway‖ and ―Immune response_HSP60 and HSP70/TLR signaling pathway‖ were 
the first and second most significant pathways for IL-1 in HCAEC (Figure 1C) which 
involved the upregulation of NFB (Table 3). IL-1 significantly upregulated the expression of 
inflammatory mediators (IL-6, IL-8, CCL2; Online Supplement Table 2) and cell adhesion 
molecules (ICAM; Table 3) whereas the expression of these genes was not regulated by 
Wnt5A. This correlates with our qRT-PCR and flow cytometry analyses and thereby confirms 
that Wnt5A does not regulate the expression of cell adhesion molecules or proinflammatory 
cytokines in HCAEC (Online Supplement Figures 1, 2).  
 
Wnt5A receptors in HCAEC 
We previously described Wnt5A/Fzd5 signaling as an essential pathway maintaining the 
production of inflammatory mediators IL-1, IL-6 and IL-8 in human macrophages9. Since 
HCAEC did not respond to Wnt5A stimulation with the production of these ―Classical‖ 
inflammatory molecules or adhesion molecules, and Ryk and Ror2 are other receptors 
known to be involved in Wnt signaling pathways16, we checked which of these three 
receptors (Fzd5, Ryk or Ror2) is responsible for Wnt5A signaling in HCAEC. Using qRT-
PCR, we measured Fzd5, Ryk and Ror2 mRNAs expressed constitutively and upon Wnt5A 
or IL-1 treatment. Wnt5A treatment did not affect the mRNA levels of Fzd5 (Figure 2A) or 
Ryk (Figure 2B). In HCAEC treated with IL-1, Ryk mRNA was increased approximately 2-
7 
 
fold while no change was observed in the Fzd5 mRNA level (Figure 2A). We then measured 
Fzd5 and Ryk mRNA transcripts constitutively expressed in HCAEC. As shown in Figure 2C, 
Ryk mRNA expression is greater than six times the expression level of Fzd5 mRNA, the 
latter being very low. Ror2 mRNA expression was undetectable (data not shown). 
Immunofluorescence staining was performed to corroborate this finding and to verify if IL-1 
upregulates Ryk receptor protein in HCAEC. HCAEC constitutively express substantial 
amounts of Ryk protein and, consistent with regulation at the mRNA level, HCAEC treated 
with IL-1 expressed significantly more Ryk protein compared with the non-treated cells 
(Figure 2D, upper panel).  Constitutive Fzd5 protein expression was scant and remained 
unchanged with IL-1β treatment (Figure 2D, lower panel).  
 
Wnt5A phosphorylates LIMK2 and CFL1 proteins through ROCK activation 
Wnt5A mainly regulated the functional cluster of genes involved in endothelial actin 
cytoskeleton remodeling including the ROCK downstream targets LIMK2 and CFL1. LIMK2 is 
a serine/threonine/tyrosine kinase which, when phosphorylated by ROCK activation, 
phosphorylates the actin depolymerization factor CFL117-19. As Wnt/Planar Cell Polarity 
signaling involves the activation of ROCK20 and Wnt5A regulated LIMK2 and CFL1, we next 
checked if LIMK2 and CFL1 proteins are phosphorylated upon treatment with Wnt5A. 
HCAEC were treated with Wnt5A and the phosphorylated forms of both endogenous LIMK2 
and CFL1 were detected by immunofluorescence staining using specific antibodies to 
phosphorylated LIMK2 and CFL1. Amounts of fluorescent phosphorylated LIMK2 and CFL1 
in cells were further quantified using Fiji software. Compared with non-treated cells, a 
substantial increase in phosphorylated LIMK2 and CFL1 was observed in HCAEC treated 
with Wnt5A for 1 h and 4 h, respectively (Figure 3A–C).  
As LIMK2 and CFL1 are phosphorylated by the activation of ROCK17, 19, we next checked if 
inhibiting ROCK prevents their phosphorylation upon treatment with Wnt5A. Wnt5A-induced 
phosphorylation of both LIMK2 and CFL1 was notably suppressed when HCAEC were 
treated with a combination of Wnt5A and the ROCK-inhibitor Y-27632 (iROCK, Figure 3A–
C).   
 
Functional experiments in living cells reveal actin stress fiber formation upon Wnt5A 
treatment 
Since ROCK-mediated LIMK2 and CFL1 phosphorylation causes increased actin fiber 
bundling and stress fiber formation18, 19, 21, and Wnt5A induced phosphorylation of LIMK2 and 
CFL1, we next checked if Wnt5A causes actin stress fiber formation. Changes in actin 
arrangement and F-actin stress fiber formation were recorded in actin-RFP transduced cells. 
In non-treated HCAEC, an accumulation of non-fibrous g-actin in the perinuclear region was 
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obvious with few thin actin filaments present. In contrast to this, live actin-RFP showed 
significantly increased stress fiber formation in Wnt5A treated HCAEC. Similar changes were 
observed in cells treated with IL-1 (Figure 4A).  
We then checked if Wnt5A-induced stress fiber formation can be prevented by the Wnt 
antagonists secreted Frizzled-related peptide (sFRP) 1 and WIF1. sFRP1, a member of 
sFRP family, contains a cysteine-rich domain homologous to the Wnt binding extracellular 
domain of Fzd and Ror receptors. WIF-Wnt binding domains are homologous to the Wnt 
binding extracellular domain of Ryk16. Treatment of HCAEC with Wnt5A in the presence of 
sFRP1 did not prevent Wnt5A-induced F-actin stress fiber formation, whereas stress fiber 
formation was notably decreased when HCAEC were treated with a combination of Wnt5A 
and WIF1 (Figure 4A). This suggests the involvement of Ryk as an upstream receptor for 
ROCK in Wnt5A triggered cytoskeletal rearrangements in HCAEC. Stress fiber formation 
induced by IL-1 remained unaffected by the presence of sFRP1 and WIF1 (Figure 4A).  
 
Wnt5A disrupts adherens junction  proteins 
As increased stress fiber formation disrupts the assembly of -catenin and VE-cadherin 
adhesion proteins in adherens junctions or inter-endothelial junctions22, we next checked if 
Wnt5A disrupts these adhesion proteins in HCAEC. HCAEC monolayers were treated with 
Wnt5A for 8 h and the organization of -catenin and VE-cadherin were examined by 
immunofluorescence staining. IL-1 treatment served as a positive control in these 
experiments. In non-treated cells, -catenin and VE-cadherin were regularly distributed along 
the cellular periphery and formed tight contacts at cell borders (Figure 4B). Upon treatment 
with Wnt5A, -catenin and VE-cadherin were lost specifically at cell borders resulting in small 
holes and separations (gaps) between cells. Similar effects were observed in HCAEC treated 
with IL-1 (arrowheads, Figure 4B). 
 
Functional experiments targeting the monolayer integrity by live recording of trans-
endothelial resistance reveal enhanced permeability through Wnt5A/Ryk signaling  
Since Wnt5A disrupted inter-endothelial adherens junctions and induced the formation of 
intercellular gaps, we proposed that Wnt5A could impair the barrier functions and increase 
the permeability of an endothelial monolayer. To prove this, HCAEC monolayers cultured in 
8W10E+ electrode arrays were treated with Wnt5A and changes in trans-endothelial 
electrical resistance of the endothelial monolayer were recorded in real time by Electric Cell-
substrate Impedance Sensing (ECIS). Upon treatment with Wnt5A, there was a significant 
decrease in the resistance of HCAEC monolayers to alternating current. The Wnt5A-induced 
changes in electrical resistivity became significantly evident after 3 h after the addition of 
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Wnt5A and lasted for more than 10 h. Likewise, treatment with IL-1 significantly decreased 
the resistance of HCAEC monolayers (Figure 5A). Our data indicate that inflammatory 
activation of HCAEC with Wnt5A or IL-1 affects endothelial barrier function and increases 
monolayer permeability. 
Since HCAEC express constitutively high levels of Ryk, and the Ryk specific Wnt antagonist 
WIF1 diminished Wnt5A-induced endothelial stress fiber formation, we checked if silencing 
Ryk expression would prevent Wnt5A induced hyperpermeability of HCAEC monolayers. To 
silence Ryk expression, HCAEC were transfected with Ryk-specific siRNA. Additionally, 
HCAEC were transfected with highly validated negative control siRNA to detect off target 
effects caused by siRNA or transfection reagents. To prove the efficiency of Ryk knockdown, 
Ryk mRNA expression was compared by qRT-PCR in cells transfected with Ryk-siRNA and 
in cells transfected with negative control siRNA. Ryk mRNA expression was approximately 
70% lower in cells transfected with Ryk-siRNA than in cells transfected with negative control 
siRNA (Online Supplement Figure 3A). Immunofluorescence staining further confirmed that 
Ryk-siRNA transfected HCAEC expressed significantly lower amounts of Ryk receptor 
compared with cells transfected with negative control siRNA (Online Supplement Figures 3B, 
3C). These results prove that efficient and specific silencing of Ryk was achieved in HCAEC.  
Next, Ryk-silenced HCAEC were seeded onto 8W10E+ electrode arrays, treated with Wnt5A 
or IL-1 and changes in trans-endothelial electrical resistance were measured in real time by 
ECIS. Treatment with Wnt5A did not alter the resistance of Ryk-silenced HCAEC. In contrast, 
IL-1 significantly decreased the resistance of Ryk-silenced HCAEC (Figure 5B). This result 
confirms that Wnt5A specifically signals through Ryk in HCAEC.   
 
Wnt5A-impaired motility of endothelial cells is restored by ROCK inhibition 
Since Wnt5A induced stress fiber formation and impaired the barrier function of endothelial 
monolayers, we hypothesized that Wnt5A could also affect the motility of endothelial cells. 
An ECIS assisted wounding assay was used to investigate whether Wnt5A influences the 
motility of HCAEC. HCAEC monolayers on single electrode (8W1E) arrays were treated with 
Wnt5A and subjected to electric current that killed cells in a defined area of the electrode and 
created a wound of standard size. The migration of viable cells to the wounded area was 
recorded in real time by ECIS. Treatment with Wnt5A significantly reduced the number of 
cells migrating to the wounded area (indicated by a significant decrease in impedance) 
resulting in delayed wound closure. A similar effect was observed in HCAEC treated with IL-
1 whereby cell migration and subsequent wound closure were significantly affected (Figure 
6A) 
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We have shown that Wnt5A-induced phosphorylation of LIMK2 and CFL1 could be 
suppressed by inhibiting ROCK. ROCK is involved in a variety of cellular processes including 
cell motility, actin cytoskeleton rearrangements and cell adhesion19. Therefore, we 
investigated whether inhibiting ROCK prevents Wnt5A-induced impairment of HCAEC 
motility in an ECIS assisted wounding assay. HCAEC treated with a combination of Wnt5A 
and the ROCK inhibitor Y-27632 showed significant increase in cell motility and faster wound 
closure compared with HCAEC treated with Wnt5A in the absence of ROCK inhibitor. Similar 
effects were observed in HCAEC treated with a combination of IL-1 and Y-27632 (Figure 
6B). This data further indicate that ROCK is involved in Wnt5A/Ryk signaling in HCAEC.  
 
 
Discussion 
 
Using a genome-wide expression survey, we characterized the targets and determined the 
biological function of paracrine inflammatory Wnt5A signaling in a tightly controlled system of 
adult human vascular endothelial cells. Our study reveals that Wnt5A primarily regulates 
genes involved in actin cytoskeleton rearrangements in endothelial cells. We have identified 
a novel Wnt5A/Ryk signaling mechanism that targets the ROCK/LIMK2/CFL1 axis to induce 
cytoskeleton remodeling and barrier dysfunction in vascular endothelial cells. Gene 
expression profiling of IL-1 performed in parallel showed that IL-1 mainly regulates genes 
and pathways associated with immune responses, thereby confirming previous findings5. The 
response to IL-1 proves the integrity of biological functions in our HCAEC system. 
Our previous study revealed that Wnt5A signals through Fzd5 to cause inflammatory 
activation of human macrophages9. In this study, we found that HCAEC constitutively 
express high levels of Ryk, and only trace amounts of Fzd5 (Figures 2C, 2D), thereby 
suggesting that Wnt5A could exert its function without upregulating the level of endogenous 
Ryk receptors. We further found that Wnt5A-induced stress fiber formation can be prevented 
by WIF1, thereby pointing to the involvement of Ryk as the receptor for Wnt5A-mediated 
cytoskeleton remodeling in HCAEC (Figure 4A). Additionally, the transcriptome analysis of 
the current study shows that Wnt5A downregulates the expression of LRP5 (Table 1). Since 
LRP5 acts as a co-receptor for Fzd5 in -catenin dependent signaling20, 23, the Wnt/ -catenin 
pathway involving Fzd receptors could be repressed by Wnt5A in HCAEC. This is supported 
by our finding that -catenin remains sequestered on the plasma membrane of HCAEC after 
Wnt5A treatment and is not transported to the nucleus (Figure 4B) to signal via the -catenin 
pathway. The subsequent functional experiments demonstrate that Wnt5A induced HCAEC 
barrier impairment can be prevented by silencing Ryk expression, thereby providing direct 
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evidence that Wnt5A signals through Ryk (Figure 5). Ryk is a member of the family of 
atypical receptor tyrosine-protein kinases. It comprises an extracellular Wnt binding domain, 
a PDZ binding motif and an intracellular atypical kinase domain lacking tyrosine kinase 
activity. Wnt5A/Ryk signaling has been functionally demonstrated in adult rat corticospinal 
axons24. Moreover, Derailed, a member of the Ryk family of receptors in Drosophila, has 
been described as acting as a receptor for Wnt5A in axon guidance25. Furthermore, 
abundant expression of the Ryk gene was reported in mouse pulmonary capillary endothelial 
cells.26 Data obtained in the present study indicate that Wnt5A signaling via ROCK activation 
induces actin cytoskeletal rearrangements and disrupts VE-cadherin-mediated intercellular 
adhesion. The involvement of Ryk but not other known Wnt receptors such as Fzd or Ror is 
further evident from the observation that Wnt5A induced actin stress fiber formation was 
prevented by the Ryk specific antagonist WIF1, while sFRP1 was uneffective (Figure 4A). 
Previous studies have already established that inactivation of ROCK and RhoA prevents 
endothelial hyperpermeability27, 28. 
Our study reveals that Wnt5A decreases the motility of HCAEC and combining Wnt5A with 
the ROCK inhibitor Y-27632 restores the migratory capacity of HCAEC (Figure 6). This is in 
full accordance with the proposed model of Wnt5A/Ryk signaling. The reduction in 
endothelial cell motility caused by Wnt5A is due to actin cytoskeleton rearrangements and 
increased stress fiber formation (Figure 4A) induced by ROCK mediated phosphorylation of 
LIMK2 and CFL proteins (iROCK, Figure 3A–C).  
Our study further demonstrates that IL-1 signaling significantly upregulates Wnt5A 
expression in HCAEC (Online Supplement Figure 4). Addressing the question of which 
transcription factors are involved in mediating IL-1 -induced expression of Wnt5A in 
endothelial cells, we found that IL-1 upregulated NF-κB (Table 3). As IL-1 induces Wnt5A 
in HCAEC, it can be inferred that IL-1 secreted by activated macrophages in systemic 
inflammation and sepsis paracrinically triggers endogenous Wnt5A signaling in vascular 
endothelial cells. Our present study further proves that Wnt5A, unlike IL-1, does not induce 
a cytokine storm (IL-6, IL-8, CCL2; Online Supplement Figure 1) or cell adhesion molecules 
(ICAM-1, VCAM-1; Online Supplement Figure 2) in endothelial cells as has been reported 
previously14. Data from our genome-wide transcriptome analysis and functional studies 
indicate that Wnt5A/Ryk signaling in HCAEC is independent of the induction of any other 
inflammatory mediators. The biological integrity of the cells in our system is proven by the 
typical inflammatory response to IL-1 (Online Supplement Figures 1, 2).                                              
Wnt5A expression is elevated in sepsis9 and our present study finds Wnt5A as a critical 
mediator of endothelial hyperpermeablity. This warrants further studies to determine the 
correlation of Wnt5A levels with vascular leakage in appropriate septic animal models. 
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However, current sepsis animal models fail to mimic the human disease for a number of 
reasons, and most of the highly successful trials in animal models did not improve patient 
survival when translated to clinical settings12, 29.  
In conclusion, the present study shows for the first time that Wnt5A/Ryk signaling impairs the 
barrier functions and affects the wound healing of a damaged monolayer of human vascular 
endothelial cells. This suggests that Wnt5A, secreted by activated macrophages during a 
systemic inflammatory response, could cause capillary leakage and subsequent edema  in 
severe sepsis. Restoring vascular integrity along with reducing edema is an established 
factor that improves the prognosis of septic shock. Considering the essential role for 
Rho/ROCK in Wnt5A signaling in adult human vascular endothelial cells, therapeutic 
approaches targeting the Wnt5A/Ryk/ROCK signaling pathway would probably improve the 
prognosis of sepsis.  
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Significance  
Vascular leakage in severe systemic inflammation and septic shock is one of the major 
reasons that mulitiorgan failure occurs. With still no good treatment option available it can 
lead to death in these patients. There is limited knowledge concerning the pathophysiology 
leading to this leakage and so there are no targeted treatment options. Wnt5A/Ryk signaling 
in human vascular endothelial cells affects the endothelial cytoskeleton, disrupts inter-
endothelial junction assembly, affects endothelial migration, and enhances monolayer 
permeability causing barrier dysfunction. The Wnt5A/Ryk pathway described here might 
provide potential novel targets for therapeutic interventions in severe systemic inflammatory 
diseases and septic shock.  
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Tables 
 
Table 1. Genes regulated by both Wnt5A and IL-1 in ―Cytoskeleton remodeling_TGF, WNT 
and cytoskeletal remodeling‖ and ―Cell adhesion_Chemokines and adhesion‖ pathways. 
 
Gene 
symbol 
Accession number Sequence description 
Regulation 
Wnt5A IL-1 
LIMK2
*† 
NM_001031801 Homo sapiens LIM domain kinase 2 Down Up 
LRP5
*
 NM_001291902 
Homo sapiens low density lipoprotein 
receptor-related protein 5 
Down Down 
MAPK12
* 
 
NM_002969 
 
Homo sapiens mitogen-activated protein 
kinase 12 
Down Down 
MAPK13
* 
 
NM_002754 
 
Homo sapiens mitogen-activated protein 
kinase 13 
Down Down 
MMP1
† 
NM_002421 
Homo sapiens matrix metallopeptidase 
1 
Up Up 
PLAU
*†
 
 
NM_001145031 
 
Homo sapiens plasminogen activator, 
urokinase 
Down Up 
TAB1
*
 NM_006116 
Homo sapiens TGF-beta activated 
kinase 1 
Down Down 
 
* Genes regulated in ―Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling‖ 
pathway. 
† Genes regulated in ―Cell adhesion_Chemokines and adhesion‖ pathway. 
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Table 2. Genes regulated only by Wnt5A in ‗‗Cytoskeleton remodeling_TGF, WNT and 
cytoskeletal remodeling‖ and ―Cell adhesion_Chemokines and adhesion‖ pathways. 
 
Gene 
symbol 
Accession number Sequence description Regulation 
AKT2
*†
 NM_001626 
Homo sapiens v-akt murine thymoma viral 
oncogene homolog 2 
Down 
ARPC1B
*†
 NM_005720 
Homo sapiens actin related protein 2/3 complex, 
subunit 1B 
Down 
CDKN1A
*
 NM_078467 
Homo sapiens cyclin-dependent kinase inhibitor 
1A  
Down 
CFL1
*† 
NM_005507 Homo sapiens cofilin-1  Down 
CRK
*†
 NM_016823 
Homo sapiens v-crk sarcoma virus CT10 
oncogene homolog (avian)  
Down 
FLNA
†
 NM_001110556 Homo sapiens filamin A Down 
MAPK3
*†
 NM_002746 
Homo sapiens mitogen-activated protein kinase 
3 
Down 
MAPK11
*
 
 
NM_002751 
Homo sapiens mitogen-activated protein kinase 
11  
Down 
MAPK14
*
 NM_139013 
Homo sapiens mitogen-activated protein kinase 
14 
Down 
TSC2
*
 NM_000548 Homo sapiens tuberous sclerosis 2 Down 
 
* Genes regulated in ―Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling‖ 
pathway 
† Genes regulated in ―Cell adhesion_Chemokines and adhesion‖ pathway 
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Table 3. Genes regulated by IL-1 in ―Immune response_HMGB1/RAGE signaling pathway‖ 
and ―Immune response_HSP60 and HSP70/TLR signaling pathway‖. 
 
Gene 
symbol 
Accession number Sequence description Regulation 
ATF2
†
 NM_001880 Homo sapiens activating transcription factor 2 Up 
CCL4
* 
NM_002984 Homo sapiens chemokine (C-C motif) ligand 4 Up 
ICAM1
*†
 NM_000201 Homo sapiens intercellular adhesion molecule 1 Up 
IL-1
*
 NM_000575 Homo sapiens interleukin 1, alpha Up 
MAP2K6
*†
 NM_002758 
Homo sapiens mitogen-activated protein kinase 
kinase 6 
Down 
NFB1
*†
 NM_003998 
Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 
Up 
NFB2
*† 
NM_001077493 
Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 2 
Up 
NFBIA
*†
 
 
NM_020529 
Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, 
alpha 
Up 
NFBIE
*† 
 
NM_004556 
Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, 
epsilon 
Up 
SERPINE1
*
 NM_000602 
Homo sapiens serpin peptidase inhibitor, clade 
E (nexin, plasminogen activator inhibitor type 1), 
member 1 
Up 
TLR2
*†
 NM_003264 Homo sapiens toll-like receptor 2 Up 
 
* Genes regulated in ―Immune response_HMGB1/RAGE signaling pathway‖ 
† Genes regulated in ―Immune response_HSP60 and HSP70/TLR signaling pathway‖ 
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Figure 1. Whole genome expression survey of the inflammatory response of HCAEC to 
IL-1 and Wnt5A. (A) Venn diagram summarizing different and common genes regulated by 
IL-1 and Wnt5A in HCAEC. Feature extracted data was analyzed using GeneSpring under 
“Biological significance” work flow. Red circle, IL-1 specific genes; blue circle, Wnt5A 
specific genes; intersection, genes regulated by both Wnt5A and IL-1. (B, C) GO pathway 
maps of regulated genes clustered according to biological processes. Pathways represented 
as histograms are ranked by the –log value (P value). Length of histogram corresponds to 
the number of genes associated with that specific pathway. Maps of the ten most significant 
processes regulated by (B) Wnt5A, corresponding to genes within blue circle of Venn 
diagram and (C) IL-1, corresponding to genes within the red circle of Venn diagram. 
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Figure 2 
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Figure 2. Expression of Fzd5 and Ryk receptors in HCAEC. Expression of mRNA levels 
of (A) Fzd5 and (B) Ryk in HCAEC treated with Wnt5A and IL-1 (IL-1b) for 8 h as outlined in 
Methods. Data were obtained from three independent qRT-PCR experiments with duplicate 
samples and expressed as the mean ± S.E.M. *P<0.05 by Student’s t-test. (C) Quantitative 
ratio of constitutive levels of Fzd5 and Ryk mRNAs in HCAEC. *P<0.05 by Student’s t-test. 
(D) Protein expression of Fzd5 and Ryk receptors in HCAEC either untreated (left panel) or 
treated with IL-1 (IL1) 24 h. Images show immunofluorescence staining using specific 
antibodies for Fzd5 and Ryk (red), F-actin (phalloidin, green) and nuclei (DAPI, blue). Zeiss 
Axioskope, magnification 200 fold.  
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Figure 3. Effects of ROCK inhibition on Wnt5A-induced phosphorylation of LIMK2 and 
cofilin-1. Immunofluorescence staining of (A) phosphorylated LIMK2 and (B) phosphorylated 
cofilin-1 (both in red) and nuclei (blue) in HCAEC treated with either Wnt5A alone or in 
combination with the ROCK inhibitor Y-27632 (iROCK1) for 1 h and 4 h respectively. Zeiss 
Axioskope, magnification 200 fold. (C) Mean cellular fluorescent intensities of phosphorylated 
LIMK2 and cofilin-1 quantified by ImageJ based Fiji software. pLIMK2, phosphorylated 
LIMK2; pCofilin-1, phosphorylated cofilin-1. 
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Figure 4. Actin stress fiber formation and adherens junction disruption in HCAEC in 
response to Wnt5A and IL-1. (A) Actin stress fibers stained by live actin-RFP in HCAEC 
either untreated (left panel) or treated with Wnt5A (middle panel) or IL-1 (IL-1, right panel), 
in the absence or presence of sFRP1 or WIF. Stained cells were captured at 8 h after 
treatment using a Zeiss Axio Observer.Z1, magnification 400 fold. (B) Immunofluorescence 
staining for -catenin and VE-cadherin (red) in HCAEC treated with either Wnt5A or IL-1 (IL-
1) for 8 h. Nuclei are stained blue. Arrowheads point to inter-endothelial gaps. Zeiss 
Axioskope, magnification 400 fold. 
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Figure 5. ECIS barrier function assays in HCAEC. Uniform confluent monolayers of 
HCAEC cultured in stabilized and collagen coated 8W10E+ ECIS culture chambers (see 
Methods and Figure 5 of Online Supplement) were treated with Wnt5A and IL-1. Resistance 
of HCAEC monolayers was continuously recorded in Ohms every 5 min at multiple 
frequencies ranging from 62.6 Hz to 64 kHz, normalized to its value at time zero, and plotted 
with respect to time. Resistance measured from duplicate wells were grouped and averaged 
to plot as a single curve with error bars representing the SD. Data shown are the resistance 
measurements conducted at 4000 Hz from four independent experiments. (A) Un transfected 
HCAEC. Black, Untreated; Green, Wnt5A; Purple, IL-1. (B) Ryk siRNA transfected HCAEC. 
Black, Untreated; Green, Wnt5A; Purple, IL-1.  
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Figure 6. ECIS assisted wound healing assay. Uniform confluent monolayers of HCAEC 
cultured in stabilized and collagen coated single electrode 8W1E ECIS culture chambers 
(Methods, Online Supplement) were treated with Wnt5A and IL-1 either alone or in 
combination with the ROCK inhibitor Y-27632 for 3 h. At time 0 h, a defined wound with a 
diameter of 250 µm was created in each of the eight wells by applying an elevated electric 
field at 1400 μA, 60 kHz for 20 sec. Immediately after wounding, impedance of HCAEC was 
continuously recorded in Ohms every 5 min at multiple frequencies ranging from 62.6 Hz to 
64 kHz and plotted with respect to time. Data shown represent the measurements conducted 
at 4000 Hz from four independent experiments. (A) HCAEC without ROCK inhibition. Red, 
Untreated; Purple, Wnt5A; Green, IL-1. (B) HCAEC with ROCK inhibition. Black, Control 
with Y-27632; Red, Wnt5A+Y-27632; Green IL-1+Y-27632. 
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Materials and Methods 
 
Cell Culture 
HCAEC (Clonetics, Lonza, Switzerland) were propagated in EBM-2 medium (Clonetics, 
Lonza) supplemented with EGM-2MV Single Quots with 5% FBS (Clonetics, Lonza) as 
described1. Cells were cultured under standard conditions (37C, 5% CO2, 80% humidity) in 
a Class 100 HEPA air filtered system (SteriCult, Fisher Scientific, Switzerland). To avoid 
masked low-level contamination in cultures, culture medium without antibiotics was used 
throughout the study. In experimental settings, cells from passages three to six were used 
and serum concentration of the medium was reduced to 2% FBS. HCAEC were treated with 
recombinant human/mouse Wnt5A (250 ng/mL; CHO-derived Gln38-Lys380, purity >80%, 
endotoxin level <1.0 EU/µg of protein; Cat. No. 645-WN, R&D systems, USA), recombinant 
human IL-1 (20 U/mL; purity >98%; PeproTech, USA), recombinant human secreted 
Frizzled-related peptide (sFRP)1 (10 μg/mL; purity >95%; Cat. No.1384-SF, R&D systems, 
USA), recombinant human WIF1 (15 μg/mL; purity >97%; Cat. No. 1341-WF-050, R&D 
systems, USA). For all pipetting steps,  Biopure ep Dualfilter T.I.P.S. sterile filter tips 
(Eppendorf, Germany) were used.  
 
RNA Isolation and Quantitative Real Time-PCR (qRT-PCR) Analyses 
RNA isolation and qRT-PCR were performed as described2 with the following modifications 
and primers. RNA was reverse transcribed into cDNA using TaqMan® Kit (Applied 
Biosystems, USA). qRT-PCR was performed using Fast SYBR® Green Master Mix and a 
7500 Fast Real-Time PCR System (Applied Biosystems, USA). Relative quantification 
analyses were performed with HPRT gene as endogenous control using RQ Study SDS 
software v1.4 (Applied Biosystems, USA). Sequence specific PCR detection primers used for 
Wnt5A, IL-6, IL-8, HPRT, MCP-1, ICAM-1, Ryk and Fzd5 are as follows: Wnt5A forward, 5'-
AGT TGC CTA CCC TAG C-3'; Wnt5A reverse, 5'-GTG CCT TCG TGC CTA T-3'; IL-6 
forward, 5’-CCT GAC CCA ACC ACA AA-3’; IL-6 reverse, 5’-AGT GTC CTA ACG CTC ATA 
C-3’; IL-8 forward, 5’-AGA CAG CAG AGC ACA CAA GC-3’; IL-8 reverse, 5’-ATG GTT CCT 
TCC GGT GGT-3’; HPRT forward, 5’-CCA GTC AAC AGG GGA CAT AAA-3’; HPRT 
reverse, 5’-CAC AAT CAA GAC ATT CTT TCC AGT-3’; MCP-1 forward, 5’-CAG CCA GAT 
GCA ATC AAT GC-3’; MCP-1 reverse, 5’-GTG GTC CAT GGA ATC CTG AA-3’; ICAM-1 
forward, 5’-TTG GAA GCC TCA TCC G-3’; ICAM-1 reverse, 5’-CAA TGT TGC GAG ACC C-
3’; Ryk forward, 5’-TGC CCT CTC CAG AGA CTT GT-3’; Ryk reverse, 5’-CAT CTC GAA 
GGG GTC AAT GT-3’; Fzd5 forward, 5’-CAT CGA CAT GGA ACG C-3’; Fzd5 reverse, 5’-
CGT GAT GGA CTT GAC GC-3’. Temperature cycling conditions of the PCR were as 
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follows; an initial denaturation step (10 min, 95°C) followed by 40 cycles of denaturation (15 
sec, 95°C), annealing (30 sec, 55°C), and extension (30 sec, 72°C).  
Constitutively expressed mRNA levels of Fzd5 and Ryk in HCAEC were calculated by the 
1/ΔCt method and values were given as arbitrary units.  
 
Microarray Based Differential Gene Expression Profiling  
Gene expression profiling by competitive two-color hybridization of cRNA probes onto 4×44K 
Human Whole Genome Oligonucleotide microarrays (Agilent Technologies) was performed 
as described3. Briefly, total RNA was isolated using RNeasy Mini Kit (Qiagen, Basel, 
Switzerland). Total RNA was quantified by Nanodrop spectrophotometry and RNA integrity 
was confirmed using the Agilent 2100 Bioanalyzer System (Agilent Tech., Basel, 
Switzerland). Only RNA samples with a RNA integrity number (RIN) >9 were used for 
microarray experiments.  From each sample, 500 ng of total RNA was reverse transcribed 
and labeled with Cy3- and Cy5-CTP using the two-color Quick Amp Labeling Kit (Agilent 
Tech., Switzerland), containing internal control probes and spike in’s (labeled Spike A mix 
with Cy-3 and Spike  B mix with Cy-5) for control of reaction performance and background 
normalization of arrays. cRNA fragmentation and hybridization onto the Human GE 4×44K 
V2 Microarray chips were performed as per the Quick Amp Labeling protocol (Agilent 
Techno., version 5.7, 2008). To avoid ozone-induced deterioration of cyanine dyes, array 
chips were washed with stabilization and drying solution (Agilent Tech., Switzerland).  
 
Microarray Data Analyses 
Scanning, feature extraction and preprocessing including data normalization of the 
microarrays were done by Microarray Scanner and Feature Extraction Software 10.7 (Agilent 
Tech. Inc.) with default settings for Agilent 4×44 K two-color arrays. The preprocessed data 
was further analyzed using GeneSpring GX 9.0 Software (Agilent Tech. Inc.) with default 
settings for two-color arrays using fold change cutoff of 1.5. Gene ontology analysis was 
performed using Metacore GeneGO software (Thomson Reuters, http://portal.genego.com). 
Genes regulated ≥2-fold in their expression and satisfying a P value <0.05 were grouped into 
pathways according to their biological functions and gene ontology classes. 
 
Immunofluorescence Staining 
HCAEC were cultured in four-chamber culture slides coated with rat tail collagen type I 
(diluted 0.01% in sterile pyrogen-free water; BD Biosciences, USA).  To stain for the 
adherens junction proteins β-catenin and VE-cadherin, HCAEC were grown to a confluent 
monolayer. After treatment with the stimuli indicated, cells were fixed with 4% formalin in 
PBS (in case of detecting adherens junction proteins) for 20 min or with a mixture of acetone 
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and methanol (1:1) for 5 min (in case of Fzd5, Ryk and Wnt5A detection). Slides were 
washed three times with PBS (pH 7.4) at room temperature (RT). Slides were treated with 
blocking solution containing 10% goat serum and 1% BSA in PBS for 1 h at RT in case of 
secondary antibodies derived from goat. Rabbit blocking solution (10% rabbit serum and 1% 
BSA in PBS) was used in case of secondary antibodies derived from rabbit. Slides were 
again washed with PBS at RT and incubated with primary antibodies diluted in blocking 
solution at 4°C overnight. The following antibodies were used for immunofluorescence: goat-
anti-Wnt5A (1:50; Cat. No. AF645, R&D Systems), rabbit-anti-Ryk (1:500; Product No. 
Ab5518, Abcam), rabbit-anti-Fzd5 (1:100; Product No. Ab14475, Abcam), rabbit-anti--
catenin (1:150; Product No. 9562, Cell Signaling Technology), rabbit-anti-VE-cadherin 
(1:100; Product No. 2158, Cell Signaling Technology), rabbit-anti-phosphorylated LIMK2 
(1:300; pT505; Product No. Ab131343, Abcam), rabbit-anti-phosphorylated CFL1 (1:500; 
pS3; Product No. Ab100836, Abcam). After three washes with PBS at RT, slides were 
incubated with Alexa 568 labeled goat anti-rabbit or rabbit anti-goat secondary antibodies 
(1:2000; Molecular Probes, Invitrogen, USA) depending on the first antibody’s species. 
Incubations with secondary antibodies were combined with Alexa Fluor 488 Phalloidin (1:80; 
Molecular Probes, Invitrogen, USA) for 1 h at RT in the dark. After three washes with PBS at 
RT, slides were counterstained with 10 μg/mL diamidino-phenylindole (DAPI; Sigma-Aldrich) 
and mounted using ProLong Gold AntifadeR (Life Technologies, USA). Images were captured 
by Axioskope microscope equipped with an Axio-CamMRm digital camera using AxioVision 
Rel.4.6 software (Carl Zeiss, Feldbach, Switzerland). The intensity of cellular fluorescent 
signals was quantified from five different positions of the respective fluorescent images using 
ImageJ based Fiji software (Fiji is Just ImageJ) and corrected for background fluorescence.  
 
Live Cell Imaging of Actin  
HCAEC grown in rat tail collagen type I coated optical 96 microwell culture plates 
(Thermoscientific, USA) were transduced with CellLight Actin-RFP probe (Cat. No. C10583, 
Life Technologies, USA) as per manufacturer’s instructions. Cells were treated with Wnt5A or 
IL-1 alone or in combination with either sFRP1 or WIF1 for 8 h. Images of the cultures were 
captured with an Axio Observer.Z1 inverted microscope equipped with Axio-Cam MRm 
digital camera using ZEN 2012 software (Carl Zeiss, Feldbach, Switzerland).  
 
Endothelial Barrier Function Assays 
The response of endothelial barrier to a particular stimulus can be assessed non-invasively 
in a fully standardized manner by continuously recording changes in trans-endothelial electric 
resistance using Electric Cell-substrate Impedance Sensing (ECIS)4, 5. Endothelial barrier 
function was recorded in real-time using the ECIS Z Theta system (Applied Biophysics) with 
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associated software v.1.2.126 PC, as described6 with the following modifications.  8W10E+ 
electrode chamber arrays were equilibrated with EBM-2 basal medium (Clonetics, Lonza, 
USA) for 24 h and coated with rat tail collagen type I (diluted 0.01% in sterile pyrogen-free 
water; BD Biosciences, USA) for 12 h. Then HCAEC in EGM2MV complete medium 
(Clonetics, Lonza, USA)  were added to the wells with a density of 80,000- 90,000 cells/well 
and grown up to 24 h to form  dense monolayers (Supplemental Figure 5). Treatments were 
then conducted by replacing the medium with fresh medium without or with stimuli (Wnt5A, 
IL-1). Measurements were conducted at multiple frequencies ranging from 62.6 Hz to 64 
kHz. 8W10E+ contains 40 electrodes per each of its eight wells that traced the cells at 40 
different locations in each well and averaged the measurements.   
 
ECIS Assisted Cell Migration Assay 
Motility/wound healing assays were performed in ECIS single electrode arrays as described7 
with the following modifications. 8W1E single electrode chambers were equilibrated with 
EBM-2 basal medium (Clonetics, Lonza, USA) for 24 h and coated with rat tail collagen type I 
(BD Biosciences, USA) for 12 h. HCAEC in EGM2MV complete medium (Clonetics, Lonza, 
USA) were added to the wells with a cell a density of 80,000- 90,000 cells/well. To attain 
confluent HCAEC monolayers, single electrode array chambers were further incubated for up 
to 24 h. Stimuli were then added as described above for barrier function assays.  3 h after 
stimulation, wounding was activated with default conditions for 8W1E arrays (1400 μA, 
60000 Hz, for 20 sec). This fully standardized method produces a highly reproducible wound 
with an exact diameter of 250 µm surrounded by undamaged living cells in 8W1E chambers. 
After wounding, impedance was continuously recorded to observe the migration of cells and 
formation of confluent monolayer within the defined wounded area.  
 
Ryk Silencing 
Specific and functionally validated small interfering RNA (siRNA) against human Ryk (Hs-
RYK-9, Cat No. SI02223074) was obtained from Qiagen. To control for “off target” effects of 
siRNAs, validated AllStars negative control siRNA (Qiagen) with no homology to any 
mammalian gene was used. For knockdown of Ryk expression, transfection complexes 
formed of Ryk-siRNA (5 nM) and 6 μL/mL HiPerFect Transfection reagent (Qiagen GmbH, 
Hilden, Germany) in EBM-2 basal medium were added to 80% confluent cultures of HCAEC 
in 24-well plates  in a total volume of 500 μL/well. After 24 h of incubation, transfected cells 
were split using Trypsin EDTA, seeded onto collagen coated 6 well plates, retransfected for a 
second round as above and incubated until the cells attained 90% confluency. At this stage, 
cells were either stimulated with Wnt5A or IL-1 for 8 h and lysed (for qRT-PCR analyses) or 
trypsinized and transferred into collagen-coated 8W10E+ arrays (for ECIS barrier function 
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measurements). Alternatively, HCAEC after one round of Ryk-siRNA transfection were 
harvested by trypsinization and seeded into collagen-coated BD Falcon 4 chamber culture 
slides (BD Biosciences, USA). There, a second round of Ryk-siRNA transfection was 
performed as in 24-well plates. After growing to a confluent monolayer, cells were fixed for 
immunostainings. Stimulations were carried out in complete EGM medium with 2% FBS 
devoid of transfection complexes. 
 
ROCK Inhibition  
To inhibit ROCK activity, Y-27632 (Cat. No. 688000, Calbiochem; Millipore, USA) was used8 
at an optimal concentration for this system of 10 mol/L. HCAEC were incubated in medium 
containing Y-27632 (10 μmol/L) alone or in combination with either Wnt5A or IL-1 for 1 h 
and 4 h. 
 
Flow Cytometry 
HCAEC stimulated with Wnt5A, IL-1 or combination of these two agents for 24 h were 
trypsinized and resuspended in PBS supplemented with 0.1% BSA (sample buffer) such that 
cell density did not exceed more than 105 cells/tube. Cells were incubated on ice with directly 
labeled mouse antibodies against human VCAM-1 (CD106, fluorescein isothiocyanate label, 
BD pharmingen), ICAM-1 (CD54, phycoerithrin labeled, BD pharmingen), E selectins 
(CD62E, allophycocyanin label, BD pharmingen) and human integrin b1 chain (CD29, 
allophycocyanin label, BD pharmingen) at a final concentration of 2 μg/ml. Isotype controls 
were performed using mouse IgG polyclonal antibodies. After washing twice with FACS 
buffer, samples were analyzed using FACS CantoII cell sorting system (BD Biosciences, 
Allschwil, Switzerland). Cells were gated according to their forward- and side-scatter pattern, 
at least 10’000 gated events were acquired for analysis. The fluorescence intensity of 
corresponding samples labeled with the isotype control antibody was used to set the 
individual threshold of antigen positivity. Data were analyzed using FlowJo 7.2.5 software.  
 
Statistical Analysis 
Data were analyzed using GraphPad Prism software version 5.04 (GraphPad Software, San 
Diego, CA). An unpaired 2-tailed Student’s t-test was used and differences were considered 
statistically significant at P<0.05. 
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SUPPLEMENTAL MATERIAL 
 
 
SUPPLEMENTAL RESULTS 
 
Effects of Wnt5A on the Expression of Pro-inflammatory Cytokines  
To investigate whether Wnt5A regulates the expression of pro-inflammatory cytokines, 
HCAEC were treated with Wnt5A (250 ng/mL) for 4 h and 8 h and the regulation of IL-6, IL-8 
and MCP-1 mRNA levels were analyzed by qRT-PCR. In parallel, HCAEC were treated with 
IL-1 for 4 h and 8 h to validate the biological function of the system. Expression of IL-6 was 
not significantly regulated by 4 h and 8 h Wnt5A treatments (Online Supplement Figure 1A). 
Similarly, HCAEC treated with Wnt5A for 4 h and 8 h showed no significant difference in the 
expression of IL-8 compared with non-treated cells (Online Supplement Figure 1B). Upon 
Wnt5A treatments for 4 h, but not 8 h, the expression of MCP-1 was significantly upregulated 
in HCAEC (Online Supplement Figure 1C).  
Treatment with IL-1 significantly upregulated the expression of IL-6, IL-8 and MCP-1 in 
HCAEC. The highest expression of IL-6 was observed 4 h after IL-1 treatment (Online 
Supplement Figure 1D), whereas the expression level of induced IL-8 remained unchanged 
after 4 h and 8 h IL-1  treatments (Online Supplement Figure 1E). IL-1 caused more than 
10- fold increase in MCP-1 expression, with its highest expression observed following 8 h 
treatment (Online Supplement Figure 1F). 
 
Wnt5A Does Not Regulate the Expression of Cell Adhesion Molecules 
Pro-inflammatory mediators secreted by activated immune cells activate endothelial cells by 
upregulating cell adhesion molecules. To determine if Wnt5A regulates the expression of cell 
adhesion molecules in vascular endothelial cells, HCAEC were treated with Wnt5A as 
described above for 24 h and the expression of VCAM-1, ICAM-1, E selectins and integrin b1 
chain were analyzed by flow cytometry. Wnt5A did not regulate or alter the expression of 
VCAM-1, ICAM-1, E selectins and integrin b1 chain. HCAEC treated with IL-1, which served 
as a positive control, showed significant upregulation of all four adhesion molecules (Online 
Supplement Figure 2A). 
These findings were confirmed by qRT-PCR. ICAM-1 mRNA expression was not changed 
following 4 h, 8 h and 24 h Wnt5A treatments (Online Supplement Figure 2B) while ICAM-1 
mRNA level was significantly upregulated following 4 h and 8 h IL-1 treatments (Online 
Supplement Figure 2C).  
  
IL-1 Induces the Expression of Wnt5A in HCAEC 
Pro-inflammatory cytokines secreted by activated immune cells upregulate inflammatory 
mediators in endothelial cells. To investigate if the pro-inflammatory cytokine IL-1 induces 
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the expression of Wnt5A in vascular endothelial cells, HCAEC were treated with IL-1 (20 
U/mL) for 8 h and the expression of Wnt5A mRNA level was measured by qRT-PCR. 
Treatment with IL-1 significantly upregulated Wnt5A mRNA level in HCAEC (Online 
Supplement Figure 4A). Immunofluorescence staining confirmed increased expression of 
Wnt5A protein in HCAEC upon IL-1 treatment (Online Supplement Figure 4B). 
 
 
 
SUPPLEMENTAL TABLES 
 
Table 1. Detailed list of the 200 genes highest regulated by Wnt5A in HCAEC.   
 
Gene symbol Accession number Sequence description Fold change 
ACOT6 NM_001037162 Homo sapiens acyl-CoA thioesterase 6  -8.324418 
MCHR2 NM_001040179 Homo sapiens melanin-concentrating hormone 
receptor 2  
-7.2782345 
SNORD3B-1 NR_003271 Homo sapiens small nucleolar RNA, C/D box 
3B-1 
-6.936168 
FGG NM_000509 Homo sapiens fibrinogen gamma chain A -6.7145305 
SNORD3B-1 NR_003271 Homo sapiens small nucleolar RNA, C/D box 
3B-1  
-6.5760064 
TRPA1 NM_007332 Homo sapiens transient receptor potential 
cation channel, subfamily A, member 1  
-6.389514 
ZSCAN5D XM_001725568 PREDICTED: Homo sapiens zinc finger and 
SCAN domain containing 5D 
-6.2849603 
OR9G4 NM_001005284 Homo sapiens olfactory receptor, family 9, 
subfamily G, member 4  
-5.88169 
CELSR1 NM_014246 Homo sapiens cadherin, EGF LAG seven-pass 
G-type receptor 1 
-5.839751 
RIMBP2 NM_015347 Homo sapiens RIMS binding protein 2  -5.6184063 
KAZN NM_015209 Homo sapiens kazrin, periplakin interacting 
protein 
-5.4967346 
FLG NM_002016 Homo sapiens filaggrin -5.4960876 
SCAND2 NR_003654 Homo sapiens SCAN domain containing 2 
pseudogene  
-5.4488153 
LILRB5 NM_006840 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM 
domains), member 5  
-5.210473 
DEFB113 NM_001037729 Homo sapiens defensin, beta 113  -5.1864524 
RNU1-5 NR_004400 Homo sapiens RNA, U1 small nuclear 5  -5.1660633 
CEACAM7 NM_006890 Homo sapiens carcinoembryonic antigen-
related cell adhesion molecule 7 
-5.1170654 
FCRL5 NM_001195388 Homo sapiens Fc receptor-like 5  -5.115607 
DOK2 NM_003974 Homo sapiens docking protein 2 -5.030525 
IL31 NM_001014336 Homo sapiens interleukin 31  -4.9612994 
SERPINI2 NM_006217 Homo sapiens serpin peptidase inhibitor, clade 
I (pancpin), member 2 
-4.946744 
NDOR1 NM_001144026 Homo sapiens NADPH dependent diflavin 
oxidoreductase 1  
-4.8756633 
PRO0611 NR_002762 Homo sapiens PRO0611 protein -4.8346343 
CSN3 NM_005212 Homo sapiens casein kappa -4.832802 
KRT42P NR_033415 Homo sapiens keratin 42 pseudogene -4.7667203 
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TRIM3 NM_006458 Homo sapiens tripartite motif containing 3  -4.7564874 
NCRNA00307 NR_038855 Homo sapiens non-protein coding RNA 307  -4.746788 
CEP44 NM_001145314 Homo sapiens centrosomal protein 44kDa  -4.694463 
CNPY1 NM_001103176 Homo sapiens canopy 1 homolog  -4.687589 
SEC14L3 NM_174975 Homo sapiens SEC14-like 3 -4.6785803 
FAM83C NM_178468 Homo sapiens family with sequence similarity 
83, member C  
-4.6747828 
EPB41 NM_203342 Homo sapiens erythrocyte membrane protein 
band 4.1  
-4.670895 
NCRNA00308 NR_038400 Homo sapiens non-protein coding RNA 308  -4.635309 
ZNF560 NM_152476 Homo sapiens zinc finger protein 560 -4.614581 
ZSCAN10 NM_032805 Homo sapiens zinc finger and SCAN domain 
containing 10 
-4.59965 
CHI3L1 NM_001276 Homo sapiens chitinase 3-like 1  -4.5791106 
LANCL2 NM_018697 Homo sapiens LanC lantibiotic synthetase 
component C-like 2  
-4.5460114 
GNG2 NM_053064 Homo sapiens guanine nucleotide binding 
protein (G protein), gamma 2 
-4.5214796 
FBF1 NM_001080542 Homo sapiens Fas (TNFRSF6) binding factor 
1  
-4.501989 
RD3 NM_183059 Homo sapiens retinal degeneration 3 -4.49653 
RBM23 NM_001077351 Homo sapiens RNA binding motif protein 23  -4.475341 
TAX1BP3 NM_014604 Homo sapiens Tax1 (human T-cell leukemia 
virus type I) binding protein 3 
-4.469355 
CLMP NM_024769 Homo sapiens CXADR-like membrane protein  -4.465107 
HHIPL1 NM_032425 Homo sapiens HHIP-like 1  -4.443919 
XIRP2 NM_152381 Homo sapiens xin actin-binding repeat 
containing 2 
-4.426423 
EEF1A1 NM_001402 Homo sapiens eukaryotic translation 
elongation factor 1 alpha 1  
-4.4053526 
CAGE1 NM_001170692 Homo sapiens cancer antigen 1  -4.352445 
MSH4 NM_002440 Homo sapiens mutS homolog 4 -4.3516383 
STK31 NM_032944 Homo sapiens serine/threonine kinase 31  -4.348402 
C1QC NM_172369 Homo sapiens complement component 1, q 
subcomponent, C chain  
-4.298029 
OR52B4 NM_001005161 Homo sapiens olfactory receptor, family 52, 
subfamily B, member 4  
-4.287528 
HPGD NM_000860 Homo sapiens hydroxyprostaglandin 
dehydrogenase 15 
-4.2874207 
NPPC NM_024409 Homo sapiens natriuretic peptide C -4.269714 
KCNG2 NM_012283 Homo sapiens potassium voltage-gated 
channel, subfamily G, member 2  
-4.261782 
CRIP3 NM_206922 Homo sapiens cysteine-rich protein 3  -4.221094 
CFHR2 NM_005666 Homo sapiens complement factor H-related 2  -4.197347 
OR2T8 NM_001005522 Homo sapiens olfactory receptor, family 2, 
subfamily T, member 8 
-4.196567 
SCARNA16 NR_003013 Homo sapiens small Cajal body-specific RNA 
16  
-4.1780257 
FRY NM_023037 Homo sapiens furry homolog  -4.1688576 
BEST1 NM_004183 Homo sapiens bestrophin 1  -4.1176815 
RNU2-2 NR_002761 Homo sapiens RNA, U2 small nuclear 2  -4.1092715 
BTBD9 NM_052893 Homo sapiens BTB (POZ) domain containing 
9  
-4.07787 
FGF22 NM_020637 Homo sapiens fibroblast growth factor 22  -4.0691175 
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TTTY21 NR_001535 Homo sapiens testis-specific transcript, Y-
linked 21  
-4.0551863 
RNU12 NR_029422 Homo sapiens RNA, U12 small nuclear  -4.0501595 
HTR3B NM_006028 Homo sapiens 5-hydroxytryptamine (serotonin) 
receptor 3B  
-4.042065 
ELAC2 NM_173717 Homo sapiens elaC homolog 2 -4.0066185 
OR6N2 NM_001005278 Homo sapiens olfactory receptor, family 6, 
subfamily N, member 2  
-4.006343 
STIP1 NM_006819 Homo sapiens stress-induced-phosphoprotein 
1 
-4.003879 
PRB4 NM_002723 Homo sapiens proline-rich protein BstNI 
subfamily 4  
-3.9900327 
KCNJ15 NM_170736 Homo sapiens potassium inwardly-rectifying 
channel, subfamily J, member 15  
-3.9797218 
GATA1 NM_002049 Homo sapiens GATA binding protein 1 -3.9709651 
SLC10A6 NM_197965 Homo sapiens solute carrier family 10 
(sodium/bile acid cotransporter family), 
member 6  
-3.9443247 
CYTH4 NM_013385 Homo sapiens cytohesin 4  -3.939965 
PLEKHM3 NM_001080475 Homo sapiens pleckstrin homology domain 
containing, family M, member 3 
-3.9233177 
SLC4A5 NM_021196 Homo sapiens solute carrier family 4, sodium 
bicarbonate cotransporter, member 5  
-3.9189212 
CACNA1I NM_021096 Homo sapiens calcium channel, voltage-
dependent, T type, alpha 1I subunit  
-3.9179988 
CER1 NM_005454 Homo sapiens cerberus 1, cysteine knot 
superfamily, homolog  
-3.9090295 
PDE1C NM_001191057 Homo sapiens phosphodiesterase 1C -3.8955886 
TTN NM_133379 Homo sapiens titin  -3.8821275 
PIGS NM_033198 Homo sapiens phosphatidylinositol glycan 
anchor biosynthesis, class S 
-3.8780873 
TSPAN2 NM_005725 Homo sapiens tetraspanin 2 -3.870439 
GABRQ NM_018558 Homo sapiens gamma-aminobutyric acid 
(GABA) receptor, theta 
-3.8608994 
TBC1D3B NM_001001417 Homo sapiens TBC1 domain family, member 
3B 
-3.8530922 
FLJ16341 NR_033980 Homo sapiens hypothetical LOC400957  -3.850772 
ADAM30 NM_021794 Homo sapiens ADAM metallopeptidase 
domain 30  
-3.849467 
WNT7A NM_004625 Homo sapiens wingless-type MMTV 
integration site family, member 7A  
-3.8393934 
LRFN5 NM_152447 Homo sapiens leucine rich repeat and 
fibronectin type III domain containing 5  
-3.7527678 
PCLO NM_014510 Homo sapiens piccolo (presynaptic cytomatrix 
protein) 
-3.7487924 
PRSS58 NM_001001317 Homo sapiens protease, serine, 58  -3.7485342 
TARP NM_001003799 Homo sapiens TCR gamma alternate reading 
frame protein  
-3.7370687 
DAPL1 NM_001017920 Homo sapiens death associated protein-like 1  -3.7273319 
HYAL4 NM_012269 Homo sapiens hyaluronoglucosaminidase 4  -3.7211566 
HEMGN NM_018437 Homo sapiens hemogen  -3.7154548 
CHST10 NM_004854 Homo sapiens carbohydrate sulfotransferase 
10  
-3.7049973 
ISX NM_001008494 Homo sapiens intestine-specific homeobox  -3.6912203 
ZSCAN5B NM_001080456 Homo sapiens zinc finger and SCAN domain 
containing 5B  
-3.673115 
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ANKRD30B NM_001145029 Homo sapiens ankyrin repeat domain 30B  -3.6584432 
RNU105A 
 
PROZ 
NR_004404 
 
NM_003891 
 
Homo sapiens RNA, U105A small nucleolar  
 
Homo sapiens protein Z, vitamin K-dependent 
plasma glycoprotein 
-3.6451502 
 
-3.63101 
 
KLK10 NM_002776 Homo sapiens kallikrein-related peptidase 10  6.575816 
EFCAB9 NM_001171183 Homo sapiens EF-hand calcium binding 
domain 9 
6.2932844 
TMEM26 NM_178505 Homo sapiens transmembrane protein 26  6.0545125 
SLC10A7 NM_032128 Homo sapiens solute carrier family 10 
(sodium/bile acid cotransporter family), 
member 7  
5.8828216 
PLCB4 NM_182797 Homo sapiens phospholipase C, beta 4  5.841824 
MCM9 NM_153255 Homo sapiens minichromosome maintenance 
complex component 9  
5.7155905 
UGT8 NM_003360 Homo sapiens UDP glycosyltransferase 8  5.6220107 
PTPRC NM_002838 Homo sapiens protein tyrosine phosphatase, 
receptor type, C  
5.4459214 
FOXJ1 NM_001454 Homo sapiens forkhead box J1  5.2694902 
KIAA0754 NM_015038 Homo sapiens KIAA0754  4.940688 
PPM1A NM_177951 Homo sapiens protein phosphatase, 
Mg2+/Mn2+ dependent, 1A  
4.856635 
MYL10 NM_138403 Homo sapiens myosin, light chain 10, 
regulatory  
4.8453765 
DLG2 NM_001364 Homo sapiens discs, large homolog 2  4.8151875 
MYOZ2 NM_016599 Homo sapiens myozenin 2  4.7882605 
NARG2 NM_024611 Homo sapiens NMDA receptor regulated 2  4.770257 
KRTAP3-3 NM_033185 Homo sapiens keratin associated protein 3-3  4.7615805 
GHR NM_000163 Homo sapiens growth hormone receptor 4.7060866 
HPCA NM_002143 Homo sapiens hippocalcin  4.619414 
FBXW2 NM_012164 Homo sapiens F-box and WD repeat domain 
containing 2  
4.504634 
HAND1 NM_004821 Homo sapiens heart and neural crest 
derivatives expressed 1  
4.4445825 
NPSR1 NM_207173 Homo sapiens neuropeptide S receptor 1  4.4138284 
SRD5A2 NM_000348 Homo sapiens steroid-5-alpha-reductase, 
alpha polypeptide 2  
4.39622 
OR2M2 NM_001004688 Homo sapiens olfactory receptor, family 2, 
subfamily M, member 2  
4.385679 
IL2RG NM_000206 Homo sapiens interleukin 2 receptor, gamma  4.3586574 
SLC7A4 NM_004173 Homo sapiens solute carrier family 7 (orphan 
transporter), member 4  
4.31417 
C6 NM_000065 Homo sapiens complement component 6  4.3134027 
C10orf81 NM_001193434 Homo sapiens chromosome 10 open reading 
frame 81 
4.31175 
NUP62CL NM_017681 Homo sapiens nucleoporin 62kDa C-terminal 
like  
4.2600613 
RAP1GAP NM_002885 Homo sapiens RAP1 GTPase activating 
protein  
4.2497783 
LNX1 NM_032622 Homo sapiens ligand of numb-protein X 1  4.212433 
C4orf19 NM_018302 Homo sapiens chromosome 4 open reading 
frame 19  
4.1853323 
C16orf73 NM_152764 Homo sapiens chromosome 16 open reading 
frame 73 
4.15877 
OOEP NM_001080507 Homo sapiens oocyte expressed protein  4.137426 
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MYH11 NM_001040114 Homo sapiens myosin, heavy chain 11 4.1324053 
CBLN4 NM_080617 Homo sapiens cerebellin 4 precursor  4.1233478 
EPDR1 NM_017549 Homo sapiens ependymin related protein 1  4.118658 
HTR3E NM_182589 Homo sapiens 5-hydroxytryptamine (serotonin) 
receptor 3, family member E  
4.114653 
FILIP1L NM_182909 Homo sapiens filamin A interacting protein 1-
like  
4.04679 
ISLR2 NM_020851 Homo sapiens immunoglobulin superfamily 
containing leucine-rich repeat 2  
4.0254397 
C10orf111 NM_153244 Homo sapiens chromosome 10 open reading 
frame 111  
4.023104 
ADAM7 NM_003817 Homo sapiens ADAM metallopeptidase 
domain 7  
3.98616 
C1orf116 NM_023938 Homo sapiens chromosome 1 open reading 
frame 116 
3.9734225 
KLK3 NM_001030050 Homo sapiens kallikrein-related peptidase 3 3.9705615 
L1CAM NM_000425 Homo sapiens L1 cell adhesion molecule  3.9692035 
MALT1 NM_006785 Homo sapiens mucosa associated lymphoid 
tissue lymphoma translocation gene 1 
3.9679544 
FPGT-TNNI3K NM_001199327 Homo sapiens FPGT-TNNI3K readthrough  3.967866 
TRIM43 NM_138800 Homo sapiens tripartite motif containing 43 3.966672 
C22orf41 NM_001123225 Homo sapiens chromosome 22 open reading 
frame 41 
3.941643 
BRSK1 NM_032430 Homo sapiens BR serine/threonine kinase 1  3.9395163 
TUBAL3 NM_024803 Homo sapiens tubulin, alpha-like 3 3.9376917 
SULT1C4 NM_006588 Homo sapiens sulfotransferase family, 
cytosolic, 1C, member 4  
3.9312081 
EPM2AIP1 NM_014805 Homo sapiens EPM2A (laforin) interacting 
protein 1  
3.9263732 
FBXL16 NM_153350 Homo sapiens F-box and leucine-rich repeat 
protein 16 
3.88959 
FLJ33360 NR_028351 Homo sapiens FLJ33360 protein  3.8839903 
B3GAT1 NM_054025 Homo sapiens beta-1,3-glucuronyltransferase 
1  
3.8738415 
KIF21A NM_017641 Homo sapiens kinesin family member 21A  3.857627 
CCK NM_000729 Homo sapiens cholecystokinin 3.8558495 
UMODL1 NM_173568 Homo sapiens uromodulin-like 1  3.854163 
C1orf126 NR_027136 Homo sapiens chromosome 1 open reading 
frame 126  
3.8402214 
FAM184A NM_024581 Homo sapiens family with sequence similarity 
184, member A  
3.837973 
GYPE NM_002102 Homo sapiens glycophorin E  3.8379157 
ALDH8A1 NM_022568 Homo sapiens aldehyde dehydrogenase 8 
family, member A1  
3.8279617 
DBF4 NM_006716 Homo sapiens DBF4  3.8249915 
TDRG1 NR_024015 Homo sapiens testis development related 
protein 1  
3.8203418 
CNTD1 NM_173478 Homo sapiens cyclin N-terminal domain 
containing 1  
3.8109999 
ST8SIA2 NM_006011 Homo sapiens ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 2  
3.8014293 
FLJ33534 NR_040080 Homo sapiens hypothetical LOC285150 3.7999313 
ARHGEF26 NM_015595 Homo sapiens Rho guanine nucleotide 
exchange factor (GEF) 26 
3.795749 
CD83 NM_004233 Homo sapiens CD83 molecule  3.7942684 
7 
 
PRSS56 NM_001195129 Homo sapiens protease, serine, 56  3.7854364 
GJC3 NM_181538 Homo sapiens gap junction protein, gamma 3 3.7840154 
DAO NM_001917 Homo sapiens D-amino-acid oxidase  3.7802026 
ZMAT1 NM_001011657 Homo sapiens zinc finger, matrin-type 1  3.7773993 
COL4A4 NM_000092 Homo sapiens collagen, type IV, alpha 4  3.766722 
HOXB9 NM_024017 Homo sapiens homeobox B9  3.7637649 
FAM135A NM_020819 Homo sapiens family with sequence similarity 
135, member A  
3.7612922 
OR2M3 NM_001004689 Homo sapiens olfactory receptor, family 2, 
subfamily M, member 3  
3.7432675 
CCDC87 NM_018219 Homo sapiens coiled-coil domain containing 
87  
3.7388036 
GPR98 NM_032119 Homo sapiens G protein-coupled receptor 98 3.7176704 
DNAH5 NM_001369 Homo sapiens dynein, axonemal, heavy chain 
5  
3.668384 
HPR NM_020995 Homo sapiens haptoglobin-related protein  3.6548119 
ACPL2 NM_152282 Homo sapiens acid phosphatase-like 2  3.6438594 
COL1A1 NM_000088 Homo sapiens collagen, type I, alpha 1  3.6359794 
INPP4B NM_003866 Homo sapiens inositol polyphosphate-4-
phosphatase, type II 
3.6334362 
NXF2 NM_022053 Homo sapiens nuclear RNA export factor 2 3.631438 
RGS1 NM_002922 Homo sapiens regulator of G-protein signalling 
1  
3.6119537 
IL36G NM_019618 Homo sapiens interleukin 36, gamma  3.6095219 
SLC8A1 NM_021097 Homo sapiens solute carrier family 8 
(sodium/calcium exchanger), member 1 
3.5803816 
ARHGEF7 NM_145735 Homo sapiens Rho guanine nucleotide 
exchange factor (GEF) 7  
3.576161 
C10orf93 NM_173572 Homo sapiens chromosome 10 open reading 
frame 93 
3.5718787 
C11orf40 NM_144663 Homo sapiens chromosome 11 open reading 
frame 40  
3.570219 
TEX19 NM_207459 Homo sapiens testis expressed 19  3.568851 
LEUTX NM_001143832 Homo sapiens leucine twenty homeobox  3.5589292 
GPCRLTM7 NM_001195021 Homo sapiens putative olfactory receptor 
GPCRLTM7 
3.5525014 
RUFY2 NM_001042417 Homo sapiens RUN and FYVE domain 
containing 2  
3.5239537 
SLC7A8 NM_182728 Homo sapiens solute carrier family 7 (amino 
acid transporter light chain, L system), 
member 8  
3.5139337 
NBPF7 NM_001047980 Homo sapiens neuroblastoma breakpoint 
family, member 7 
3.5125823 
SORBS1 NM_001034954 Homo sapiens sorbin and SH3 domain 
containing 1  
3.5078912 
ARHGAP42 NM_152432 Homo sapiens Rho GTPase activating protein 
42  
3.4985898 
SOX3 NM_005634 Homo sapiens SRY (sex determining region 
Y)-box 3 
3.493397 
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Table 2.  Detailed list of the 200 genes highest regulated by IL-1 in HCAEC. 
 
Gene symbol Accession number Sequence description Fold change 
MYCN NM_005378 Homo sapiens v-myc myelocytomatosis viral 
related oncogene, neuroblastoma derived  
-48.749245 
INHBB NM_002193 Homo sapiens inhibin, beta B -29.917957 
CLEC4GP1 NR_002931 Homo sapiens C-type lectin domain family 4, 
member G pseudogene 1  
-19.890667 
DNASE1L3 NM_004944 Homo sapiens deoxyribonuclease I-like 3 -10.576039 
ADRA1B NM_000679 Homo sapiens adrenergic, alpha-1B-, receptor -9.219272 
GJA4 NM_002060 Homo sapiens gap junction protein, alpha 4 -8.887568 
PLEKHA7 NM_175058 Homo sapiens pleckstrin homology domain 
containing, family A member 7  
-8.722773 
HRCT1 NM_001039792 Homo sapiens histidine rich carboxyl terminus 
1 
-8.206352 
LIMCH1 NM_014988 Homo sapiens LIM and calponin homology 
domains 1  
-7.9732385 
EBF3 NM_001005463 Homo sapiens early B-cell factor 3 -7.9386687 
LYVE1 NM_006691 Homo sapiens lymphatic vessel endothelial 
hyaluronan receptor 1 
-7.8651233 
ZNF395 NM_018660 Homo sapiens zinc finger protein 395  -7.3937955 
CCDC48 NM_024768 Homo sapiens coiled-coil domain containing 
48  
-7.049505 
LHX6 NM_014368 Homo sapiens LIM homeobox 6  -6.879648 
KHK NM_000221 Homo sapiens ketohexokinase  -6.8313956 
TMEM236 NM_001098844 Homo sapiens transmembrane protein 236 -6.775998 
ZNF366 NM_152625 Homo sapiens zinc finger protein 366 -6.765643 
TMEM37 NM_183240 Homo sapiens transmembrane protein 37  -6.6180515 
FRY NM_023037 Homo sapiens furry homolog  -6.5588756 
AQP1 NM_198098 Homo sapiens aquaporin 1  -6.194014 
NRG2 NM_013982 Homo sapiens neuregulin 2  -6.034277 
AMICA1 NM_153206 Homo sapiens adhesion molecule, interacts 
with CXADR antigen 1 
-6.0145006 
PRO0611 NR_002762 Homo sapiens PRO0611 protein -5.9683604 
B4GALNT4 NM_178537 Homo sapiens beta-1,4-N-acetyl-
galactosaminyl transferase 4  
-5.8034816 
THBD NM_000361 Homo sapiens thrombomodulin  -5.7642055 
FAM26D NM_153036 Homo sapiens family with sequence similarity 
26, member D  
-5.702154 
NCRNA00323 NR_024100 Homo sapiens non-protein coding RNA 323  -5.6987195 
PRICKLE1 NM_153026 Homo sapiens prickle homolog 1   -5.6285944 
CLDN19 NM_148960 Homo sapiens claudin 19 -5.538379 
SEC14L3 NM_174975 Homo sapiens SEC14-like 3  -5.520614 
NCRNA00320 NR_024090 Homo sapiens non-protein coding RNA 320  -5.5172276 
EHD3 NM_014600 Homo sapiens EH-domain containing 3  -5.488953 
GALNTL2 NM_054110 Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2  
-5.475902 
RASSF9 NM_005447 Homo sapiens Ras association (RalGDS/AF-6) 
domain family (N-terminal) member 9  
-5.4308662 
ADAM11 NM_002390 Homo sapiens ADAM metallopeptidase 
domain 11  
-5.4001203 
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FRY NM_023037 Homo sapiens furry homolog  -5.3702507 
SNX22 NM_024798 Homo sapiens sorting nexin 22 -5.349246 
SSX2IP NM_014021 Homo sapiens synovial sarcoma, X breakpoint 
2 interacting protein 
-5.312884 
HES7 NM_001165967 Homo sapiens hairy and enhancer of split 7 -5.297948 
DBP NM_001352 Homo sapiens D site of albumin promoter 
(albumin D-box) binding protein 
-5.2756314 
RAB37 NM_175738 Homo sapiens RAB37, member RAS 
oncogene family 
-5.251631 
GIMAP7 NM_153236 Homo sapiens GTPase, IMAP family member 
7  
-5.246414 
RUNX1T1 NM_004349 Homo sapiens runt-related transcription factor 
1; translocated to, 1  
-5.2318254 
RPRML NM_203400 Homo sapiens reprimo-like  -5.2271395 
CLEC14A NM_175060 Homo sapiens C-type lectin domain family 14, 
member A 
-5.111908 
CLDN22 NM_001111319 Homo sapiens claudin 22  -5.0853024 
SOCS2 NM_003877 Homo sapiens suppressor of cytokine 
signalling 2  
-5.0844283 
CLDN3 NM_001306 Homo sapiens claudin 3  -5.064153 
BDNF NM_170735 Homo sapiens brain-derived neurotrophic 
factor  
-5.0212407 
FAM201A NR_027294 Homo sapiens family with sequence similarity 
201, member A  
-5.014723 
GIMAP5 NM_018384 Homo sapiens GTPase, IMAP family member 
5  
-4.9949155 
SYN2 NM_133625 Homo sapiens synapsin II  -4.962457 
NR0B1 NM_000475 Homo sapiens nuclear receptor subfamily 0, 
group B, member 1  
-4.959428 
BMP4 NM_001202 Homo sapiens bone morphogenetic protein 4 -4.9232016 
GSTTP2 NR_003082 Homo sapiens glutathione S-transferase theta 
pseudogene 2  
-4.8909044 
NCRNA00277 NR_026949 Homo sapiens non-protein coding RNA 277  -4.854132 
FILIP1 NM_015687 Homo sapiens filamin A interacting protein 1  -4.845783 
TXNRD3NB NM_001039783 Homo sapiens thioredoxin reductase 3 
neighbor  
-4.7800193 
ANKRD34A NM_001039888 Homo sapiens ankyrin repeat domain 34A  -4.7779975 
KIAA1875 NR_024207 Homo sapiens KIAA1875  -4.774847 
TRIL NM_014817 Homo sapiens TLR4 interactor with leucine-
rich repeats 
-4.7655497 
IMPA2 NM_014214 Homo sapiens inositol(myo)-1(or 4)-
monophosphatase 2 
-4.7185154 
FLYWCH1 NM_032296 Homo sapiens FLYWCH-type zinc finger 1 -4.7098217 
ANKRD20A9P NR_027995 Homo sapiens ankyrin repeat domain 20 
family, member A9, pseudogene  
-4.7062373 
LMCD1 NM_014583 Homo sapiens LIM and cysteine-rich domains 
1 
-4.7046704 
TMEM178 NM_152390 Homo sapiens transmembrane protein 178   -4.6681147 
SOX18 NM_018419 Homo sapiens SRY (sex determining region 
Y)-box 18   
-4.6410155 
HRK NM_003806 Homo sapiens harakiri, BCL2 interacting 
protein 
-4.603894 
CELSR1 NM_014246 Homo sapiens cadherin, EGF LAG seven-pass 
G-type receptor 1  
-4.5569406 
TRIM45 NM_025188 Homo sapiens tripartite motif containing 45  -4.5300555 
LHX9 NM_020204 Homo sapiens LIM homeobox 9  -4.5149674 
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ACOT6 NM_001037162 Homo sapiens acyl-CoA thioesterase 6  -4.5146165 
RLN2 NM_005059 Homo sapiens relaxin 2  -4.510096 
IGSF6 NM_005849 Homo sapiens immunoglobulin superfamily, 
member 6  
-4.4997478 
SERTAD4 NM_019605 Homo sapiens SERTA domain containing 4  -4.455149 
NFE2L2 NM_006164 Homo sapiens nuclear factor (erythroid-
derived 2)-like 2  
-4.4319816 
ERV3-1 NM_001007253 Homo sapiens endogenous retrovirus group 3, 
member 1 
-4.407914 
NHSL2 NM_001013627 Homo sapiens NHS-like 2  -4.3638372 
CCDC165 NM_015210 Homo sapiens coiled-coil domain containing 
165 
-4.3601694 
ST8SIA4 NM_005668 Homo sapiens ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 4  
-4.3535028 
FAM183B NR_028347 Homo sapiens family with sequence similarity 
183, member B  
-4.3384457 
PNMAL1 NM_018215 Homo sapiens PNMA-like 1 -4.3220973 
ARHGAP20 NM_020809 Homo sapiens Rho GTPase activating protein 
20  
-4.322003 
NLRP12 NM_033297 Homo sapiens NLR family, pyrin domain 
containing 12  
-4.293668 
LYPD1 NM_144586 Homo sapiens LY6/PLAUR domain containing 
1 
-4.2919726 
RARB NM_000965 Homo sapiens retinoic acid receptor, beta -4.282265 
SAMD13 NM_001010971 Homo sapiens sterile alpha motif domain 
containing 13  
-4.2682867 
OR4C12 NM_001005270 Homo sapiens olfactory receptor, family 4, 
subfamily C, member 12 
-4.255225 
GIMAP1 NM_130759 Homo sapiens GTPase, IMAP family member 
1  
-4.236272 
DPRXP4 NR_002221 Homo sapiens divergent-paired related 
homeobox pseudogene 4  
-4.225941 
CSPG5 NM_006574 Homo sapiens chondroitin sulfate proteoglycan 
5  
-4.224571 
CCDC30 NM_001080850 Homo sapiens coiled-coil domain containing 
30 
-4.208119 
WNT7A NM_004625 Homo sapiens wingless-type MMTV 
integration site family, member 7A 
-4.1847167 
PPARG NM_138711 Homo sapiens peroxisome proliferator-
activated receptor gamma 
-4.1499724 
MAMLD1 NM_005491 Homo sapiens mastermind-like domain 
containing 1  
-4.1428905 
PLB1 NM_153021 Homo sapiens phospholipase B1  -4.141613 
BCL11A NM_022893 Homo sapiens B-cell CLL/lymphoma 11A  -4.129264 
ZNF521 NM_015461 Homo sapiens zinc finger protein 521  -4.1025825 
NEURL1B NM_001142651 Homo sapiens neuralized homolog 1B -4.080128 
FAM90A7 NM_001136572 Homo sapiens family with sequence similarity 
90, member A7   
-4.076752 
IL1B NM_000576 Homo sapiens interleukin 1, beta  628.58215 
CCL8 NM_005623 Homo sapiens chemokine (C-C motif) ligand 8  567.51654 
SELE NM_000450 Homo sapiens selectin E  523.0239 
CXCL1 NM_001511 Homo sapiens chemokine (C-X-C motif) ligand 
1  
501.29193 
CXCL3 NM_002090 Homo sapiens chemokine (C-X-C motif) ligand 
3  
429.9673 
CXCL2 NM_002089 Homo sapiens chemokine (C-X-C motif) ligand 364.44318 
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IL8 NM_000584 Homo sapiens interleukin 8  324.8047 
TNF NM_000594 Homo sapiens tumor necrosis factor 271.97995 
CCL3 NM_002983 Homo sapiens chemokine (C-C motif) ligand 3  239.2062 
CCL20 NM_004591 Homo sapiens chemokine (C-C motif) ligand 
20  
206.19748 
CXCR7 NM_020311 Homo sapiens chemokine (C-X-C motif) 
receptor 7 
193.35707 
C15orf48 NM_032413 Homo sapiens chromosome 15 open reading 
frame 48  
188.21423 
CXCL6 NM_002993 Homo sapiens chemokine (C-X-C motif) ligand 
6 
182.55176 
C2CD4A NM_207322 Homo sapiens C2 calcium-dependent domain 
containing 4A 
119.190605 
NEURL3 NR_026875 Homo sapiens neuralized homolog 3 
(Drosophila) pseudogene  
110.60467 
UBD NM_006398 Homo sapiens ubiquitin D  100.76968 
CD69 NM_001781 Homo sapiens CD69 molecule  90.45913 
TRAF1 NM_005658 Homo sapiens TNF receptor-associated factor 
1 
84.80847 
IL6 NM_000600 Homo sapiens interleukin 6 82.71982 
CXCL11 NM_005409 Homo sapiens chemokine (C-X-C motif) ligand 
11  
81.203156 
RSAD2 NM_080657 Homo sapiens radical S-adenosyl methionine 
domain containing 2 
80.846924 
BIRC3 NM_001165 Homo sapiens baculoviral IAP repeat 
containing 3 
67.27173 
LTB NM_002341 Homo sapiens lymphotoxin beta   65.086105 
IL1A NM_000575 Homo sapiens interleukin 1, alpha  63.525673 
TNFAIP3 NM_006290 Homo sapiens tumor necrosis factor, alpha-
induced protein 3  
60.4407 
TNIP3 NM_024873 Homo sapiens TNFAIP3 interacting protein 3  59.825535 
VCAM1 NM_001078 Homo sapiens vascular cell adhesion molecule 
1  
57.014397 
TLR2 NM_003264 Homo sapiens toll-like receptor 2  56.306362 
F3 NM_001993 Homo sapiens coagulation factor III  50.284866 
PTGS2 NM_000963 Homo sapiens prostaglandin-endoperoxide 
synthase 2  
44.905956 
CXCL1 NM_001511 Homo sapiens chemokine (C-X-C motif) ligand 
1  
40.032032 
SGPP2 NM_152386 Homo sapiens sphingosine-1-phosphate 
phosphatase 2  
38.973095 
RGS16 NM_002928 Homo sapiens regulator of G-protein signalling 
16 
38.702847 
RCSD1 NM_052862 Homo sapiens RCSD domain containing 1 38.01366 
SOD2 NM_001024465 Homo sapiens superoxide dismutase 2, 
mitochondrial  
36.718346 
TNFAIP2 NM_006291 Homo sapiens tumor necrosis factor, alpha-
induced protein 2  
35.506237 
CSF3 NM_000759 Homo sapiens colony stimulating factor 3  35.368214 
TNFAIP6 NM_007115 Homo sapiens tumor necrosis factor, alpha-
induced protein 6  
35.234 
C3 NM_000064 Homo sapiens complement component 3  33.966663 
C1S NM_001734 Homo sapiens complement component 1, s 
subcomponent  
33.94064 
NFKBIZ NM_031419 Homo sapiens nuclear factor of kappa light 33.30885 
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polypeptide gene enhancer in B-cells inhibitor, 
zeta  
CCL2 NM_002982 Homo sapiens chemokine (C-C motif) ligand 2  31.177633 
CLEC2D NM_013269 Homo sapiens C-type lectin domain family 2, 
member D  
30.127642 
FAM65C NM_080829 Homo sapiens family with sequence similarity 
65, member C  
29.93501 
IL18R1 NM_003855 Homo sapiens interleukin 18 receptor 1  29.57203 
NOD2 NM_022162 Homo sapiens nucleotide-binding 
oligomerization domain containing 2 
29.374725 
CXCL10 NM_001565 Homo sapiens chemokine (C-X-C motif) ligand 
10  
27.42973 
CFB NM_001710 Homo sapiens complement factor B  27.262953 
CCL5 NM_002985 Homo sapiens chemokine (C-C motif) ligand 5  26.525106 
NR4A3 NM_173200 Homo sapiens nuclear receptor subfamily 4, 
group A, member 3  
25.799444 
BDKRB2 NM_000623 Homo sapiens bradykinin receptor B2  25.538664 
EBI3 NM_005755 Homo sapiens Epstein-Barr virus induced 3  25.296314 
MAP3K8 NM_005204 Homo sapiens mitogen-activated protein 
kinase kinase kinase 8  
24.689005 
TNFRSF9 NM_001561 Homo sapiens tumor necrosis factor receptor 
superfamily, member 9  
24.13026 
SLC7A2 NM_001008539 Homo sapiens solute carrier family 7 (cationic 
amino acid transporter, y+ system), member 2  
24.04523 
CXCL10 NM_001565 Homo sapiens chemokine (C-X-C motif) ligand 
10 
23.984573 
KIRREL2 NM_199180 Homo sapiens kin of IRRE like 2 23.426357 
LITAF NM_004862 Homo sapiens lipopolysaccharide-induced 
TNF factor 
23.305717 
ICAM1 NM_000201 Homo sapiens intercellular adhesion molecule 
1 
23.237846 
RTP4 NM_022147 Homo sapiens receptor (chemosensory) 
transporter protein 4  
22.30666 
C3 NM_000064 Homo sapiens complement component 3  21.691349 
SELE NM_000450 Homo sapiens selectin E  21.351578 
MMP10 NM_002425 Homo sapiens matrix metallopeptidase 10 21.229311 
CMPK2 NM_207315 Homo sapiens cytidine monophosphate (UMP-
CMP) kinase 2, mitochondrial  
21.192596 
GOT1L1 NM_152413 Homo sapiens glutamic-oxaloacetic 
transaminase 1-like 1  
20.017305 
CLDN1 NM_021101 Homo sapiens claudin 1 19.82994 
IL18R1 NM_003855 Homo sapiens interleukin 18 receptor 1  19.33128 
BCL2A1 NM_004049 Homo sapiens BCL2-related protein A1  19.308804 
SLC6A4 NM_001045 Homo sapiens solute carrier family 6  18.38842 
VSTM1 NM_198481 Homo sapiens V-set and transmembrane 
domain containing 1  
18.058065 
CCL4 NM_002984 Homo sapiens chemokine (C-C motif) ligand 4  17.710985 
CCL4 NM_002984 Homo sapiens chemokine (C-C motif) ligand 4 17.653017 
LAD1 NM_005558 Homo sapiens ladinin 1  17.627607 
OASL NM_003733 Homo sapiens 2'-5'-oligoadenylate synthetase-
like  
17.497292 
CLDN14 NM_144492 Homo sapiens claudin 14  17.131746 
SOCS1 NM_003745 Homo sapiens suppressor of cytokine 
signalling 1  
16.820028 
CXCL2 NM_002089 Homo sapiens chemokine (C-X-C motif) ligand 16.501673 
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PITX2 NM_153426 Homo sapiens paired-like homeodomain 2  15.021445 
IFIT2 NM_001547 Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 2  
15.00921 
PRRX1 NM_006902 Homo sapiens paired related homeobox 1 14.835137 
OXTR NM_000916 Homo sapiens oxytocin receptor  14.744355 
CSF3 NM_000759 Homo sapiens colony stimulating factor 3 14.631831 
NFKBIA NM_020529 Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, 
alpha  
14.564752 
MX2 NM_002463 Homo sapiens myxovirus (influenza virus) 
resistance 2  
14.004878 
ITGB8 NM_002214 Homo sapiens integrin, beta 8  13.91287 
CSF2 NM_000758 Homo sapiens colony stimulating factor 2 13.673741 
C6orf58 NM_001010905 Homo sapiens chromosome 6 open reading 
frame 58  
13.255741 
IL7R NM_002185 Homo sapiens interleukin 7 receptor  13.228039 
LIF NM_002309 Homo sapiens leukemia inhibitory factor  13.028622 
NPTX1 NM_002522 Homo sapiens neuronal pentraxin I  12.880365 
IFIT2 NM_001547 Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 2  
12.85912 
FGF18 NM_003862 Homo sapiens fibroblast growth factor 18 12.7818 
GBP1 NM_002053 Homo sapiens guanylate binding protein 1, 
interferon-inducible 
12.647643 
RAB11FIP1 NM_001002814 Homo sapiens RAB11 family interacting 
protein 1  
12.551967 
ELOVL7 NM_024930 Homo sapiens ELOVL fatty acid elongase 7  12.131871 
C11orf96 NM_001145033 Homo sapiens chromosome 11 open reading 
frame 96 
12.129249 
CSF1 NM_172210 Homo sapiens colony stimulating factor 1  12.096482 
TMEM106A NM_145041 Homo sapiens transmembrane protein 106A 12.058173 
CD69 NR_026672 Homo sapiens CD69 molecule  12.0577545 
GBP5 NM_052942 Homo sapiens guanylate binding protein 5  11.924029 
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SUPPLEMENTAL FIGURES  
 
Figure 1 
 
A            B 
 
 
C      D 
 
 
E      F 
 
 
Figure 1. Regulation of inflammatory cytokines by Wnt5A and IL-1. Expression of 
mRNA levels of IL-6 (A, D), IL-8 (B, E) and MCP-1 (C, F) in HCAEC treated with Wnt5A (A, 
B, C) or  IL-1 (D, E, F) for 4 h and 8 h. Data were obtained from three independent qRT-
PCR experiments run in duplicates and expressed as the mean ± S.E.M. *P<0.05 by 
Student’s t-test 
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Figure 2 
 
           A 
 
                
B               C 
 
 
Figure 2. Endothelial cell adhesion molecules expression. (A) Flow cytometry analyses 
of VCAM-1 (CD106), ICAM-1 (CD54), E selectins (CD62E) and human integrin b1 chain 
(CD29) expression in Wnt5A and IL-1 (IL-1b)-treated HCAEC. (B,C) qRT-PCR analyses of 
ICAM-1 mRNA expression in HCAEC treated with (B) Wnt5A and (C) IL-1 for 4 h, 8 h and 
24 h. Data were obtained from three independent experiments run in duplicates and 
expressed as the mean ± S.E.M. *P<0.05 by Student’s t-test. 
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Figure 3  
A 
 
 
 
Figure 3. Knockdown of Ryk expression. (A) Changes in the mRNA expression level of 
Ryk in HCAEC transfected with 5 nM negative control siRNA (neg.c.siRNA) and Ryk siRNA. 
Data were obtained from three independent qRT-PCR experiments run in duplicates and 
expressed as the mean ± S.E.M. *P<0.05 by Student’s t-test. Immunofluorescence staining 
for Ryk protein expression in (B) negative control siRNA transfected and (C) Ryk-siRNA 
transfected HCAEC. Ryk (red), nuclei (DAPI, blue). Zeiss Axioskope, magnification 200 fold. 
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Figure 4 
 
A 
 
 
B 
 
 
Figure 4. Wnt5A expression induced by IL-1 treatment.  (A) Fold changes in the 
expression of Wnt5A mRNA in HCAEC treated with IL-1 (IL-1b) for 8 h. Data were obtained 
from three independent qRT-PCR experiments run in duplicates and expressed as the mean 
± S.E.M. *P<0.05 by Student’s t-test. (B) Immunofluorescence staining for Wnt5A protein 
expression in non-treated and 8 h IL-1-treated HCAEC. Wnt5A (red), F-actin (phalloidin, 
green), and nuclei (DAPI, blue). Zeiss Axioskope, magnification 200 fold. 
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Figure 5 
 
 
Figure 5. Formation of confluent HCAEC monolayer in 8W10E+ ECIS array. HCAEC 
seeded into an 8W10E+ array with a density of 80,000- 90,000 cells/well. Soon after cell 
seeding, resistance measurements (in Ohms) were started and are shown as normalized 
resistance (subsequent values were divided by initial values). Rise in resistance with respect 
to time indicates that cells were forming contacts between each other. The steady state 
(marked by *) indicates the stage at which maximum resistance is reached to form a tight 
monolayer. Resistance measurements were conducted in duplicate wells which were 
grouped and averaged to plot as single curve. Error bars of curves represent SD. Figure 
shown depict the resistance measurements conducted at 4000 Hz. Red and Blue, Untreated. 
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Abstract 
Microvascular leakage due to endothelial barrier dysfunction is a prominent feature of T 
helper 2 (Th2) cytokine mediated allergic inflammation. Interleukin-4 (IL-4) is a potent Th2 
cytokine, known to impair the barrier function of endothelial cells. However, the effectors 
mediating IL-4 induced cytoskeleton remodeling and consequent endothelial barrier 
dysfunction remain poorly defined. Here we have used whole genome transcriptome profiling 
and gene ontology analyses to identify the genes and processes regulated by IL-4 signaling 
in human coronary artery endothelial cells (HCAEC). The study revealed Wnt5A as an 
effector that can mediate actin cytoskeleton remodeling in IL-4 activated HCAEC through the 
regulation of LIM kinase (LIMK) and Cofilin (CFL). Following IL-4 treatment, LIMK and CFL 
were phosphorylated, thereby indicating the possibility of actin stress fiber formation. Imaging 
of actin showed the formation of stress fibers in IL-4 treated live HCAEC. Stress fiber 
formation was notably decreased in the presence of Wnt inhibitory factor 1 (WIF1). Non-
invasive impedance measurements demonstrated that IL-4 increased the permeability and 
impaired the barrier function of HCAEC monolayers. Silencing Wnt5A significantly reduced 
permeability and improved the barrier function of HCAEC monolayers upon IL-4 treatment. 
Our study identifies Wnt5A as a novel marker of IL-4 activated vascular endothelium and 
demonstrates a critical role for Wnt5A in mediating IL-4 induced endothelial barrier 
dysfunction. Wnt5A could be a potential therapeutic target for reducing microvascular 
leakage and edema formation in Th2 driven inflammatory diseases.  
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Introduction  
Interleukin-4 (IL-4) is a multifunctional pleiotropic type I cytokine secreted by activated T 
helper (Th) 2 cells, basophils, eosinophils and mast cells [1,2]. Functionally, IL-4 induces the 
differentiation of antigen stimulated naïve T cells to a Th2 phenotype [3,4]. It also regulates 
immunoglobulin (Ig) class switching so that B lymphocytes express IgE [5], and regulates 
apoptosis, cell proliferation and expression of several genes in different cell types such as 
fibroblasts, macrophages, endothelial and epithelial cells [1,2]. IL-4 drives the ‘alternative 
activation of macrophages’ to produce the M2 phenotype, which is crucially involved in type 2 
immunity. Thus, through its effects on multiple cell types and by binding to alternative cell 
surface receptors [1], IL-4 plays critical roles in allergic inflammation [6], immune response to 
extracellular parasites including helminths, autoimmunity [2] and tumor inflammation and 
metastasis [1,7]. 
Recent evidence suggests a potential role for IL-4 in generating a proinflammatory 
environment in vascular endothelial cells (VEC) [8]. VEC are essential for maintaining 
vascular homeostasis in normal physiological conditions [9]. Under pathophysiological 
conditions, activated blood components, pathogens or inflammatory mediators such as 
cytokines act upon VEC and heavily alter their functions, conferring on them an inflamed 
phenotype. These alterations include a change from the anticoagulant phenotype to a 
procoagulant state, increased production of vasoactive substances, expression of cell 
adhesion molecules, synthesis of inflammatory mediators including chemoattractants, and 
endothelial barrier dysfunction causing microvascular leakage. It has been demonstrated that 
IL-4 upregulates the expression of vascular cell adhesion molecule (VCAM)-1 [10-12], IL-6 
[12-14] and monocyte chemotactic protein (MCP) [12,14] in human umbilical vein endothelial 
cells (HUVEC). Moreover, stimulation with IL-4 increased the adhesion of peripheral blood 
monocytes [15] and T cells [16] to HUVEC. IL-4 has been shown to induce cytoskeletal 
rearrangements in HUVEC and significantly regulate their proliferation [17]. Further, IL-4 acts 
as a modest mitogen for both macro and microvascular endothelial cells [8,17-19]. IL-4 has 
proatherogenic effects and induces the apoptosis of endothelial cells causing increased 
endothelial cell turnover [20]. It has been demonstrated that IL-4 induces hyperpermeability 
of HUVEC, causing vascular leakage [21], however, effectors responsible for IL-4 induced 
endothelial hyperpermeability and consequent barrier dysfunction remain unidentified. 
Moreover, these previous studies addressing the effects of IL-4 on endothelial inflammation 
used HUVEC as the primary endothelial cell model system. HUVEC that are obtained from 
the immune naïve foetal tissue shows significant variations in function compared with adult 
vascular endothelium and hence may be an inappropriate primary cell model of vascular 
endothelium [22]. The targets and effects of IL-4 signaling in adult VEC, therefore, may vary 
from HUVEC and have to be elucidated.  
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In the present study, we used transcriptome profiling to identify the genes regulated by 
paracrine IL-4 signaling in our established in vitro model of adult VEC, cultured human 
coronary artery endothelial cells (HCAEC) [23]. Here we identify Wnt5A as one of the genes 
significantly upregulated by IL-4 treatment. We further demonstrate a critical role for IL-4 
induced Wnt5A in impairing barrier function of endothelial monolayers. Our findings suggest 
a prominent role for Wnt5A in causing microvascular leakage associated with IL-4 driven 
allergic inflammation and other pathophysiological conditions. 
 
Methods 
Cell Culture 
HCAEC and human pulmonary artery endothelial cells (HPAEC) purchased from Clonetics 
(Lonza, USA) were cultured in EBM-2 medium (Clonetics, Lonza, USA) supplemented with 
EGM-2MV Single Quots and 5% FBS (Clonetics, Lonza) as described previously [23]. For 
experiments, cells at passages three to six were used and the serum in culture medium was 
decreased to 2% FBS. Macrophages derived from human PBMC were cultured as described 
[24]. Cells were cultured under standard conditions (37C, 5% CO2, 80% humidity) in a 
Class 100 HEPA air filtered system (SteriCult, Fisher Scientific, Switzerland). Culture 
medium without antibiotics was used to prevent masked low-level contamination in cell 
cultures. Treatments were carried out using recombinant human (rh) IL-4 (4 ng/mL; purity 
>98%; PeproTech, USA), rh IL-6 (20 U/mL; purity >98%; PeproTech, USA), rh soluble 
Frizzled-related peptide-1 (sFRP1; 10 μg/mL; purity > 95%; R&D systems, USA), rh/mouse 
Wnt5A (250 ng/mL; CHO-derived Gln38-Lys380, purity >80%, endotoxin level <1.0 EU/µg of 
protein; R&D systems, USA) and rh Wnt inhibitory factor 1 (WIF1; 15 μg/mL; purity >97%; 
R&D systems, USA). Sterile biopure ep Dualfilter T.I.P.S.sterile filter tips (Eppendorf, 
Germany) were used throughout the study. 
 
RNA Isolation and Quantitative Real-Time PCR (qRT-PCR) Analyses 
RNA isolation and qRT-PCR using the HPRT gene as endogenous control were performed 
as described previously [25]. Sequence specific PCR detection primers used for Wnt5A, IL-6 
and HPRT are as follows: Wnt5A forward, 5'-AGT TGC CTA CCC TAG C-3'; Wnt5A reverse, 
5'-GTG CCT TCG TGC CTA T-3'; IL-6 forward, 5'-CCT GAC CCA ACC ACA AA-3'; IL-6 
reverse, 5'-AGT GTC CTA ACG CTC ATA C-3'; HPRT forward, 5'-CCA GTC AAC AGG GGA 
CAT AAA-3'; HPRT reverse, 5'-CAC AAT CAA GAC ATT CTT TCC AGT-3'. Thermal cycling 
conditions set in the 7500 Fast Real-Time PCR System (Applied Biosystems, USA) involved 
an initial denaturation step (10 min, 95°C) followed by 40 cycles of denaturation (15 sec, 
95°C), annealing (30 sec, 55°C), and extension (30 sec, 72°C). 
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Differential Gene Expression Profiling 
Microarray based gene expression profiling and scanning, feature extraction and data 
normalization of microarrays were performed as described previously [25]. Complete data 
sets for the IL-4 regulated transcriptome in HCAEC are available in the NCBI GEO data 
repository, accession number GSE64860. 
 
Microarray Data Analyses 
The preprocessed microarray data was analyzed using GeneSpring GX 9.0 Software (Agilent 
Tech. Inc.) with default settings for two color arrays and a fold change (FC) cutoff of 2. Using 
MetaCore™ GeneGO software (Thomson Reuters, http://portal.genego.com), genes 
regulated ≥2 fold in their expression and satisfying a P value <0.05 were grouped into 
pathways according to their biologic functions and gene ontology (GO) classes. 
 
Immunofluorescence Staining 
HCAEC were grown in four-chamber culture slides coated with rat tail collagen type I (diluted 
0.01% in sterile pyrogen-free water; BD Biosciences, USA). To stain for VE-cadherin, 
HCAEC were grown to a confluent monolayer. After treatment with appropriate stimuli, cells 
were fixed with 4% formalin in PBS for 20 min. After washing three times with PBS (pH 7.4) 
at room temperature (RT), slides were treated with blocking solution for 1 h at RT. 
Depending on the source of secondary antibodies, blocking solution containing either 10% 
goat serum and 1% BSA (for secondary antibodies derived from goat) or 10% rabbit serum 
and 1% BSA in PBS (for secondary antibodies derived from rabbit) was used. After washing 
three times with PBS at RT, slides were incubated with primary antibodies diluted in blocking 
solution at 4°C overnight. The following antibodies were used with dilutions indicated: rabbit 
anti-VE-cadherin, polyclonal (1:100; Product No. 2158, Cell Signaling Technology), rabbit 
anti-phospho LIMK2, polyclonal (1:300; Product No. Ab131343, Abcam), rabbit anti-phospho 
CFL, polyclonal (1:500; Product No. Ab100836, Abcam), goat anti-Wnt5A, polyclonal (1:500; 
Cat. No. AF645, R&D Systems). Slides were then washed three times with PBS at RT. 
Depending on the first antibody’s species, slides were incubated with Alexa 568 labelled goat 
anti-rabbit or rabbit anti-goat secondary antibodies (1:2000; Molecular Probes, Invitrogen, 
USA) for 1 h at RT in the dark. Incubations with secondary antibody were combined with 
Alexa Fluor 488 Phalloidin (1:80; Molecular Probes, Invitrogen, USA) to visualize F-actin. 
Slides were washed three times with PBS at RT, counterstained with 10 μg/mL diamidino-
phenylindole (DAPI; Sigma-Aldrich) and mounted using ProLong® Gold Antifade (Life 
Technologies, USA). Images were captured using an Axioskope microscope equipped with 
an AxioCam MRm digital camera and the associated AxioVision Rel.4.6 software (Carl Zeiss, 
Feldbach Switzerland). Fluorescent intensity was quantified from five different areas of the 
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respective fluorescent images using ImageJ based Fiji software (Fiji is just ImageJ) and 
corrected for background fluorescence to obtain cellular fluorescent intensity. 
 
Inhibition of Rho associated protein serine/threonine kinases (ROCK)  
Y-27632 (Calbiochem; Millipore, USA) at a concentration of 10 μM [26] was used to inhibit 
the activation of ROCK. ROCK inhibition experiments were performed by incubating cells in 
medium containing Y-27632 alone or in combination with IL-4 for 1 h and 4 h. 
 
Live Cell Imaging of Actin  
HCAEC monolayers were grown in rat tail collagen type I coated optical 96 microwell culture 
plates (Thermo Scientific, USA). Cells were incubated with CellLight® Actin-RFP probe (Cat. 
No. C10583, Life Technologies, USA) according to manufacturer’s instructions. After medium 
change, cells were treated with IL-4 or Wnt5A alone or in combination with sFRP1 or WIF1. 
Cells were further incubated up to 12 h. Images of live actin cytoskeleton organization were 
obtained using the Axio Observer.Z1 inverted microscope equipped with an AxioCam MRm 
digital camera and the associated ZEN 2012 software (Carl Zeiss, Feldbach, Switzerland). 
 
Wnt5A Silencing  
To knockdown Wnt5A expression, HCAEC grown up to 80% confluency in 24-well plates 
were incubated with transfection complexes formed from Wnt5A-siRNA (5 nM; Hs_Wnt5A_6, 
Cat. No. SI03025596; Qiagen) and 6 μL/mL HiPerFect Transfection reagent (Qiagen GmbH, 
Hilden, Germany) in EBM-2 basal medium (Clonetics, Lonza, USA) for 24 h. After splitting 
using Trypsin EDTA, transfected cells were seeded onto collagen coated 6 well plates, 
retransfected for an additional round as above and incubated until the cells reached 90% 
confluency. HCAEC were also transfected with validated AllStars negative control siRNA 
(Qiagen) in parallel to control for ‘off target’ effects of siRNAs. Cells were then either treated 
with IL-4 for 8 h and lysed (for qRT-PCR analyses) or trypsinized and seeded into collagen-
coated 8W10E+ arrays (for ECIS barrier function assays, see below). Treatments were 
carried out in EGM-2 MV medium with 2% FBS devoid of transfection complexes. To 
immunostain for Wnt5A, HCAEC transfected once with Wnt5A-siRNA were harvested by 
trypsinization and seeded into collagen-coated BD Falcon 4 chamber culture slides (BD 
Biosciences, USA). There, an additional round of Wnt5A-siRNA transfection was performed 
as in 24-well plates, incubated until the cells attained monolayer confluency and fixed for 
immunostaining.  
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Electric Cell-substrate Impedance Sensing (ECIS) of Endothelial Barrier Function  
Using ECIS, the response of endothelial barrier to the stimulus can be assessed by 
continuously recording changes in transendothelial resistance (TEER) [27,28]. Endothelial 
barrier function was detected in real time using the ECIS® Z-theta system (Applied 
Biophysics) with associated software v.1.2.126 PC as follows: after equilibrating with EBM-2 
basal medium (Clonetics, Lonza, USA) for 24 h, 8W10E+ arrays were coated with rat tail 
collagen type I (diluted 0.01% in sterile pyrogen-free water; BD Biosciences, USA) for 12 h. A 
monodisperse suspension of HCAEC in EGM-2 MV medium (Clonetics, Lonza, USA) 
supplemented with 5% FBS was added to the arrays at a density of 80,000–90,000 cells/well 
and incubated up to 24 h to form a uniform dense monolayer (S1 Fig.). Treatments were 
carried out in fresh medium with or without stimuli. Resistance of HCAEC monolayer was 
measured in Ohms at multiple frequencies ranging from 62.6 Hz to 64 kHz. Each of the eight 
wells of the 8W10E+ arrays contain 40 electrodes that trace the cells at 40 different locations 
in each well. The measurements from each well were averaged.  
 
Automated Cell Migration Assay Using ECIS 
The non-invasive ECIS assisted wound healing assay makes a highly reproducible wound 
with a specific diameter of 250 µm without damaging cells in the surrounding region in 8W1E 
arrays [29]. It was used for studying cell migration and was performed as follows: 
equilibration and collagen coating of 8W1E single electrode arrays were performed as 
described above for 8W10E+ arrays. A monodisperse suspension of HCAEC in EGM-2 MV 
medium (Clonetics, Lonza, USA) supplemented with 5% FBS was added to the arrays at a 
density of 80,000–90,000 cells/well and incubated up to 24 h to form a uniform dense 
monolayer. Treatments were carried out as described above for barrier function assays. 
Three hours after treatment, wounding was activated with default conditions for 8W1E arrays 
(1400 μA, 60000 Hz for 20 sec). This killed the treated cells adhering to the electrode surface 
in 8W1E slides to create a wound. Thereafter, impedance was continuously recorded to 
observe the migration of cells to the wounded area to form a confluent HCAEC monolayer.  
 
Statistical Analysis 
Data were analyzed using GraphPad Prism software version 5.04 (GraphPad Software, San 
Diego, CA). An unpaired 2-tailed Student’s t-test was used and differences were considered 
statistically significant at P<0.05.  
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Results 
Gene expression changes in IL-4 treated adult human VEC 
To identify all genes regulated by IL-4 treatment in HCAEC, we performed dual channel 
oligonucleotide based transcriptome profiling. The transcriptome profile of HCAEC treated 
with IL-4 for 8 h was compared to that of non-treated cells using whole human genome 
oligomicroarrays. The preprocessed gene expression data was analyzed by GeneSpring 
software to identify the genes in treated cells that showed a minimum two fold change in 
expression compared with non-treated cells. IL-4 regulated 2747 genes, of which 1395 
genes were upregulated and 1352 genes were down regulated. PMCH, HAS3, CCL26, 
OTOGL, TMTC1, CH25H, VCAM1, DKK2, SLC10A7, MASP1, COL3A1 and WNT5A were 
the genes most upregulated by IL-4. The top one hundred genes upregulated by IL-4 in 
HCAEC are listed in S1 Table. LRRC14B, DNAH2, TMEM191B, FAM47B, GPR116, TTC9, 
NOG, OR13C8, GPRC6A, CSN3, TMEM236 and PRKG2 were the genes most 
downregulated by IL-4. The top one hundred genes downregulated by IL-4 in HCAEC are 
listed in S2 Table.  
All differentially regulated genes contained in the preprocessed microarray data were 
subjected to GO analyses using MetaCore™ GeneGO software. Using this tool, genes 
regulated at least two fold in their expression were clustered on the basis of their function to 
generate statistically significant cellular pathways. Among the top twenty five biological 
pathways regulated by IL-4, six were associated with immune responses (Figs. 1A and 1B). 
The ‘Immune response_Oncostatin M signaling via JAK-Stat in human cells’ is the pathway 
most significantly regulated by IL-4 treatment in HCAEC (Fig. 1A). Genes of this pathway 
regulated by IL-4 (e.g. CCL2, IL6ST, MMP1 and VEGFA; Table 1) are mainly associated with 
immune responses involving monocyte-endothelial interactions and endothelial 
permeabilization. The ‘Development_Regulation of epithelial-to-mesenchymal transition 
(EMT)’ is the second most significant biological process for IL-4 in HCAEC (Fig. 1A). Among 
the genes of this pathway regulated by IL-4 (Table 1), DLL4 and PDGFB are involved in cell 
proliferation and migration, SNAI1 and ZEB1 are involved in promoting the transition of cells 
from epithelial to mesenchymal state, SNAI2 is involved in repressing the expression of 
cellular junctional proteins and Wnt5A is involved in cell migration and inflammation.  
The ‘Cytoskeleton remodeling_TGF, Wnt and cytoskeletal remodeling’ pathway is the third 
most significant biological process for IL-4 in HCAEC (Fig. 1A). Among the genes regulated 
in this pathway are Wnt5A, Wnt1, VEGFA, LIMK2 and CFL1 (Table 1). The MetaCore™ map 
of this pathway showing these genes within their signaling context indicates that IL-4 
upregulates Wnt as most significant ligand for the cytoskeleton remodeling (Fig. 2, upper 
right quarter), and causes downstream regulation of LIMK2 and CFL1 (Fig. 2, lower left 
quarter). LIMK2 and CFL1 are responsible for actin polymerization. Among the other genes 
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of this pathway are KDR and FZDs (Fig. 2, Table 1), which are involved in VEGF and Wnt 
signaling. 
Data from our study confirm previous findings that IL-4 upregulatesVCAM-1 [10-12], IL-6 [12-
14], MCP [12,14] and LIFR [12] in VEC (S1 Table). Thus, it corroborates the proposed role of 
IL-4 as an ‘alternative inflammatory’ cytokine. With respect to transcription factors mediating 
IL-4 induced gene expression in VEC, the present study demonstrates that IL-4 upregulates 
the expression of genes encoding FOSB (a member of the activator protein-1 family), GATA3 
and EGR1 (S3 Table). 
 
Confirmation of Wnt5A expression by qRT-PCR and immunofluorescence staining 
Since Wnt5A was previously identified as an inflammatory mediator, and expression of the 
gene is shown to be significantly upregulated by IL-4 in microarray analysis, we measured 
Wnt5A mRNA levels in HCAEC treated with IL-4 for 8 h using qRT-PCR. Consistent with the 
microarray data, IL-4 significantly upregulated Wnt5A mRNA levels (Fig. 3A). The induction 
of IL-6 mRNA was considered as indication of positive IL-4 stimulation of HCAEC (Fig. 3B). 
To confirm that IL-4 induced Wnt5A expression is not only specific for HCAEC but also for 
endothelial cells from different vascular beds, we measured Wnt5A mRNA level in IL-4 
treated HPAEC. Consistent with findings obtained in HCAEC, 8 h treatment with IL-4 
significantly upregulated Wnt5A in HPAEC (Fig. 3A). We further confirmed Wnt5A induction 
at the protein level by immunofluorescence staining. In accordance with qRT-PCR and 
microarray data, treatment with IL-4 notably increased the levels of Wnt5A protein in HCAEC 
(Fig. 3C).  
 
LIM kinase (LIMK) 2 and Cofilin-1 (CFL1) are phosphorylated in IL-4 treated HCAEC 
GO analysis of gene expression data shows that IL-4 regulated the LIMK2 and CFL1 genes, 
which are involved in cytoskeleton remodeling (Fig. 2, Table 1). LIMK2, a 
serine/threonine/tyrosine kinase, is a downstream target of ROCK. When phosphorylated by 
the activated ROCK, LIMK2 phosphorylates the actin depolymerization factor CFL1 [30-32]. 
Therefore, we investigated whether LIMK2 and CFL1 proteins are phosphorylated following 
IL-4 treatment in HCAEC. Immunofluorescence staining employing specific antibodies were 
used to detect the phosphorylated forms of LIMK2 (pLIMK2) and CFL1 (pCFL1). Compared 
to non-treated cells, pLIMK2 (Fig. 4, upper panel) and pCFL1 (Fig. 4, lower panel) levels 
were markedly increased in HCAEC treated with IL-4 for 1 h and 4 h respectively. Combining 
IL-4 with the ROCK inhibitor Y-27632 notably suppressed the phosphorylation of LIMK2 
(Figs. 4A and 4B) and CFL1 (Figs. 4A and 4B) in HCAEC.  
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IL-4 induced stress fiber formation can be decreased by Wnt antagonist 
Since inactivation of CFL1 by phosphorylation prevents actin depolymerization resulting in F-
actin stress fiber formation [31-33], and IL-4 treatment induced its phosphorylation, we next 
investigated whether IL-4 causes stress fiber formation. Alterations in actin organization and 
stress fiber formation were visualized by imaging actin-RFP in IL-4 treated live HCAEC. 
Actin-RFP showed only a few thin stress fibers in non-treated HCAEC whereas formation of 
thick actin stress fibers were visible  in IL-4 treated cells (Fig. 5).  
Functional clustering of the IL-4 regulated transcriptome showed upregulation of Wnt5A, and 
this occurs upstream of LIMK2 and CFL1 regulation in the cytoskeleton remodeling process 
(Fig. 2). Having verified upregulated Wnt5A expression and increased stress fiber formation 
through LIMK2 and CFL1 phosphorylation in IL-4 treated HCAEC, we next investigated the 
role of Wnt5A in IL-4 induced stress fiber formation using Wnt antagonists. As Frizzleds 
(Fzds) have long been considered the receptors for Wnts, and transcriptome profiling in this 
study showed upregulation of some Fzd genes by IL-4 in HCAEC, we first attempted to block 
Wnt5A/Fzd signaling using sFRP1. Treating HCAEC with IL-4 in the presence of sFRP1 did 
not influence actin stress fiber formation (Fig. 5). As Ryk is described as an alternative 
receptor for Wnts [34], we next tested whether inhibiting Wnt5A/Ryk interaction by using 
WIF1 has an effect on IL-4 induced stress fiber formation. Stress fiber formation was notably 
suppressed when HCAEC were treated with a combination of IL-4 and WIF1 (Fig. 5). 
HCAEC showed increased stress fiber formation upon Wnt5A treatment, however this was 
notably suppressed after treatment with a combination of Wnt5A and WIF1 (Fig. 5). 
 
IL-4 disrupts the assembly of VE-cadherin in inter-endothelial junctions (IEJs) 
Actin stress fiber formation leads to disassembly of VE-cadherin in IEJs and causes 
intercellular gap formation in endothelial monolayers [35]. Since IL-4 induced stress fiber 
formation, we next investigated if IL-4 affected VE-cadherin assembly in HCAEC. 
Immunofluorescence staining showed continuous distribution of VE-cadherin along the 
cellular periphery, and tight intercellular contacts in non-treated HCAEC monolayers (Fig. 
6A). In contrast, IL-4 treated HCAEC monolayers showed small inter-endothelial gaps with 
marked loss of VE-cadherin at intercellular regions (Fig. 6B).  
 
IL-4 induced endothelial hyperpermeability is decreased by silencing Wnt5A  
Stress fiber formation and IEJ disruption accompanied by inter-endothelial gap formation 
impairs barrier function and increases permeability of endothelial monolayers [35]. Since IL-4 
upregulated Wnt5A, and inhibiting Wnt5A with WIF1 decreased IL-4 induced stress fiber 
formation in HCAEC, we investigated whether Wnt5A mediated IL-4 induced endothelial 
hyperpermeability. Alterations in TEER of tight HCAEC monolayers cultured in 8W10E+ 
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slides were recorded in real time by ECIS. Treatment with IL-4 significantly reduced the 
TEER of HCAEC monolayers to alternating current (AC). Notably, IL-4 induced alterations in 
TEER became apparent 3 h after treatment with IL-4 and persisted for more than 8 h (Fig. 
7A). 
Next, we tested whether silencing Wnt5A improves the barrier function of IL-4 treated 
HCAEC monolayers. HCAEC were transfected with siRNA against Wnt5A. qRT-PCR showed 
that Wnt5A mRNA expression was approximately 60% lower in Wnt5A-siRNA transfected 
cells than in cells transfected with negative control siRNA (S2A Fig.). Accordingly, 
immunofluorescence staining showed decreased Wnt5A protein expression in Wnt5A-siRNA 
transfected HCAEC compared with negative control siRNA transfected cells (S2B and S2C 
Figs.).   
Upon IL-4 treatment, Wnt5A silenced HCAEC showed significantly increased TEER 
compared with non-transfected HCAEC (Fig. 7A). In HCAEC transfected with negative 
control siRNA, the response to IL-4 was not altered (Fig. 7B).  
Since IL-4 upregulated IL-6 in HCAEC in the present study (Fig. 3B), and IL-6 has been 
reported to increase permeability of HUVEC [36] and bovine vascular endothelial cells 
(BVEC) [37], we also investigated whether IL-6 increased permeability of HCAEC 
monolayers. Treatment with IL-6 did not alter the TEER of HCAEC monolayer to AC, thereby 
indicating that IL-6 does not influence the permeability characteristics of HCAEC (Fig. 7C).  
 
IL-4 impairs migration of HCAEC, which can be restored by ROCK inhibition 
Since IL-4 increased the formation of actin stress fibers and caused inter-endothelial gap 
formation, we investigated whether IL-4 would also affect the motility of HCAEC. In an ECIS 
supported wound healing and cell migration assay, IL-4 treated HCAEC exhibited a lower 
impedance and required a longer time to heal the wound compared with non-treated cells 
(Fig. 8A). This indicates that IL-4 significantly reduces endothelial cell motility, causing 
delayed wound closure.  
The present study shows that IL-4 induced phosphorylation of LIMK2 and CFL1 can be 
decreased by inhibiting ROCK. Since ROCK regulates cytoskeleton remodeling, cell–cell 
adhesion and cell motility [32], we investigated whether inhibiting ROCK prevents IL-4 
induced impairment of HCAEC motility. Cells treated with a combination of IL-4 and the 
ROCK inhibitor Y-27632 showed signifcantly higher motility rates and faster wound closure 
than cells treated with only IL-4 (Fig. 8B).  
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IL-4 upregulates Wnt5A expression in human macrophages 
Since macrophages also play a pivotal role in Th2 inflammation, we asked whether Wnt5A 
expression is also upregulated in IL-4 activated human M2 type macrophages. Treatment 
with IL-4 significantly upregulated Wnt5A mRNA expression in macrophages (Fig. 9). 
 
Discussion 
VEC play an important role in maintaining vascular homeostasis. During inflammation, 
soluble mediators secreted by activated immune cells paracrinically act on VEC and 
significantly alter their functions to confer ‘inflamed’ or ‘activated’ phenotypes on them. IL-4 is 
a potent Th2 cytokine known to cause activation of VEC and induce endothelial barrier 
dysfunction [21]. However, the exact mechanisms responsible for IL-4 dependent endothelial 
dysfunction in VEC remained unclear. In the present study, we detected all genes regulated 
by paracrine IL-4 signaling in adult VEC by whole human genome microarray based 
transcriptome profiling (Fig. 1, S1 and S2 Tables).  
This is the first study to demonstrate that IL-4 significantly upregulates Wnt5A expression in 
adult VEC. A previous study demonstrated that HUVEC treated with a combination of TNF-α, 
IL-1 and IL-8 upregulated the expression of Wnt5A mRNA [38]. Wnt5A is a non-canonical 
Wnt ligand, recently identified as a pro-inflammatory mediator of macrophage activation in 
vascular inflammation [24]. Wnt5A has been demonstrated to enhance the permeability of 
HUVEC monolayers in a 14C sucrose permeability test [39] and IL-4 caused morphological 
changes and induced inter-endothelial gap formation in HUVEC [17]. Furthermore IL-4 has 
been demonstrated to induce hyperpermeability of HUVEC [21]. Inter-endothelial gap 
formation caused by cytoskeletal rearrangements impairs the barrier functions of endothelial 
monolayers and is the principal pathway causing endothelial hyperpermeability and 
subsequent edema formation in inflammation [40]. Endothelial hyperpermeability accounts 
for increased efflux of plasma through microvessel walls into neighboring tissues, leading to 
the formation of protein rich tissue edema. Edema formation resulting from vascular leakage 
is an important consequence of allergic inflammation [21] and a most common side effect of 
IL-4 therapy in human cancer patients [41]. Addressing a potential role for Wnt5A in IL-4 
induced endothelial cytoskeleton remodeling, GO analyses for the current study point to 
Wnt5A as a potential ligand for the ‘Cytoskeleton remodeling_TGF, Wnt and cytoskeletal 
remodeling’ pathway (Fig. 2). A prominent role for Wnt5A in mediating IL-4 induced 
cytoskeleton remodeling is evident from our observation that IL-4 induced actin stress fiber 
formation can be prevented by blocking Wnt5A signaling (Fig. 5). Further proof for the 
involvement of Wnt5A is provided by functional experiments demonstrating that the 
enhanced permeability of HCAEC monolayers upon IL-4 treatment can be significantly 
decreased by silencing Wnt5A expression (Fig. 7A). Our findings support the crucial role of 
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Wnt5A in stress fiber formation and inter-endothelial gap formation, leading to impaired 
barrier function in IL-4 treated HCAEC.  
Wnt5A signals mainly through Fzd receptors but can also function through Ryk, a member of 
the family of atypical receptor tyrosine-protein kinases (RTKs). Ryk consists of an 
extracellular Wnt-binding domain, a PDZ binding motif and an intracellular inactive tyrosine 
kinase domain. Its Wnt-binding domain is homologous to the extracellular Wnt antagonist, 
WIF protein. sFRP1 is another Wnt antagonist that contains a frizzled like cysteine-rich 
domain (CRD) homologous to the extracellular Wnt-binding domains of Fzd receptors [34]. 
The availability of the receptor, presence of Wnt antagonists and the cellular environment 
determines which receptors Wnts engages and the signals that are generated. The 
involvement of Ryk, but not Fzd receptors, in IL-4 induced Wnt5A signaling in HCAECs is 
obvious from our observation that stress fiber formation was prevented in the presence of 
WIF1 but not sFRP1 (Fig. 5). Others have demonstrated that Wnt5A/Ryk signaling through 
Rho-kinase activation inhibits axon growth in rats [42]. We propose that in HCAEC, Wnt5A 
signaling through Ryk receptor activates ROCK that in turn phosphorylates LIMK2. Activated 
pLIMK2 in turn phosphorylates CFL1 that is then deactivated, and as a consequence, allows 
actin fiber polymerization. This disrupts VE-cadherin assembly in IEJs leading to the 
formation of inter-endothelial gaps, as we have observed in the present study (Fig. 6B). The 
involvement of ROCK as a downstream effector of Wnt5A/Ryk signaling in HCAEC is very 
well supported by the observations that phosphorylation of LIMK2 and CFL1 following IL-4 
treatment can be decreased by inhibiting ROCK (Fig. 4). The function of ROCK in IL-4 
induced cytoskeleton remodeling is further evident from the standardized ECIS cell migration 
assay that shows improved migratory and wound healing capacity of cells treated with a 
combination of IL-4 and ROCK inhibitor (Figs. 8A and 8B).  
Intriguingly, the present study confirms that IL-6 is upregulated by IL-4 in HCAEC but IL-6 
does not influence TEER in the ECIS based standardized permeability assay (Fig. 7C), even 
though it increases permeability in HUVEC [36] and BVEC [37]. Further studies are 
warranted to confirm that IL-6 is not responsible for increased VEC permeability, or whether 
this effect of IL-6 varies between endothelial cells from different vascular beds and thus 
depends on endothelial heterogeneity.  
The whole genome transcriptome analysis of IL-4 treated HCAEC further revealed induction 
of vascular endothelial growth factor (VEGF)-A (Table 1, Fig. 2). A previous study showed 
that IL-4 increased the production of VEGF in unstimulated synovial fibroblasts [43]. VEGF-A 
acts as a proangiogenic factor in wound healing. It enhances endothelial cell migration from 
pre-existing blood vessels and promotes the recruitment of endothelial progenitor cells 
(EPCs) from peripheral circulation [44]. Surprisingly, the present study demonstrates an 
inhibitory effect of IL-4 on endothelial cell migration while upregulating VEGF-A. Even though 
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this contradicts the effects of VEGF in stimulating endothelial cell migration, it could be 
explained by the observation that IL-4 downregulates expression of VEGFR-2 (Table 1, Fig. 
2). VEGFR-2 (also known as KDR) is a receptor specific for VEGF [44] and downregulation 
would block autocrine VEGF-A signaling in endothelial cells. This is a likely feedback 
mechanism inhibiting angiogenesis. As soluble factors secreted by VEC paracrinically act on 
other immune cells such as macrophages, it is also possible that VEGF-A produced by VEC 
interacts with VEGF receptors expressed on other immune cells. This view is well supported 
by previous studies which demonstrated that VEGF-A acted as a chemoattractant for 
monocytes expressing VEGF receptor 1 [45-48].  
Among the genes highly expressed upon IL-4 treatment  of HCAEC (S1 Table), pro-melanin-
concentrating hormone (PMCH) has also been described previously as highly induced by 
activated Th2 cells [49]. IL-4 triggered expression of hyaluronan synthase 3 (HAS3) may 
facilitate the adhesion and migration of activated immune cells and cancer cells during 
inflammatory response and cancer metastasis, respectively. Induction of CCL26 by IL-4 has 
already been described in VEC and it acts as a chemokine for eosinophils [50].  
 
Conclusions 
Our study indicates that Wnt5A is crucially involved in cytoskeleton rearrangement mediated 
by IL-4 in VEC. We further show that Wnt5A signals downstream through the ROCK–LIMK2–
CFL1 pathway and show that Ryk is a possible receptor for Wnt5A signaling in VEC. Here 
we demonstrate a crucial role for Wnt5A in IL-4 induced actin cytoskeleton remodeling and 
consequent barrier dysfunction and hyperpermeability of VEC. Therapeutic approaches 
targeting Wnt5A may reduce microvascular leakage and subsequent edema formation 
associated with IL-4 driven pathophysiological conditions such as allergic inflammation, 
tumor inflammation, and angioedema. Moreover, we show for the first time that IL-4 induces 
Wnt5A in human M2 type macrophages, which is different to the Toll-like receptor (TLR) 
mediated Wnt5A induction described previously [24]. Together, this establishes Wnt5A as a 
component of both classically and alternatively activated macrophages. Further studies 
delineating the specific role of Wnt5A in alternatively activated macrophages would provide 
novel insights into the inflammatory responses in diseases associated with Th2 activity.  
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Table 1. Key genes regulated by IL-4 in ‘Immune response_Oncostatin M signaling via 
JAK-Stat in human cells’, ‘Development_Regulation of epithelial-to-mesenchymal 
transition (EMT)’ and ‘Cytoskeleton remodeling_TGF, Wnt and cytoskeletal 
remodeling’ pathways in HCAEC. 
 
aGenes regulated by IL-4 in ‘Immune response_Oncostatin M signaling via JAK-Stat in 
human cells’ pathway. 
bGenes regulated by IL-4 in ‘Development_Regulation of epithelial-to-mesenchymal transition 
(EMT)’ pathway. 
cGenes regulated by IL-4 in ‘Cytoskeleton remodeling_TGF, Wnt and cytoskeletal 
remodeling’ pathway. 
Gene Symbol Accession Sequence Description Regulation 
CAV1
c
 NM_001172895 Homo sapiens caveolin 1 Down 
CCL2
a 
 
NM_002982 Homo sapiens chemokine (C-C motif) ligand 2 Up 
 
CFL1
c
 NM_005507 Homo sapiens cofilin 1  Down 
CCND1
a,c 
NM_053056 Homo sapiens cyclin D1 Down 
DLL4
b  
NM_019074 
 
Homo sapiens delta-like 4 Down 
FZD4
b,c 
NM_012193 Homo sapiens frizzled class receptor 4 Up 
FZD8
b,c 
NM_031866 Homo sapiens frizzled class receptor 8 Up 
FOXO3
c 
NM_001455 Homo sapiens forkhead box O3 Up 
HEY1
b 
NM_001040708 
 
Homo sapiens hes-related family bHLH 
transcription factor with YRPW motif 1 
Down 
IL6ST
a 
NM_001190981 Homo sapiens interleukin 6 signal transducer Up 
JAG1
b 
NM_000214 Homo sapiens jagged 1 Up 
KDR
c 
NM_002253 Homo sapiens kinase insert domain receptor Down 
LIFRα
a 
NM_002310 Homo sapiens leukemia inhibitory factor 
receptor alpha 
Up 
LIMK2
c 
NM_001031801 Homo sapiens LIM domain kinase 2 Down 
MAPK13
c 
NM_002754 Homo sapiens mitogen-activated protein kinase 
13 
Down 
MAP2K3
c 
NM_002756 Homo sapiens mitogen-activated protein kinase 
kinase 3 
Down 
MMP1
a 
NM_002421 Homo sapiens matrix metallopeptidase 1 Up 
MMP7
c
 NM_002423 Homo sapiens matrix metallopeptidase 7 Up 
MYLK
c 
NM_053025 Homo sapiens myosin light chain kinase Down 
MYLK2
c 
NM_033118 Homo sapiens myosin light chain kinase 2 Down 
PDGF
b
 NM_002608 Homo sapiens platelet-derived growth factor 
beta polypeptide 
Down 
SNAI1
b 
NM_005985 
 
Homo sapiens snail homolog 1 Down 
SNAI2
b 
NM_003068 
 
Homo sapiens snail homolog 2 Down 
TGF2
b NM_003238 Homo sapiens transforming growth factor, beta 
2 
Up 
TGF3
b NM_003239 Homo sapiens transforming growth factor, beta 
3 
Up 
VEGFA
a,c 
NM_001025366 Homo sapiens vascular endothelial growth factor 
A 
Up 
WNT5A
b,c 
NM_003392 Homo sapiens wingless-type MMTV integration 
site family, member 5A 
Up 
ZEB1
b 
NM_001128128 Homo sapiens zinc finger E-box binding 
homeobox 1 
Down 
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Figure 1 
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Fig. 1. The twenty five biological pathways most significantly (P<0.05) regulated by IL-
4 treatment in HCAEC. (A, B) Pathways represented as histograms are ranked by the –log 
value (P value). Length of histogram corresponds to the number of genes associated with 
that specific pathway.  
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Figure 2 
 
 
 
 
 
 
Fig. 2. Metacore™ map showing the signaling context of the genes contained in the 
‘Cytoskeleton remodeling_TGF, Wnt and cytoskeletal remodeling’ pathway. Genes 
regulated by IL-4 are marked by red and blue thermometer icons representing upregulated 
and downregulated gene expression respectively.  
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Figure 3 
 
 
 
 
 
Fig. 3. Expression of Wnt5A in IL-4 treated HCAEC. Fold changes in the expression of (A) 
Wnt5A mRNA in 8 h IL-4 treated HCAEC and HPAEC and (B) IL-6 mRNA in 8 h IL-4 treated 
HCAEC. Data were obtained from three independent qRT-PCR experiments run with 
duplicate samples and expressed as the mean ± SEM. *P<0.05, **P<0.005 using an 
unpaired Student’s t-test. (C) Wnt5A protein expression in non-treated and IL-4 treated 
HCAEC. Wnt5A is immunostained (red). Zeiss Axioskope, magnification 20×.  
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Figure 4 
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Fig. 4. Phosphorylation of LIMK2 and CFL1 in IL-4 treated HCAEC. (A) pLIMK2 and 
pCofilin-1 were immunostained (red) in HCAEC treated with IL-4 either alone or in 
combination with Y-27632. F-actin (fluorescent phalloidin, green) and nuclei (DAPI, blue) 
were also stained. Zeiss Axioskope, magnification 20×. (B) Mean cellular fluorescent 
intensities of pLIMK2 and pCFL1 quantified by Fiji software.  
 
 
 
 
 
 
 
 
Figure 5 
 
 
 
 
 
Fig. 5. Stress fiber formation in IL-4 treated HCAEC. Live actin-RFP staining showing the 
formation of actin stress fibers in HCAEC treated with IL-4 or Wnt5A in the absence or 
presence of sFRP1 and WIF1. Zeiss Axio Observer.Z1, magnification 40×. 
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Figure 6 
 
 
 
 
 
Fig. 6. Assembly of VE-cadherin in IL-4 treated HCAEC. VE-cadherin immunostained 
(red) in HCAEC either non-treated (A) or treated with IL- 4 for 8 h (B). Nuclei (DAPI, blue). 
Zeiss Axioskope, magnification 40×. 
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Figure 7 
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Fig. 7. ECIS barrier function assays showing the effect of Wnt5A in IL-4 induced 
hyperpermeability of HCAEC. Uniform confluent monolayers of HCAEC cultured in 
stabilized and collagen coated ECIS 8W10E+ arrays were treated with IL-4. TEER of HCAEC 
monolayers was measured in Ohms continuously at multiple frequencies ranging from 62.6 
Hz to 64 kHz, normalized to its value at time zero and plotted with respect to time. 
Stimulations conducted in duplicate wells were grouped and averaged to plot a single curve 
with error bars representing SD. Figures shown depict the resistance measurements 
conducted at 4000 Hz and represent four independent experiments. (A) 1, non-treated 
Wnt5A-siRNA transfected HCAEC; 2, non-treated non-transfected HCAEC; 3, IL-4 treated 
Wnt5A-siRNA transfected HCAEC; 4, IL-4 treated non-transfected HCAEC. (B) 1, non-
treated negative control siRNA transfected HCAEC; 2, IL-4 treated negative control siRNA 
transfected HCAEC; 3, IL-4 treated non-transfected HCAEC. (C) Black, non-treated; green, 
IL-6. 
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Figure 8 
 
 
 
 
 
Fig. 8. Automated wound healing assay showing decreased motility of IL-4 treated 
HCAEC. Uniform confluent monolayers of HCAEC cultured in stabilized and collagen coated 
ECIS 8W1E cultureware were treated with IL-4 either alone or in combination with Y-27632. 
Three hours after treatment, wells were subjected to an elevated electric field to create a 
wound. Measurements were started immediately after wounding. Impedance of HCAEC 
monolayer was measured in Ohms every 5 min at multiple frequencies ranging from 62.6 Hz 
to 64 kHz and plotted with respect to time. Representative figures depict the impedance of 
wells after wounding was applied. Figures shown depict the measurements conducted at 
4000 Hz and represent four independent experiments. (A) Black, non-treated; Blue, IL-4. (B) 
Black, control with Y27632; Green, IL-4 + Y27632. 
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Figure 9 
 
 
 
Fig. 9. Wnt5A expression in IL-4 activated human macrophages. Fold changes in the 
expression of Wnt5A mRNA in IL-4 treated human macrophages. Data were obtained from 
two independent qRT-PCR experiments run with duplicate samples using RNA isolated from 
macrophages from four different donors and expressed as the mean ± SEM. *P<0.05 using 
an unpaired Student’s t- test. 
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S1 Table. The top 100 genes upregulated by IL-4 in HCAEC. 
  
Gene symbol Accession Sequence description Fold change 
PMCH NM_002674 Homo sapiens pro-melanin-concentrating 
hormone  
41,795143 
HAS3 NM_005329 Homo sapiens hyaluronan synthase 3 40,64191 
CCL26 NM_006072 Homo sapiens chemokine (C-C motif) 
ligand 26  
37,32348 
OTOGL NM_173591 Homo sapiens otogelin-like  28,089672 
TMTC1 NM_175861 Homo sapiens transmembrane and 
tetratricopeptide repeat containing 1  
26,668077 
CH25H NM_003956 Homo sapiens cholesterol 25-hydroxylase  21,65999 
VCAM1 NM_001078 Homo sapiens vascular cell adhesion 
molecule 1  
19,443674 
DKK2 NM_014421 Homo sapiens dickkopf homolog 2  12,351812 
SLC10A7 NM_032128 Homo sapiens solute carrier family 10 
(sodium/bile acid cotransporter family), 
member 7  
12,2331505 
MASP1 NM_001031849 Homo sapiens mannan-binding lectin serine 
peptidase 1 
11,580042 
COL3A1 NM_000090 Homo sapiens collagen, type III, alpha 1  10,082533 
WNT5A NM_003392 Homo sapiens wingless-type MMTV 
integration site family, member 5A  
9,96113 
PKD1L1 NM_138295 Homo sapiens polycystic kidney disease 1 
like 1  
9,657538 
SOCS1 NM_003745 Homo sapiens suppressor of cytokine 
signalling 1  
9,610145 
IGF1 NM_000618 Homo sapiens insulin-like growth factor 1  9,396036 
ERAP1 NM_016442 Homo sapiens endoplasmic reticulum 
aminopeptidase 1  
9,268832 
PLCB4 NM_182797 Homo sapiens phospholipase C, beta 4  8,71052 
HS3ST1 NM_005114 Homo sapiens heparan sulfate 
(glucosamine) 3-O-sulfotransferase 1  
8,354389 
FILIP1L NM_182909 Homo sapiens filamin A interacting protein 
1-like  
8,258449 
NCF2 NM_000433 Homo sapiens neutrophil cytosolic factor 2 8,030248 
MAP3K8 NM_005204 Homo sapiens mitogen-activated protein 
kinase kinase kinase 8  
7,8828645 
BMP2 NM_001200 Homo sapiens bone morphogenetic protein 
2  
7,6503243 
LIFR NM_002310 Homo sapiens leukemia inhibitory factor 
receptor alpha 
7,4233665 
BATF3 NM_018664 Homo sapiens basic leucine zipper 
transcription factor, ATF-like 3  
7,255049 
FOXC1 NM_001453 Homo sapiens forkhead box C1 7,21699 
CISH NM_145071 Homo sapiens cytokine inducible SH2- 7,0423675 
2 
 
containing protein 
EGR1 NM_001964 Homo sapiens early growth response 1  7,0303206 
MMP7 NM_002423 Homo sapiens matrix metallopeptidase 7 6,91629 
AGXT2L1 NM_031279 Homo sapiens alanine-glyoxylate 
aminotransferase 2-like 1  
6,9126115 
FAM115C NM_173678 Homo sapiens family with sequence 
similarity 115, member C 
6,896242 
SELP NM_003005 Homo sapiens selectin P 6,8684745 
VSTM1 NM_198481 Homo sapiens V-set and transmembrane 
domain containing 1 
6,8496885 
RTP4 NM_022147 Homo sapiens receptor (chemosensory) 
transporter protein 4  
6,7024455 
CHRNB2 NM_000748 Homo sapiens cholinergic receptor, 
nicotinic, beta 2 
6,6299343 
VIT NM_001177972 Homo sapiens vitrin  6,553535 
GDF6 NM_001001557 Homo sapiens growth differentiation factor 
6  
6,516541 
SLC1A6 NM_005071 Homo sapiens solute carrier family 1 (high 
affinity aspartate/glutamate transporter), 
member 6  
6,510828 
IGFL2 NM_001002915 Homo sapiens IGF-like family member 2  6,4454446 
EFCAB9 NM_001171183 Homo sapiens EF-hand calcium binding 
domain 9 
6,444065 
OLFML2A NM_182487 Homo sapiens olfactomedin-like 2A  6,3796315 
MYH11 NM_001040114 Homo sapiens myosin, heavy chain 11 6,3696566 
SP5 NM_001003845 Homo sapiens Sp5 transcription factor  6,3607006 
C5orf46 NM_206966 Homo sapiens chromosome 5 open reading 
frame 46 
6,228292 
UBD NM_006398 Homo sapiens ubiquitin D  6,2165623 
C11orf70 NM_001195005 Homo sapiens chromosome 11 open 
reading frame 70 
6,2152133 
TMTC1 NM_175861 Homo sapiens transmembrane and 
tetratricopeptide repeat containing 1  
6,153664 
DACT1 NM_016651 Homo sapiens dapper, antagonist of beta-
catenin, homolog 1  
6,1239324 
MTMR7 NM_004686 Homo sapiens myotubularin related protein 
7  
6,1005383 
POU4F1 NM_006237 Homo sapiens POU class 4 homeobox 1 5,999347 
CXCR7 NM_020311 Homo sapiens chemokine (C-X-C motif) 
receptor 7 
5,9171534 
PCDHGC4 NM_032406 Homo sapiens protocadherin gamma 
subfamily C, 4  
5,8364773 
FABP4 NM_001442 Homo sapiens fatty acid binding protein 4 5,8192124 
CCL11 NM_002986 Homo sapiens chemokine (C-C motif) 
ligand 11 
5,7279153 
IL6ST NM_002184 Homo sapiens interleukin 6 signal 
transducer  
5,718929 
DUOX1 NM_017434 Homo sapiens dual oxidase 1  5,7007294 
TSLP NM_033035 Homo sapiens thymic stromal 
lymphopoietin  
5,688645 
FXYD1 NM_005031 Homo sapiens FXYD domain containing 
ion transport regulator 1 
5,568317 
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KCND2 NM_012281 Homo sapiens potassium voltage-gated 
channel, Shal-related subfamily, member 2  
5,4865217 
NAP1L3 NM_004538 Homo sapiens nucleosome assembly 
protein 1-like 3 
5,437414 
SOX12 NM_006943 Homo sapiens SRY (sex determining region 
Y)-box 12 
5,4160028 
TMEM87B NM_032824 Homo sapiens transmembrane protein 87B 5,389064 
C22orf33 NM_178552 Homo sapiens chromosome 22 open 
reading frame 33  
5,3850923 
ELMOD1 NM_018712 Homo sapiens ELMO/CED-12 domain 
containing 1  
5,357257 
INHBA NM_002192 Homo sapiens inhibin, beta A  5,324977 
HTR3C NM_130770 Homo sapiens 5-hydroxytryptamine 
(serotonin) receptor 3, family member C  
5,283623 
C2orf81 NM_001145054 Homo sapiens chromosome 2 open reading 
frame 81 
5,1805587 
PTCH1 NM_001083602 Homo sapiens patched 1 5,1540847 
CCL20 NM_004591 Homo sapiens chemokine (C-C motif) 
ligand 20  
5,0769067 
ANKRD55 NM_024669 Homo sapiens ankyrin repeat domain 55  4,962989 
C2CD4A NM_207322 Homo sapiens C2 calcium-dependent 
domain containing 4A  
4,910864 
HTR2B NM_000867 Homo sapiens 5-hydroxytryptamine 
(serotonin) receptor 2B 
4,856557 
IL6 NM_000600 Homo sapiens interleukin 6  4,831578 
C17orf109 NM_001162995 Homo sapiens chromosome 17 open 
reading frame 109 
4,821182 
C6 NM_000065 Homo sapiens complement component 6  4,8188324 
MYOM1 NM_003803 Homo sapiens myomesin 1 4,792512 
LOX NM_002317 Homo sapiens lysyl oxidase  4,7536435 
C1orf172 NM_152365 Homo sapiens chromosome 1 open reading 
frame 172 
4,7347064 
RBPMS2 NM_194272 Homo sapiens RNA binding protein with 
multiple splicing 2  
4,720724 
ZNF415 NM_001136038 Homo sapiens zinc finger protein 415  4,7036552 
IL1RL1 NM_016232 Homo sapiens interleukin 1 receptor-like 1  4,659585 
AMIGO2 NM_181847 Homo sapiens adhesion molecule with Ig-
like domain 2  
4,650363 
MYB NM_005375 Homo sapiens v-myb myeloblastosis viral 
oncogene homolog  
4,6442075 
ZFR2 NM_015174 Homo sapiens zinc finger RNA binding 
protein 2  
4,6371136 
SERPINB13 NM_012397 Homo sapiens serpin peptidase inhibitor, 
clade B (ovalbumin), member 13   
4,599599 
CRHBP NM_001882 Homo sapiens corticotropin releasing 
hormone binding protein  
4,5980325 
FSCN3 NM_020369 Homo sapiens fascin homolog 3, actin-
bundling protein, testicular  
4,592466 
DBF4 NM_006716 Homo sapiens DBF4 homolog  4,5902414 
LRP1B NM_018557 Homo sapiens low density lipoprotein 
receptor-related protein 1B  
4,5893173 
AIM1 NM_001624 Homo sapiens absent in melanoma 1  4,5863357 
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KIR2DS4 NM_012314 Homo sapiens killer cell immunoglobulin-
like receptor, two domains, short 
cytoplasmic tail, 4 
4,5634003 
HIST2H2BE NM_003528 Homo sapiens histone cluster 2, H2be 4,558278 
NUP62CL NM_017681 Homo sapiens nucleoporin 62kDa C-
terminal like 
4,5011163 
BCL11A NM_022893 Homo sapiens B-cell CLL/lymphoma 11A  4,495745 
FPR2 NM_001462 Homo sapiens formyl peptide receptor 2  4,471268 
EMR2 NM_013447 Homo sapiens egf-like module containing, 
mucin-like, hormone receptor-like 2  
4,437741 
FLRT3 NM_198391 Homo sapiens fibronectin leucine rich 
transmembrane protein 3  
4,4005938 
OXTR NM_000916 Homo sapiens oxytocin receptor 4,391427 
ADAMTSL3 NM_207517 Homo sapiens ADAMTS-like 3  4,3507504 
SPDYE5 NM_001099435 Homo sapiens speedy homolog E5  4,3375187 
EFCAB3 NM_173503 Homo sapiens EF-hand calcium binding 
domain 3 
4,3256946 
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S2 Table. The top 100 genes downregulated by IL-4 in HCAEC. 
 
Gene symbol Accession Sequence description Fold change 
LRRC14B NM_001080478 Homo sapiens leucine rich repeat 
containing 14B  
-12,945567 
DNAH2 NM_020877 Homo sapiens dynein, axonemal, heavy 
chain 2  
-9,480801 
TMEM191B NM_001242313 Homo sapiens transmembrane protein 191B  -8,606891 
FAM47B NM_152631 Homo sapiens family with sequence 
similarity 47, member B  
-8,436531 
GPR116 NM_001098518 Homo sapiens G protein-coupled receptor 
116  
-7,9685755 
TTC9 NM_015351 Homo sapiens tetratricopeptide repeat 
domain 9  
-7,767549 
NOG NM_005450 Homo sapiens noggin -7,578256 
OR13C8 NM_001004483 Homo sapiens olfactory receptor, family 13, 
subfamily C, member 8  
-7,5168667 
GPRC6A NM_148963 Homo sapiens G protein-coupled receptor, 
family C, group 6, member A  
-7,467667 
CSN3 NM_005212 Homo sapiens casein kappa  -7,366031 
TMEM236 NM_001098844 Homo sapiens transmembrane protein 236  -7,1928277 
PRKG2 NM_006259 Homo sapiens protein kinase, cGMP-
dependent, type II  
-7,114787 
DGKB NM_145695 Homo sapiens diacylglycerol kinase, beta 
90kDa  
-7,055235 
CSTL1 NM_138283 Homo sapiens cystatin-like 1  -7,038949 
GALNT14 NM_024572 Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 
-6,925887 
N4BP3 NM_015111 Homo sapiens NEDD4 binding protein 3 -6,8579197 
ARHGEF38 NM_001242729 Homo sapiens Rho guanine nucleotide 
exchange factor (GEF) 38  
-6,75289 
MRVI1 NM_130385 Homo sapiens murine retrovirus integration 
site 1 homolog  
-6,6988463 
EPN3 NM_017957 Homo sapiens epsin 3  -6,594775 
FSIP2 NM_173651 Homo sapiens fibrous sheath interacting 
protein 2  
-6,4968653 
SGPP2 NM_152386 Homo sapiens sphingosine-1-phosphate 
phosphatase 2  
-5,6272907 
STARD6 NM_139171 Homo sapiens StAR-related lipid transfer 
(START) domain containing 6  
-5,626096 
SLC22A12 NM_144585 Homo sapiens solute carrier family 22 
(organic anion/urate transporter), member 
12  
-5,625856 
FCRL6 NM_001004310 Homo sapiens Fc receptor-like 6  -5,603581 
GPR151 NM_194251 Homo sapiens G protein-coupled receptor 
151  
-5,515336 
TTC16 NM_144965 Homo sapiens tetratricopeptide repeat 
domain 16  
-5,5019436 
SGCD NM_000337 Homo sapiens sarcoglycan, delta  -5,411149 
OSTN NM_198184 Homo sapiens osteocrin -5,3031754 
PCDHGB1 NM_032095 Homo sapiens protocadherin gamma -5,2786555 
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subfamily B, 1  
NEK10 NM_199347 Homo sapiens NIMA (never in mitosis gene 
a)- related kinase 10  
-5,2474537 
FREM3 NM_001168235 Homo sapiens FRAS1 related extracellular 
matrix 3  
-5,1939254 
NLRP10 NM_176821 Homo sapiens NLR family, pyrin domain 
containing 10  
-5,183514 
REM1 NM_014012 Homo sapiens RAS (RAD and GEM)-like 
GTP-binding 1  
-5,148359 
TCHHL1 NM_001008536 Homo sapiens trichohyalin-like 1  -5,1217394 
ZNF846 NM_001077624 Homo sapiens zinc finger protein 846  -5,025068 
LEKR1 NM_001004316 Homo sapiens leucine, glutamate and lysine 
rich 1  
-5,012441 
TPTE2 NM_199254 Homo sapiens transmembrane 
phosphoinositide 3-phosphatase and tensin 
homolog 2  
-5,006573 
TAS2R5 NM_018980 Homo sapiens taste receptor, type 2, 
member 5  
-5,004593 
CEACAM3 NM_001815 Homo sapiens carcinoembryonic antigen-
related cell adhesion molecule 3  
-4,9621882 
ZNF551 NM_138347 Homo sapiens zinc finger protein 551  -4,959369 
SEMA4D NM_006378 Homo sapiens sema domain, 
immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4D 
-4,948316 
KIT NM_000222 Homo sapiens v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog  
-4,931853 
ANKRD20A2 NM_001012421 Homo sapiens ankyrin repeat domain 20 
family, member A2 
-4,89075 
EPHA10 NM_173641 Homo sapiens EPH receptor A10  -4,870359 
SEMA5B NM_001031702 Homo sapiens sema domain, seven 
thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 5B  
-4,8688235 
SPRR4 NM_173080 Homo sapiens small proline-rich protein 4  -4,8533287 
MYL3 NM_000258 Homo sapiens myosin, light chain 3 -4,8104806 
PLB1 NM_153021 Homo sapiens phospholipase B1  -4,73602 
CHI3L1 NM_001276 Homo sapiens chitinase 3-like 1  -4,7334285 
FMN2 NM_020066 Homo sapiens formin 2  -4,7102337 
INMT NM_001199219 Homo sapiens indolethylamine N-
methyltransferase  
-4,67023 
ZCCHC13 NM_203303 Homo sapiens zinc finger, CCHC domain 
containing 13  
-4,646102 
HAPLN1 NM_001884 Homo sapiens hyaluronan and proteoglycan 
link protein 1  
-4,6067057 
DNAJB8 NM_153330 Homo sapiens DnaJ (Hsp40) homolog, 
subfamily B, member 8  
-4,6007133 
RGS7BP NM_001029875 Homo sapiens regulator of G-protein 
signalling 7 binding protein  
-4,581259 
XAGE5 NM_130775 Homo sapiens X antigen family, member 5  -4,4819264 
RNASE2 NM_002934 Homo sapiens ribonuclease, RNase A 
family, 2  
-4,4812913 
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MUC12 NM_001164462 Homo sapiens mucin 12, cell surface 
associated  
-4,476315 
ALPK2 NM_052947 Homo sapiens alpha-kinase 2  -4,464628 
FMR1NB NM_152578 Homo sapiens fragile X mental retardation 
1 neighbor  
-4,4601526 
ACOT6 NM_001037162 Homo sapiens acyl-CoA thioesterase 6  -4,4558067 
ZNF436 NM_001077195 Homo sapiens zinc finger protein 436  -4,439032 
PPP1R1A NM_006741 Homo sapiens protein phosphatase 1, 
regulatory (inhibitor) subunit 1A  
-4,4109473 
HS6ST3 NM_153456 Homo sapiens heparan sulfate 6-O-
sulfotransferase 3  
-4,379276 
CXorf22 NM_152632 Homo sapiens chromosome X open reading 
frame 22  
-4,3745127 
KAZN NM_015209 Homo sapiens kazrin, periplakin interacting 
protein  
-4,3690753 
SPANXB2 NM_145664 Homo sapiens SPANX family, member B2  -4,362014 
SPINK5 NM_001127698 Homo sapiens serine peptidase inhibitor, 
Kazal type 5  
-4,3541923 
DDIT4L NM_145244 Homo sapiens DNA-damage-inducible 
transcript 4-like 
-4,311884 
VCX2 NM_016378 Homo sapiens variable charge, X-linked 2  -4,2942934 
CCKBR NM_176875 Homo sapiens cholecystokinin B receptor  -4,259044 
KIAA1199 NM_018689 Homo sapiens KIAA1199  -4,2481823 
ATP2A3 NM_174958 Homo sapiens ATPase, Ca++ transporting, 
ubiquitous  
-4,239258 
SPANXN3 NM_001009609 Homo sapiens SPANX family, member N3  -4,2082605 
KRT6B NM_005555 Homo sapiens keratin 6B  -4,2064652 
APLN NM_017413 Homo sapiens apelin  -4,198813 
PCDHA1 NM_031410 Homo sapiens protocadherin alpha 1  -4,17986 
ZP2 NM_003460 Homo sapiens zona pellucida glycoprotein 
2  
-4,1756864 
SMOC2 NM_022138 Homo sapiens SPARC related modular 
calcium binding 2  
-4,1644816 
SPINK4 NM_014471 Homo sapiens serine peptidase inhibitor, 
Kazal type 4  
-4,1478534 
C1orf49 NM_032126 Homo sapiens chromosome 1 open reading 
frame 49  
-4,146102 
CYP3A43 NM_022820 Homo sapiens cytochrome P450, family 3, 
subfamily A, polypeptide 43 
-4,1281586 
GPR112 NM_153834 Homo sapiens G protein-coupled receptor 
112  
-4,1099563 
ZNF253 NM_021047 Homo sapiens zinc finger protein 253  -4,0930114 
TPD52L3 NM_033516 Homo sapiens tumor protein D52-like 3  -4,05051 
GZMK NM_002104 Homo sapiens granzyme K  -4,0004787 
LOC55908 NM_018687 Homo sapiens hepatocellular carcinoma-
associated gene TD26  
-3,9874408 
SPEF2 NM_024867 Homo sapiens sperm flagellar 2  -3,9677868 
ZNF208 NM_007153 Homo sapiens zinc finger protein 208 -3,9518707 
PTCHD2 NM_020780 Homo sapiens patched domain containing 2  -3,9511278 
PARVG NM_022141 Homo sapiens parvin, gamma (PARVG), 
transcript variant 1, mRNA  
-3,9182448 
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FTCD NM_206965 Homo sapiens formiminotransferase 
cyclodeaminase (FTCD), transcript variant 
A, mRNA  
-3,9056072 
NKAIN2 NM_001040214 Homo sapiens Na+/K+ transporting ATPase 
interacting 2 (NKAIN2), transcript variant 
1, mRNA  
-3,877624 
DMGDH NM_013391 Homo sapiens dimethylglycine 
dehydrogenase (DMGDH), nuclear gene 
encoding mitochondrial protein, mRNA  
-3,8753538 
SPATA13 NM_001166271 Homo sapiens spermatogenesis associated 
13 (SPATA13), transcript variant 1, mRNA  
-3,860474 
PTPN3 NM_002829 Homo sapiens protein tyrosine phosphatase, 
non-receptor type 3 (PTPN3), transcript 
variant 1, mRNA  
-3,79502 
C10orf99 NM_207373 Homo sapiens chromosome 10 open 
reading frame 99 (C10orf99), mRNA  
-3,792719 
MYH4 NM_017533 Homo sapiens myosin, heavy chain 4, 
skeletal muscle (MYH4), mRNA  
-3,7923658 
C5orf52 NM_001145132 Homo sapiens chromosome 5 open reading 
frame 52 (C5orf52), mRNA  
-3,7702193 
HAVCR1 NM_012206 Homo sapiens hepatitis A virus cellular 
receptor 1 (HAVCR1), transcript variant 1, 
mRNA  
-3,7554414 
 
 
 
 
 
 
 
S3 Table. Regulation of genes coding for transcription factors in IL-4 treated HCAEC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene symbol 
 
Accession Sequence description Fold change 
  
EGR1 
 
NM_001964 Homo sapiens early growth response 1 7.030321 
 
FOSB NM_006732 Homo sapiens FBJ murine osteosarcoma 
viral oncogene homolog B 
3.307321 
 
GATA3 NM_001002295 Homo sapiens GATA binding protein 3 3.068881 
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SUPPLEMENTAL FIGURES 
 
 
 
S1 Fig. 
 
 
 
 
S1 Fig. HCAEC monolayer formation in ECIS arrays. Immediately after seeding HCAEC 
into 8W10E+  arrays with a density of 80,000- 90,000 cells/well, resistance measurements (in 
Ohms) were started and are shown as normalized resistance (subsequent values were 
divided by initial values). Increase in resistance over time indicates an increase in the 
formation of intercellular contacts. The steady state of resistance represents a tight 
monolayer stage exhibiting stable barrier function. Each single curve represents the 
resistance measurements conducted in duplicate wells which were grouped and averaged. 
Error bars of curves represent SD. Figures shown depict the resistance measurements 
conducted at 4000 Hz. 
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S2 Fig. 
 
 
 
S2 Fig. Wnt5A knockdown efficiency. (A) Expression levels of Wnt5A mRNA in HCAEC 
transfected with 5 nM negative (neg.) control siRNA and Wnt5A siRNA. Data were obtained 
from three independent qRT-PCR experiments run with duplicate samples and expressed as 
the mean ± SEM. *P<0.005 of Student’s t-test. Representative immunofluorescence staining 
depicting Wnt5A protein expression (red) in negative control siRNA transfected (B) and 
Wnt5A siRNA transfected (C) HCAEC. Green: F-actin, Blue: nuclei. Zeiss Axioskope, 
Magnification 20×.  
 
29 
 
7. CONCLUSIONS 
 
The present study describes a novel inflammatory Wnt5A signaling mechanism affecting 
monolayer integrity and barrier function in human vascular endothelial cells. This pathway acts 
independent of the presence other inflammatory mediators such as TNF, IL-1 or IL-6 as 
summarized in Figure 6. 
 
 
 
Figure 6. The paracrine and autocrine action of macrophage-derived and IL-4-induced  
Wnt5A on human vascular endothelial cells. Tight intercellular contacts at AJ in resting 
endothelial cells (left side of figure) are disrupted upon Wnt5A/Ryk signaling to form inter-
endothelial gaps (right side of figure). MA, macrophages; Ag, Antigen; TCR, T cell receptor; IL-
4R, IL-4 receptor; IFNgR, Interferon-γ receptor; TH1, type 1 helper T cell. 
 
Whole genome transcriptome profiling and GO analyses revealed that Wnt5A mainly regulated 
the process of cytoskeleton remodelling involving LIMK-2 and CFL-1 in HCAEC. Wnt5A-induced 
phosphorylation of LIMK-2 and CFL-1 through activation of ROCK increased actin stress fiber 
formation and disrupted AJ proteins in IEJ (Figure 6). We demonstrated that Wnt5A-induced 
cytoskeleton remodelling could also affect endothelial cell motility and impair endothelial barrier 
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function. By application of the Ryk-specific Wnt antagonist WIF-1, and by silencing Ryk 
expression, we proved Ryk as the Wnt5A receptor upstream to the ROCK/LIMK-2/CFL-1 
pathway regulating actin cytoskeleton remodelling. We further identified Wnt5A/Ryk signaling as 
the effector mechanism responsible for cytoskeleton remodelling and increased permeability in 
IL-4-treated HCAEC (Figure 6). Data obtained in these studies indicate a critical role for Wnt5A 
in mediating endothelial permeability in severe systemic inflammatory diseases like 
sepsis/septic shock, and in IL-4 driven allergic inflammation.  
In conclusion, Wnt5A/Ryk signaling is a novel pro-inflammatory mechanism inducing barrier 
dysfunction in the vascular endothelium. The present study advances the current knowledge of 
systemic inflammation and opens new perspectives for therapeutic intervention in patients with 
severe systemic inflammatory diseases.  
Further investigations are needed to unravel the intriguing finding of Wnt5A being induced by 
two different pathways that are evolutionary highly conserved, TLR-dependent and IL-4 
dependent signaling. 
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